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Abstract
High-throughput non-invasive prenatal testing for fetal
rhesus D status in RhD-negative women not known to be
sensitised to the RhD antigen: a systematic review and
economic evaluation
Pedro Saramago,1 Huiqin Yang,2 Alexis Llewellyn,3
Ruth Walker,3 Melissa Harden,3 Stephen Palmer,1
Susan Griffin1 and Mark Simmonds3*
1Centre for Health Economics, University of York, York, UK
2Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School,
Exeter, UK
3Centre for Reviews and Dissemination, University of York, York, UK
*Corresponding author mark.simmonds@york.ac.uk
Background: High-throughput non-invasive prenatal testing (NIPT) for fetal rhesus (D antigen) (RhD)
status could avoid unnecessary treatment with routine anti-D immunoglobulin for RhD-negative women
carrying a RhD-negative fetus, although this may lead to an increased risk of RhD sensitisations.
Objectives: To systematically review the evidence on the diagnostic accuracy, clinical effectiveness and
implementation of high-throughput NIPT and to develop a cost-effectiveness model.
Methods: We searched MEDLINE and other databases, from inception to February 2016, for studies of
high-throughput NIPT free-cell fetal deoxyribonucleic acid (DNA) tests of maternal plasma to determine
fetal RhD status in RhD-negative pregnant women who were not known to be sensitised to the RhD
antigen. Study quality was assessed with the Quality Assessment of Diagnostic Accuracy Studies 2
(QUADAS-2) and A Cochrane Risk of Bias Assessment Tool: for Non-Randomised Studies of Interventions
(ACROBAT-NRSI). Summary estimates of false-positive rates (FPRs) and false-negative rates (FNRs) were
calculated using bivariate models. Clinical effectiveness evidence was used to conduct a simulation study.
We developed a de novo probabilistic decision tree-based cohort model that considered four alternative
ways in which the results of NIPT could guide the use of anti-D immunoglobulin antenatally and post
partum. Sensitivity analyses (SAs) were conducted to address key uncertainties and model assumptions.
Results: Eight studies were included in the diagnostic accuracy review, seven studies were included in the
clinical effectiveness review and 12 studies were included in the review of implementation. Meta-analyses
included women mostly at or post 11 weeks’ gestation. The pooled FNR (women at risk of sensitisation) was
0.34% [95% confidence interval (CI) 0.15% to 0.76%] and the pooled FPR (women needlessly receiving
anti-D) was 3.86% (95% CI 2.54% to 5.82%). SAs did not materially alter the overall results. Data on
clinical outcomes, including sensitisation rates, were limited. Our simulation suggests that NIPT could
substantially reduce unnecessary use of antenatal anti-D with only a small increase in the risk of sensitisation.
All large implementation studies suggested that large-scale implementation of high-throughput NIPT was
feasible. Seven cost-effectiveness studies were included in the review, which found that the potential for the
use of NIPT to produce cost savings was dependent on the cost of the test. Our de novo model suggested
that high-throughput NIPT is likely to be cost saving compared with the current practice of providing routine
antenatal anti-D prophylaxis to all women who are RhD negative. The extent of the cost saving appeared to
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be sufficient to outweigh the small increase in sensitisations. However, the magnitude of the cost saving is
highly sensitive to the cost of NIPT itself.
Limitations: There was very limited evidence relating to the clinical effectiveness of high-throughput NIPT,
with no evidence on potential adverse effects. The generalisability of the findings to non-white women
and multiple pregnancies is unclear.
Conclusions: High-throughput NIPT is sufficiently accurate to detect fetal RhD status in RhD-negative
women from 11 weeks’ gestation and would considerably reduce unnecessary treatment with routine
anti-D immunoglobulin, potentially resulting in cost savings of between £485,000 and £671,000 per
100,000 pregnancies if the cost of implementing NIPT is in line with that reflected in this evaluation.
Future work: Further research on the diagnostic accuracy of NIPT in non-white women is needed.
Study registration: This study is registered as PROSPERO CRD42015029497.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Glossary
Cost-effectiveness analysis An economic analysis that converts effects into health terms and describes
the costs for additional health gain.
Decision modelling A theoretical construct that allows the comparison of the relationship between costs
and outcomes of alternative health-care interventions.
False negative An incorrect negative test result – the number of diseased persons with a negative
test result.
False positive An incorrect positive test result – the number of non-diseased persons with a positive
test result.
Incremental cost-effectiveness ratio The difference in the mean costs of two interventions in the
population of interest divided by the difference in the mean outcomes in the population of interest.
Index test The test for which performance is being evaluated.
Markov model An analytic method particularly suited to modelling repeated events or the progression of
a chronic disease over time.
Meta-analysis Statistical techniques used to combine the results of two or more studies and obtain a
combined estimate of effect.
Metaregression A statistical technique used to explore the relationship between study characteristics and
study results.
Opportunity costs The cost of forgone outcomes that could have been achieved through
alternative investments.
Receiver operating characteristic curve A graph that illustrates the trade-offs between sensitivity and
specificity that result from varying the diagnostic threshold.
Reference standard The best currently available diagnostic test against which the index test is compared.
Sensitivity The proportion of people with the target disorder who have a positive test result.
Specificity The proportion of people without the target disorder who have a negative test result.
True negative A correct negative test result – the number of non-diseased persons with a negative
test result.
True positive A correct positive test result – the number of diseased persons with a positive test result.
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ACROBAT-
NRSI
A Cochrane Risk Of Bias
Assessment Tool: for
Non-Randomised Studies
of Interventions
BNF British National Formulary
CDSR Cochrane Database of Systematic
Reviews
CENTRAL Cochrane Central Register of
Controlled Trials
CI confidence interval
CINAHL Cumulative Index to Nursing and
Allied Health Literature
DARE Database of Abstracts of Reviews
of Effects
DNA deoxyribonucleic acid
FMH fetal–maternal haemorrhage
FNR false-negative rate
FPR false-positive rate
HSROC hierarchical summary receiver
operating characteristic
HTA Health Technology Assessment
ICER incremental cost-effectiveness ratio
IU international unit
MeSH medical subject heading
NHB net health benefit
NHS EED NHS Economic Evaluations
Database
NICE National Institute for Health and
Care Excellence
NIPT non-invasive prenatal testing
PCR polymerase chain reaction
PP1 postpartum scenario 1
PP2 postpartum scenario 2
PP3 postpartum scenario 3
PP4 postpartum scenario 4
QALY quality-adjusted life-year
QUADAS-2 Quality Assessment of Diagnostic
Accuracy Studies 2
RAADP routine antenatal anti-D prophylaxis
RhD rhesus blood group (D antigen)
ROC receiver operating characteristic
RR relative risk
SA sensitivity analysis
TA technology appraisal
Note
This monograph is based on the Technology Assessment Report produced for NICE. The full
report contained a considerable number of data that were deemed confidential. The full
report was used by the Appraisal Committee at NICE in their deliberations. The full report
with each piece of confidential data removed and replaced by the statement ‘confidential
information (or data) removed’ is available on the NICE website: www.nice.org.uk.
The present monograph presents as full a version of the report as is possible while retaining
readability, but some sections, sentences, tables and figures have been removed. Readers
should bear in mind that the discussion, conclusions and implications for practice and research
are based on all the data considered in the original full NICE report.
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Plain English summary
About 3 in 20 women in the UK have a blood type called rhesus blood group (D antigen) (RhD)negative. If they become pregnant, around 6 in 10 of these women will have babies who have the
opposite blood type (RhD positive) and the woman’s immune system can react to the baby’s blood
(a process called ‘sensitisation’). Following sensitisation, commonly in a subsequent pregnancy, the
woman’s immune system may attack the baby’s blood, which potentially has severe consequences, such as
a need for blood transfusions or even the death of the baby. The risk of sensitisation can be substantially
reduced by injecting women with a blood-based product called anti-D immunoglobulin. Currently, all
pregnant women with RhD-negative blood are offered this injection during later pregnancy and after birth.
However, women carrying a RhD-negative baby do not need this injection. Non-invasive prenatal testing
(NIPT) may determine the blood type of the baby during pregnancy and so the anti-D injection can be
avoided in women who do not need it.
This report investigated whether or not using NIPT was a reliable, effective and safe way to manage
RhD-negative pregnant women and whether or not it could reduce costs for the NHS. Based on eight
studies, the test was found to be highly accurate, with an incorrect result in about 2% of women, which
translates to between 3 and 27 additional sensitisations per 100,000 pregnancies compared with current
practice, and a small risk of loss in health. However, the test is inconclusive in around 7% of women who
could still be offered the anti-D injection, and there is an increased risk of adverse health outcomes for
sensitised women. The evidence suggests that using NIPT would reduce the number of women receiving
anti-D unnecessarily but would lead to a small increase in the number of additional sensitisations and that
this may or may not be cost saving depending on the additional cost of NIPT.
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Scientific summary
Background
Approximately 17% of women giving birth in England and Wales are rhesus blood group (D antigen)
(RhD) negative. Pregnant women who have RhD-negative blood type may carry a RhD-positive fetus.
The entry of fetal RhD-positive cells into the maternal circulation can cause a mother who is RhD negative
to produce anti-D antibodies against the RhD antigen. This process, called sensitisation, can happen at any
time during pregnancy, although it is most common in the third trimester and during childbirth.
In a subsequent pregnancy with a RhD-positive fetus in women who have been sensitised, the woman’s
anti-D antibodies may respond to the presence of RhD-positive blood in the fetus, which may result in
haemolytic disease of the fetus and newborn infant. Prophylaxis with anti-RhD immunoglobulin can
substantially reduce the risk of sensitisation in RhD-negative women and the prevalence of haemolytic
disease of the fetus and newborn infant.
High-throughput non-invasive prenatal testing (NIPT) for fetal RhD status may enable anti-D immunoglobulin
to be withheld from RhD-negative women who are carrying a RhD-negative fetus. These women could avoid
unnecessary treatment with routine anti-D immunoglobulin, as well as the potential risk associated with
the administration of blood products, although this may also lead to an increased risk of RhD sensitisations.
In addition, these women may not need the provision of anti-D immunoglobulin following potentially
sensitising events and there may no longer be a need for serological cord testing at birth. However, the
clinical effectiveness and cost-effectiveness of high-throughput NIPT for fetal rhesus D status in RhD-negative
women not known to be sensitised to the RhD antigen for the NHS is uncertain.
Objectives
This assessment aims to evaluate both the clinical effectiveness and cost-effectiveness of using
high-throughput NIPT to identify fetal rhesus D status in RhD-negative women not known to be
sensitised to the RhD antigen and any consequent changes in treatment management.
Methods
Assessment of clinical effectiveness
Three systematic reviews were conducted. A range of bibliographic sources, including MEDLINE and
EMBASE, were searched from inception to February 2016 for published and unpublished literature.
For diagnostic accuracy outcomes, we included prospective cohort studies reporting absolute numbers,
which allowed for the calculation of diagnostic accuracy. For clinical effectiveness outcomes, we included
any study in which high-throughput NIPT was used, in which anti-D prophylaxis was given as required and
that reported relevant clinical outcomes. For implementation outcomes, we considered all publications
reporting issues related to the implementation of, or practical advice relating to, high-throughput NIPT.
For all reviews, the eligible population were pregnant women who were RhD negative and not known to
be sensitised to RhD antigen. The index test was high-throughput NIPT free-cell fetal deoxyribonucleic acid
tests of maternal plasma used to determine fetal RhD status. The reference standard was serological cord
blood testing at birth or any other suitable postnatal blood test of the infant.
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Two researchers independently screened the titles and abstracts of all reports identified by the search
strategy and full-text papers were subsequently obtained for assessment. Data extraction and quality
assessment were undertaken by one researcher and checked by a second. The risk of bias of diagnostic
accuracy studies was assessed using a modified Quality Assessment of Diagnostic Accuracy Studies 2
(QUADAS-2) checklist.
For diagnostic accuracy outcomes, bivariate models were fitted to calculate summary estimates of
false-positive rates (FPRs) and false-negative rates (FNRs) with 95% confidence intervals (CIs).
For clinical effectiveness outcomes, data including sensitisation, NIPT uptake, anti-D prophylaxis uptake,
reduction in anti-D use and adverse events were synthesised narratively. For the review of implementation
studies, the following data were synthesised narratively: study findings, issues for implementation, practical
guidance and recommendations for research. In addition, we performed a simulation study to simulate
possible clinical outcomes of high-throughput NIPT in the UK based on results from the diagnostic accuracy
review and existing reviews of antenatal anti-D prophylaxis.
Assessment of cost-effectiveness
A range of bibliographic databases were searched to identify relevant cost-effectiveness evidence. Citation
searches were also undertaken. Only full economic evaluations were considered for review. Characteristics
from the review findings were extracted and critically appraised using a published checklist. Studies were
assessed with respect to the way in which NIPT was assumed to have an impact on the care pathway.
A de novo decision-analytic model using a decision tree cohort approach was developed to estimate, based
on best available data, the costs and health outcomes. Four scenarios were designed to evaluate different
impacts of NIPT on the existing postpartum care pathway. These evaluated how NIPT could impact on the
use of cord serology, fetal–maternal haemorrhage (FMH) tests and anti-D immunoglobulin following
delivery. First and subsequent pregnancies, together with the long-term consequences of sensitisations, in
terms of costs and utilities, are evaluated within the model, with a yearly cycle and a lifetime horizon. The
main outcomes of interest within the model were the total lifetime costs and total lifetime quality-adjusted
life-years (QALYs) for each of the alternative pathways. The decision model was populated using the results
from the systematic clinical review on the diagnostic accuracy of high-throughput NIPT. Various assumptions
were based on the previous independent economic evaluation developed for NICE technology appraisal (TA)
156 on routine antenatal anti-D prophylaxis (RAADP). Primary model results are the total expected costs and
expected QALYs for each alternative strategy. Population net health benefits are used to summarise the
cost-effectiveness results in addition to the cost-effectiveness ratio. Uncertainty regarding the appropriate
source of data, the appropriate assumptions or model structure and other scenarios are explored using
one-way and two-way sensitivity analyses (SAs).
Results
Diagnostic accuracy
Eight studies were included in the diagnostic review of high-throughput NIPT, which were conducted in
five European countries. There were three high-quality studies in which NIPT was performed by the NHS
Blood and Transplant International Blood Group Reference Laboratory (Bristol, UK). The reference standard
in all studies was cord blood serology at birth. The majority of included studies were judged as having a
low risk of bias, but two studies were judged as having a high risk of bias.
Meta-analyses included women mostly at or post 11 weeks’ gestation and showed very high diagnostic
accuracy of high-throughput NIPT. In the primary analyses, in which women with inconclusive test results
were treated as having tested positive, the pooled FNR (i.e. women at risk of sensitisation) was 0.34%
(95% CI 0.15% to 0.76%) and the pooled FPR (i.e. women receiving anti-D unnecessarily) was 3.86%
(95% CI 2.54% to 5.82%). SAs did not materially alter the overall result.
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The diagnostic accuracy performance of high-throughput NIPT varied by gestational age. The data suggest
that high-throughput NIPT was less accurate before around 11 weeks’ gestation (i.e. in first trimester),
but diagnostic accuracy was consistent at any time after 11 weeks’ gestation. We were unable to conduct
a subgroup analysis based on ethnicity because of a lack of relevant data from included studies.
Clinical effectiveness
Seven studies were included in the clinical effectiveness review. All studies were judged as having a high
risk of bias. One large cohort study reported that implementation of NIPT for targeted antenatal anti-D
prophylaxis was associated with a significant risk reduction in sensitisation (adjusted odds ratio 0.41,
95% CI 0.22 to 0.87) compared with historical controls.
Three non-comparative studies reported on the reduction in administration of anti-D. All suggested that
anti-D administration was largely avoided in women with a RhD-negative fetus.
The compliance rate with antenatal anti-D prophylaxis ranged from 86% to 96.1% (four studies) and
compliance rates with postpartum anti-D ranged from 92% to 99.7% (three studies) in women who
undertook NIPT and received a positive result. High-throughput NIPT uptake rates ranged from 70% to
> 95% (seven studies). None of the included studies reported data on adverse events associated with NIPT.
The results from the simulation study suggested that use of NIPT to determine antenatal anti-D use would
substantially reduce the number of women receiving anti-D unnecessarily, from 38.9% to 5.7%, consistent
with evidence identified by the review. The use of NIPT would cause an extra three sensitisations per
100,000 women if cord blood testing is continued (at least in women with a negative NIPT result) as the
basis for administering postpartum anti-D. If cord blood testing is withdrawn (except for women who did
not receive NIPT or who had an inconclusive test result) and NIPT is used to decide on postpartum anti-D
administration, then there would be an extra 13 sensitisations per 100,000 women. These additional
sensitisations are few compared with the underlying rate of sensitisation with antenatal anti-D (280 per
100,000 women). These results suggest that cord blood testing could potentially be withdrawn and NIPT
results (if available and conclusive) may be used to prescribe postpartum anti-D. This conclusion will
depend partly on whether or not the 10 extra sensitisations per 100,000 RhD-negative women caused by
withdrawing cord blood testing can be considered an ethically acceptable increase.
Evidence on implementation
Twelve studies were included in the review of implementation. Most of the included studies were large
cohort studies reporting implementation data alongside diagnostic accuracy data, although one study was
a survey based in the UK (London). All the cohort studies suggested that high-throughput RhD genotyping
of fetuses in all RhD-negative women was feasible. Key issues of implementation included ensuring anti-D
prophylaxis compliance, the effective management of transporting samples and greater knowledge of NIPT
among physicians, midwives and pregnant women.
Cost-effectiveness
The de novo health economic model suggested that high-throughput NIPT appears cost saving but also less
effective than current practice, irrespective of the postpartum scenario evaluated. However, the magnitude
of the potential cost savings appeared sufficient to outweigh the small increase in sensitisations and the
associated small QALY loss when using NIPT compared with current practice. Based on a cross-section of
100,000 pregnancies, the probable magnitude of cost savings ranged between £485,000 and £671,000
across the separate postpartum strategies. In the base-case analysis, the strategy in which the NIPT result
is used to guide RAADP only (i.e. all women continue to receive cord serology with FMH and postpartum
anti-D immunoglobulin) had the highest probability of being cost-effective.
The magnitude of the cost saving appeared highly sensitive to the cost of NIPT itself to the NHS, which
comprises the base unit cost per test, the level of any royalty fee and any increase in antenatal care costs
DOI: 10.3310/hta22130 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 13
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Saramago et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xxv
required to accommodate an additional test. A small increase in the cost assumed of (confidential
information has been removed) or more per test would alter these conclusions.
Our findings indicate that the timing of the test does not appear influential in determining the
cost-effectiveness results, either in terms of diagnostic accuracy or in terms of the extent of management
costs for potentially sensitising events that can be avoided. Another important consideration is the rate of
high-throughput NIPT inconclusive results. Our findings demonstrate that even with a high-throughput
NIPT inconclusive result rate of close to 15%, the introduction of NIPT appears to compare favourably with
current practice.
Discussion
Limitations and uncertainties
Few studies reporting clinical effectiveness data of using high-throughput NIPT to detect fetal RhD status in
RhD-negative women were identified. Results of the simulation study are sensitive to the parameters used
and should be considered speculative.
Owing to the limited evidence, the potential clinical impact of high-throughput NIPT on the care pathway
remains unclear. No studies compared NIPT with universal administration of RAADP. No studies were
identified reporting comparative data relating to patient-related outcomes, such as quality of life or
anxiety. Whether or not the diagnostic performance of high-throughput NIPT differs between different
ethnic groups remains unclear.
There remains uncertainty regarding the cost of introducing the high-throughput NIPT, as the unit cost will
potentially vary with throughput and may be subject to an additional royalty fee.
Generalisability of the findings
Diagnostic data from three UK (Bristol) studies are mostly generalisable to the UK setting. Differences in
high-throughput NIPT devices and in antenatal care within different countries mean that the generalisability
of the findings from those non-UK studies to the UK setting is likely to be limited, particularly for the
reviews of clinical effectiveness and implementation studies. Owing to a lack of UK-based evidence, the
generalisability of studies reporting compliance rates to antenatal anti-D treatment to the UK setting
remains uncertain. As most participants in included studies were white Europeans, the generalisability of
these findings to a non-white population also remains uncertain.
Conclusions
Implications for service provision
High-throughput NIPT is highly accurate for the detection of fetal rhesus D status in RhD-negative women,
if performed after 11 weeks’ gestation. Only 1% of women will have an incorrect test result (nearly all
false positives) and around 7% will have an inconclusive result.
The use of NIPT can largely remove unnecessary exposure to prophylactic anti-D treatment, without
substantially altering the rate of sensitisations. However, there will be a small number of women (about
0.1%) with a false-negative test result who are put at increased risk of sensitisation because they do not
receive antenatal anti-D prophylaxis. This risk is unlikely to be substantially increased if postnatal cord
blood testing is withdrawn. The test could be administered at any time after the first trimester without
adversely affecting accuracy. Achieving high compliance rates may be important for the success of using
NIPT, particularly through ensuring high compliance with NIPT and continuing to offer antenatal anti-D to
women who refuse, or miss, NIPT.
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Cost-effectiveness
Targeted provision of anti-D immunoglobulin prophylaxis through the use of high-throughput NIPT
prophylaxis is estimated to be cost saving compared with the current practice of providing prophylactic
prenatal anti-D immunoglobulin to all women who are RhD negative. A postpartum strategy that
distinguishes between inconclusive results and positive results offers the greatest cost savings. The
potential savings appear highly sensitive to the cost of NIPT.
Suggested research priorities
Evidence on the diagnostic accuracy of NIPT in women of non-white ethnicity is needed, for which large
prospective cohort studies collecting diagnostic accuracy data will be required. This is of particular concern,
as non-white women may be more likely to have inconclusive test results.
Further evidence on the clinical impact of NIPT is needed. If it is implemented, appropriate auditing of NIPT
and anti-D administration processes should be considered, recording clinical outcomes, such as sensitisation
rates, NIPT and anti-D compliance, and quality of life.
Further clarifications over the potential additional costs for blood drawing, the transportation of samples
and antenatal care visits to administer the test and deliver counselling and results are needed.
Further research to comprehensively appreciate the full impact of sensitisations on mothers and children
is warranted.
Study registration
This study is registered as PROSPERO CRD42015029497.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Background
Description of the health problem
Pregnant women who have a rhesus blood group (D antigen) (RhD)-negative blood type may carry a
RhD-positive fetus. The presence of fetal RhD-positive cells in the maternal circulation can cause a mother
who is RhD negative to produce anti-D antibodies against the RhD antigen. This process, called sensitisation,
can happen at any time during pregnancy, although it is most common in the third trimester and during
childbirth. Sensitisation can follow events in pregnancy known to be associated with fetal–maternal
haemorrhage (FMH). Potentially sensitising events include some medical interventions (e.g. chorionic villus
sampling, amniocentesis or external cephalic version), terminations, late miscarriages, antepartum
haemorrhage and abdominal trauma.
The process of sensitisation itself has no adverse effects to the mother and does not usually affect the
pregnancy during which it occurs. However, in a subsequent pregnancy with a RhD-positive fetus in
women who have been sensitised to the RhD antigen, the woman’s anti-D antibodies may respond to the
presence of RhD-positive blood in the fetus, resulting in haemolytic disease of the fetus and newborn
infant. This can cause severe fetal anaemia, which may lead to fetal heart failure, fluid retention and
swelling (hydrops) and intrauterine death.
Prophylaxis with anti-RhD immunoglobulin can substantially reduce the risk of sensitisation in RhD-negative
women and the prevalence of haemolytic disease of the fetus and newborn infant.1 Before anti-D
immunoglobulin was available, the incidence of RhD sensitisation in RhD-negative women following the
birth of two RhD-positive babies was approximately 16%. Haemolytic disease of the fetus and newborn
infant was a significant cause of morbidity and mortality, which occurred in approximately 1% of all births.
Since the introduction of routine postnatal administration of anti-D immunoglobulin, the incidence of RhD
sensitisation dropped to approximately 2%. The introduction of routine antenatal prophylaxis during the
third trimester of pregnancy has led to a further reduction in the sensitisation rate to between 0.17% and
0.28%. This has led to a decrease in mortality associated with haemolytic disease of the fetus and newborn
infant, from 46 in 100,000 births before 1969 to 1.6 in 100,000 births by 1991.2
In England, there were 646,904 births from April 2013 to March 2014, of which approximately 15%
(97,036 births) were to RhD-negative women.3 Approximately 40% of these women will carry a RhD-negative
fetus (around 39,000 per year) and therefore do not need administration of anti-D immunoglobulin. White
populations of European descent have an approximately 15% incidence of RhD negativity; however, this is
3–5% in populations of African American ethnicity and is very rare in those of Eastern Asian origin.4 Despite
the mixing of genes, the majority of RhD-negative white people are RhD negative a result of gene deletion,
and RHD gene variants are relatively rare in white people, who account for < 1% of all RhD-negative people.
However, in people with black African ethnicity, an inactive RHD gene (known as the RHD pseudogene
RHDψ), which is mostly the result of genes that contain RhD sequences but do not produce the D antigen,
is present in 66% of RhD-negative people. The distribution of this gene varies between people with black
African ethnicity and people with other African origins,5 with 24% of people with African American ethnicity
and 17% of people with black South African ethnicity having the gene.6
Current service provision and care pathway
The National Institute for Health and Care Excellence (NICE) guideline on antenatal care (2008)7 recommends
that women should be offered testing for blood group and rhesus D status in early pregnancy. All women
identified as RhD negative will be tested for the presence of RhD antibodies, regardless of whether or not
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they are known to be sensitised. In those identified as RhD negative, administration of anti-D immunoglobulin
is recommended both as prophylaxis and following potential sensitising events to prevent sensitisation.
Routine antenatal prophylaxis with anti-D immunoglobulin can be given as two doses at weeks 28 and 34 of
pregnancy or as a single dose between 28 and 30 weeks.7 Following potentially sensitising events, anti-D
immunoglobulin should be administered within 72 hours of the event.2
Anti-D immunoglobulin is produced from pooled plasma from large numbers of RhD-negative donors who
have been transfused with RhD-positive red cells to stimulate the production of RhD antibodies. Thus, it
carries a risk of transmission of human blood-borne viral and prion diseases. Despite this risk, the National
Comparative Audit of Blood Transfusion from 20138 reports that of the women eligible for anti-D
immunoglobulin, 99.0% received anti-D immunoglobulin.
For pregnant women who are RhD negative and are sensitised to RhD antigen, the Royal College of
Obstetricians and Gynaecologists has published guidance on the management of women with red cell
antibodies during pregnancy.9 This guideline recommends that all RhD-negative women who are sensitised
to RhD antigen should attend pre-pregnancy counselling with a clinician who has knowledge and expertise
of this condition, have their blood group and antibody status determined at the booking appointment
(ideally by 10 weeks of gestation) and at 28 weeks of gestation and be offered non-invasive fetal RhD
genotyping using maternal blood if maternal RhD antibodies are present. Once a RhD-positive fetus is
identified, additional monitoring and treatment are required during the pregnancy.
Description of the technology under assessment
Summary of technologies (index tests)
The technology under assessment is high-throughput non-invasive prenatal testing (NIPT) for fetal
rhesus D status (International Blood Group Reference Laboratory, NHS Blood and Transplant, Bristol, UK).
High-throughput NIPT of fetal RhD status uses a real-time quantitative polymerase chain reaction (PCR)
method for predicting the fetal RhD genotype from fetal deoxyribonucleic acid (DNA) in the plasma of
RhD-negative women. The test principle is based on the analysis of cell-free fetal DNA, that is, small
fragments of fetal extracellular DNA shed from the placenta and circulating freely in the maternal plasma.
The level of cell-free fetal DNA in maternal blood increases throughout the pregnancy. A woman who
is RhD negative does not have a copy of the RHD gene; therefore, the presence of a RHD gene in a
RhD-negative pregnant woman suggests a RhD-positive fetus.
High-throughput NIPT is performed using samples of maternal anticoagulated blood. DNA extraction is
performed using an automated robotic platform, which can rapidly process samples. The robotic platform
is used as a liquid handler to dispense samples and reagents. In the UK, primers and probes for specific
exons of the RHD gene are used, with a number of controls being tested (such as RhD-positive DNA,
RhD-negative DNA, RHD pseudogene positive DNA and no DNA). An algorithm is employed to determine
the fetal RhD status. The samples can be tested in batches of between 32 and 88 samples. The time to
complete the test from sample receipt to report generation is 5–6 hours.
High-throughput NIPT for fetal RhD status may enable anti-D immunoglobulin to be withheld from
RhD-negative women who are carrying a RhD-negative fetus. These women could avoid unnecessary
treatment with routine anti-D immunoglobulin, along with the potential risk associated with administration
of blood products. In addition, these women may not need the provision of anti-D immunoglobulin following
potentially sensitising events and there may no longer be a need for serological cord testing at birth.
Identification of important subgroups
There are potential challenges for the detection of fetal rhesus D status when performing NIPT in pregnant
women. Dealing with the presence of RHD pseudogene poses a challenge. The majority of RhD-negative
BACKGROUND
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individuals with white European ethnicity have the pseudogene as a result of gene deletion; however, in
people with African ethnicity the Rh-negative phenotype is mainly the result of genes that contain RhD
sequences but do not produce D antigen (RHD pseudogene).5 In the presence of the RHD pseudogene,
prenatal determination of fetal Rh type from maternal blood would reveal a RhD-positive type, but this
would be confirmed as RhD negative by serology because of the abundant maternal D gene sequences
that are not expressed but are amplified. This may, therefore, lead to higher rates of false-positive results
when performing NIPT in this population.
There is a diverse array of Rh variant genes and it is generally accepted that at least two exons of RHD
should be targeted for accurate RhD status prediction. For instance, targeting only exon 7 (or exon 10)
would not detect the presence of the RHD pseudogene and other variants and targeting only exon 10
would not detect the presence of the RHD pseudogene or the hybrid RHD-CE-D(s) gene, which are
commonly present in people with African ethnicity.
Evidence suggests that the diagnostic accuracy of NIPT may vary according to different gestational ages at
the time of sampling. Two meta-analyses found that the diagnostic accuracy of NIPT was higher in the first
trimester than in the second and third trimester.10,11 However, a recent UK cohort study found that fetal
RhD genotyping was more accurate for the prediction of RhD status if it was performed after, rather than
before, 11 weeks’ gestation.12
In this assessment we aim to investigate findings of high-throughput NIPT from a number of subgroups,
such as those based on different gestational ages and different ethnicities as well as on the usage of
different exons of RHD, if data are available.
Current usage in the NHS
Currently, all high-throughput NIPT for fetal RhD status determination in the UK is performed by the
NHS Blood and Transplant International Blood Group Reference Laboratory in Bristol. If all pregnant
RhD-negative women in England were to be tested, approximately 100,000 samples would be tested each
year. An increased capacity would be required for the International Blood Group Reference Laboratory to
be able to cope with this demand by employing additional staff and acquiring more analytical platforms.
Beyond this, extending the testing service to other laboratories is an alternative option. Blood samples
would need to be transported from local hospital laboratories to the International Blood Group Reference
Laboratory in Bristol or other laboratories. The established NHS Blood and Transplant transport system
would be used to deliver blood samples across the country. This would need to be achieved in reasonable
time, although there is evidence to suggest that cell-free fetal DNA is very stable.13 There would also need
to be reporting systems in place to ensure the accurate transmission of test results back to the women and
their physicians and midwives.
Expected costs associated with technology
The potential costs associated with high-throughput NIPT to the NHS comprise two components. First,
there is the unit cost of the diagnostic test itself, which varies with the level of throughput and to which a
royalty fee may be added. An estimated unit cost for high-throughput NIPT of (confidential information has
been removed) and a royalty payment of (confidential information has been removed) were considered.
It should be noted that these estimates were provided in confidence by the company with the underlying
assumption that the International Blood Group Reference Laboratory in Bristol will be the sole provider of
the test nationally. Second, the potential costs of incorporating the test into routine antenatal care must
be considered, which may bring additional costs relating to the time for antenatal care appointments to
provide information about the test, counselling and delivering test results and also relating to blood drawing
and blood sample transportation.
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Chapter 2 Definition of the decision problem
Decision problem
The clinical effectiveness and cost-effectiveness of high-throughput NIPT for assessing fetal rhesus D
status in RhD-negative women not known to be sensitised to the RhD antigen for the NHS is uncertain.
High-throughput NIPT for fetal RhD status may enable anti-D immunoglobulin to be withheld from
RhD-negative women who are carrying a RhD-negative fetus. This subgroup of women could therefore
avoid unnecessary prophylaxis with anti-D immunoglobulin during pregnancy, as well as the risk associated
with exposure to blood products, which may have important resource implications for the NHS.
However, relying on NIPT to determine anti-D immunoglobulin use could lead to more women becoming
sensitised, because women who incorrectly test negative on NIPT will not receive anti-D and so are at
increased risk of sensitisation. This risk will be increased if cord blood testing is also withdrawn and
postpartum anti-D given on the basis of the NIPT results. It is also unclear whether or not the cost of
instituting NIPT screening will outweigh the savings from the reduced use of anti-D treatment.
This report, undertaken for the NICE Diagnostics Assessment Programme, examines the clinical
effectiveness and cost-effectiveness of high-throughput NIPT. It considers the value of NIPT as a diagnostic
test for RhD status, the clinical impact of using NIPT to determine anti-D immunotherapy use and the
cost implications of implementing a NIPT screening programme. The report will allow NICE to make
recommendations about how well the high-throughput NIPT works and whether or not the benefits are
worth the cost of the tests for use in the NHS.
This report contains reference to confidential information provided as part of the NICE appraisal process.
This information has been removed from the report and the results, discussions and conclusions of the
report do not include the confidential information. These sections are clearly marked in the report.
Overall aims and objectives of the assessment
The purpose of this project was to assess the clinical effectiveness and cost-effectiveness of using
high-throughput NIPT to identify fetal RhD status with any consequent changes in treatment management.
In this assessment we addressed the following key objectives:
(a) to perform a systematic review and meta-analysis of the diagnostic accuracy of high-throughput NIPT
for fetal RhD status
(b) to perform a systematic review of the clinical impacts of high-throughput NIPT, including incidence of
sensitisation events, and adverse effects to the mother and fetus
(c) to systematically review the cost-effectiveness evidence on high-throughput NIPT and its impact on the
management of pregnant women
(d) to produce a de novo cost-effectiveness model assessing the cost-effectiveness of high-throughput
NIPT to identify fetal RhD status in RhD-negative women not known to be sensitised to the
RhD antigen
(e) to assess the impact of alternative scenarios related to the timing of the test and the impact of the
test on the use of antenatal anti-D prophylaxis for sensitising events and postdelivery testing.
This report is divided into two sections: clinical effectiveness (covering objectives a and b) is discussed in
Chapter 3; and cost-effectiveness (covering objectives c–e) is discussed in Chapter 4.
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Chapter 3 Assessment of clinical effectiveness
The review of clinical effectiveness of high-throughput NIPT was broken down into the following threesystematic reviews:
1. A review of the diagnostic accuracy of high-throughput NIPT for detecting RhD-positive fetuses.
2. A review of the clinical effectiveness of high-throughput NIPT, including numbers of sensitisations, test
compliance and incidence of adverse events.
3. A review of the implementation of high-throughput NIPT in countries or regions in which it has been
used, examining feasibility, guidance or recommendations for practice and need for further research.
In addition to these three reviews, we searched for existing systematic reviews of antenatal anti-D
prophylaxis, identifying numbers of sensitisations, compliance and incidence of adverse events. Data from
these existing reviews then facilitated the modelling of the probable clinical impact of high-throughput
NIPT and supported the subsequent cost-effectiveness analyses.
The methodology of these reviews is described in the following sections.
Methodology of the clinical effectiveness reviews
The methods for systematic reviews of the diagnostic accuracy and clinical impacts of high-throughput
NIPT for fetal RhD status are provided in the following sections.
Searches
The literature search aimed to systematically identify studies relating to the clinical effectiveness and
cost-effectiveness of high-throughput, non-invasive, prenatal blood testing to determine fetal rhesus D
status.
The search strategy was developed in MEDLINE (via Ovid) and then adapted for use in the other resources
searched. The strategy included terms for rhesus D status combined, using the Boolean operator AND,
with terms for the test. No language, date or geographical limits were applied and study design search
filters were not used. EndNote X7 software (Thomson Reuters, CA, USA) was used to manage the
references for the project.
Search strategies were developed by an information specialist with input from the project team. The search
strategy was checked by a second information specialist.
The following databases were searched for relevant clinical effectiveness or cost-effectiveness studies from
inception to November 2015: MEDLINE, MEDLINE In-Process & Other Non-Indexed Citations, Cumulative
Index to Nursing and Allied Health Literature (CINAHL), Cochrane Central Register of Controlled Trials
(CENTRAL), Cochrane Database of Systematic Reviews (CDSR), Database of Abstracts of Reviews of Effects
(DARE), EMBASE, Health Technology Assessment (HTA) database, Maternity and Infant Care, NHS
Economic Evaluations Database (NHS EED), PubMed and the Science Citation Index.
In addition, the following resources were searched for ongoing, unpublished or grey literature:
ClinicalTrials.gov, Conference Proceedings Citation Index: Science, EU Clinical Trials Register, PROSPERO
and the World Health Organization’s International Clinical Trials Registry Platform portal.
The following websites were searched to identify any relevant guidelines: National Guidelines
Clearinghouse, NICE, NHS Evidence, the Royal College of Obstetricians and Gynaecologists, the Turning
Research into Practice database and the UK National Screening Committee. Reference lists of relevant
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reviews and included studies were checked to identify additional potentially relevant reports. The searches
were updated in February 2016. A full search strategy can be found in Appendix 1.
Selection criteria
Types of studies
Diagnostic accuracy
Prospective cohort studies in which the index test (high-throughput NIPT) and reference standard test (cord
blood sampling) were done independently in the same group of women to assess fetal RhD status were
included. Included studies also had to report sufficient data to construct a 2 × 2 contingency table such
that the cells in the table can be labelled as true positive, false positive, true negative and false negative.
Clinical effectiveness outcomes
Any experimental or observational study (controlled or non-controlled) was included provided that
high-throughput NIPT was used to determine fetal RhD status and anti-D prophylaxis was given as
required. Studies also had to report relevant clinical outcomes as listed in the following sections.
Implementation
Any publications discussing existing or experimental high-throughput NIPT screening programmes were
included. Papers had to report issues related to the implementation of, or practical advice relating to,
high-throughput NIPT as a screening tool to guide use of anti-D prophylaxis. This included publications
that contained no numerical data but discussed practical issues of implementation, presented useful
guidance or informed research recommendations.
Antenatal anti-D prophylaxis
Any systematic review reporting any aspect of the process of using routine antenatal anti-D to prevent
sensitisation was included.
The following types of report were excluded: editorials and opinions, case reports and reports focusing
only on technical aspects of the NIPT technology (such as technical descriptions of the testing process or
specifications of machinery). Studies with a sample size of ≤ 10 were excluded. In the case of multiple
reports for a given study or when the possibility of overlapping populations could not be excluded, the
most recent or most complete reports were selected.
Population
For all reviews, the eligible population was pregnant women who were RhD negative and not known to be
sensitised to RhD antigen.
Intervention
For all studies, high-throughput NIPT free-cell fetal DNA tests of maternal plasma used to determine fetal
RhD status were eligible for inclusion. ‘High-throughput’ is a subjective concept and there is no clear
consensus on its definition. For pragmatic reasons, we considered as high-throughput any NIPT that was
conducted using an automated robotic platform (including automated DNA extraction and liquid handling)
and that was able to process large numbers of samples rapidly for large-scale screening purposes. Studies
in which this test was used for diagnosis (rather than screening) of sensitised women were excluded.
For clinical effectiveness studies, high-throughput NIPT had to be used to enable targeted anti-D
prophylaxis.
Reference standard
For diagnostic accuracy studies, the reference standard considered was serological cord blood testing at
birth or any other suitable postnatal blood test of the infant.
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Outcomes
The following outcomes were included:
l test accuracy, including sensitivity and specificity
l number of inconclusive results, with reasons (e.g. no DNA detected)
l number of pregnant women who accept the test
l number of doses of anti-D immunoglobulin given (routine antenatal, following potentially sensitising
events and postnatal)
l uptake of anti-D (antenatal and postnatal) immunoglobulin
l number of infections from anti-D immunoglobulin
l number of sensitisations
l number of cases of haemolytic disease of the fetus and newborn infant in subsequent pregnancies
l adverse effects of testing
l health-related quality of life.
At least two reviewers independently screened the titles and abstracts (if available) of all reports identified
by the search strategy. Full-text copies of all studies deemed to be potentially relevant were obtained and
two reviewers independently assessed them for inclusion. Any disagreements were resolved by consensus
or by a third reviewer.
Data extraction
We selected the most recent or most complete report in cases of multiple reports for a given study or
when we could not exclude the possibility of overlapping populations.
The data extraction forms were developed and piloted. One reviewer independently extracted details from
full-text studies of study design, participants, index, comparator and reference standard tests and outcome
data. The data extraction was checked by another reviewer. Any disagreements were resolved by
consensus or by recourse to a third reviewer.
For studies reporting diagnostic data, we extracted the number of true positives, true negatives, false
positives and false negatives for each index test evaluated in each study to construct 2 × 2 tables. If such
data were not provided by the study authors, we attempted to contact them to construct the 2 × 2 table
for the study population or the prespecified subgroups. Otherwise, we calculated the number of true
positives, true negatives, false positives and false negatives from the summary estimates of sensitivity and
specificity of the index test, if available. If reported, we extracted data on the number of undetermined or
uninterpretable results. For studies in which only a subgroup of patients was included in the review, we
extracted, analysed and presented data for this subgroup only. If some data were unclear or missing,
we attempted to contact study authors to obtain additional data.
For studies reporting clinical outcomes, we extracted data as the numbers of women or fetuses
experiencing the specified outcome. Mean differences, relative risks (RRs) or odds ratios [with 95%
confidence intervals (CIs)] were extracted from comparative studies, when reported as unadjusted data.
For the implementation review, we summarised the findings and conclusions of the included publications
using the following broad categories: study results and findings, issues for implementation, practical
guidance and recommendations for research.
For the review of anti-D prophylaxis, we extracted summary results from syntheses or meta-analyses of
studies on each clinical outcome reported. Mean differences, RRs or odds ratios with 95% CIs were
extracted, when reported.
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Critical appraisal
One reviewer independently assessed the quality of all included studies in terms of risk of bias. Risk of bias
from diagnostic accuracy studies was assessed using a modified version of the Quality Assessment of
Diagnostic Accuracy Studies 2 (QUADAS-2) checklist.14 The QUADAS-2 tool was adapted to ensure that it
is applicable to assessing the quality of studies of non-invasive prenatal tests for detecting rhesus D status.
The QUADAS-2 tool consists of four key domains: (1) patient selection, (2) index test, (3) reference
standard and (4) flow of patients through the study and timing of the index test(s) and reference standard.
Each domain was assessed in terms of the risk of bias. The first three domains were also assessed for
concerns regarding their applicability in terms of whether or not the participants and setting; the index
test, its conduct or interpretation; and the target condition, as defined by the reference standard, were
applicable to nationwide screening in the UK.
A Cochrane Risk Of Bias Assessment Tool: for Non-Randomised Studies of Interventions (ACROBAT-NRSI)
was used to assess risk of bias for each outcome of all comparative studies reporting other eligible clinical
outcomes. The quality assessment was checked by another reviewer. Any disagreements were resolved by
consensus or by recourse to a third party.
The quality of the studies in the implementation review was not assessed, as there is no validated tool for
assessing the quality of studies on the implementation of health interventions.
Methods of data synthesis
Using extracted diagnostic accuracy data from the 2 × 2 tables, estimates of sensitivity, specificity,
false-positive rates (FPRs) and false-negative rates (FNRs) were calculated and presented on forest plots and
in receiver operating characteristic (ROC) space to examine the variability in diagnostic test accuracy within
and between studies. In the primary analysis, undetermined or uninterpretable results were counted as
being test positive, in accordance with current practice.
The hierarchical bivariate model described by Reitsma et al.15 was fitted, which calculates summary estimates
of sensitivity, specificity, FPRs, FNRs and the associated 95% CIs. The hierarchical summary receiver operating
characteristic (HSROC) model16 was fitted to produce summary ROC curves. Results of both models were
presented in ROC plots.
Other eligible clinical outcomes were pooled if at least two studies reported on the same outcome and if
data were reported consistently enough for analysis to be feasible. Otherwise, results were synthesised
narratively. When meta-analyses were performed, data were pooled using standard random-effects
DerSimonian and Laird meta-analyses. Analyses were conducted in R version 3 (The R Foundation for
Statistical Computing, Vienna, Austria) and/or Stata® version 14 (StataCorp LP, College Station, TX, USA)
software, as appropriate.
Investigation of heterogeneity
For diagnostic accuracy data, forest plots and ROC space were inspected to check for heterogeneity
between study results. Subgroup analyses were conducted, when feasible, by performing separate
bivariate and HSROC models in defined subgroups of studies.
If sufficient studies were available, we considered the following factors as potential sources of
heterogeneity:
l gestational age at time of NIPT
l type of NIPT (e.g. test as used in Bristol vs. other)
l ethnicity (e.g. European vs. African).
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For other clinical outcomes, when possible, heterogeneity was assessed using the I2-statistic value and
visual inspection of forest plots. Subgroup analyses and metaregression were used when feasible. Possible
sources of heterogeneity were discussed and accounted for in the interpretation of the results.
Sensitivity analyses
We conducted sensitivity analyses (SAs) to explore:
l the impact of including and excluding undetermined or uninterpretable NIPT results on the pooled test
accuracy estimates
l test accuracy in UK (Bristol)-based studies12,17,18 only.
When participants from several studies were recruited from the same cohorts and significant overlap was
suspected, data from only one study, with the most reliable reporting, were included in the main analyses.
Narrative synthesis
When quantitative synthesis and meta-analysis were not feasible, results for each study or systematic
review were tabulated, categorised by outcome. For the review of implementation, we performed a
narrative review of the findings of each included study, summarising their conclusions in terms of study
findings, issues for implementation, practical guidance and recommendations for research.
Simulation study of clinical effectiveness
During the course of this report we found very little evidence on the probable clinical effectiveness of
high-throughput NIPT and its impact on future sensitisation rates and adverse events. In order to investigate
these issues, we opted to perform a simulation study to simulate possible outcomes of high-throughput
NIPT in the UK, based on results from the diagnostic accuracy review and the results of published systematic
reviews of antenatal anti-D prophylaxis and relevant audit data identified through additional literature
searches.
The simulation sought to estimate the following in the UK population:
l rates of women with a RhD-positive fetus
l rates of women with positive/negative/inconclusive NIPT results
l rates of women who receive NIPT and/or antenatal anti-D prophylaxis
l number of sensitisations
l number of adverse effects on fetuses in subsequent pregnancies.
Data were extracted from the diagnostic accuracy review, existing systematic reviews of antenatal anti-D
prophylaxis and other primary sources, when necessary.
We considered the following clinical scenarios:
l no antenatal anti-D and postpartum anti-D based on cord blood serology only (control)
l antenatal anti-D offered to all RhD-negative women (current practice)
l antenatal anti-D offered based on NIPT and postpartum anti-D based on cord blood test for all
RhD-negative women
l antenatal and postpartum anti-D offered based on NIPT only. No cord blood testing.
Scenario 3 is equivalent (in clinical outcomes) to performing cord blood testing on women with negative
NIPT but offering postpartum anti-D to all test-positive women without cord blood testing. Scenario 4 is
equivalent (in clinical outcomes) to withdrawing cord blood testing and postpartum anti-D for women with
negative NIPT but offering cord blood testing and postpartum anti-D (if needed) to all test-positive women.
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A Monte Carlo simulation of 10 million women was performed in R. Monte Carlo analysis is a modelling
method that uses random number generation to simulate the running of multiple scenarios to define all
potential outcomes of an event. We compared the amount of antenatal anti-D prescribed, the level of
unnecessary anti-D use and the relative numbers of sensitisations and other adverse outcomes for
each scenario.
Clinical effectiveness results
This chapter is structured as follows. The next section provides information on the quantity of research
available, including characteristics and risk of bias of the included studies. This is then followed by the
results sections with diagnostic accuracy, clinical effectiveness and implementation of high-throughput
NIPT presented separately.
Quantity and quality of research available
Number of studies included
The literature searches of bibliographic databases identified 3921 references. After initial screening of
titles and abstracts, 227 were considered to be potentially relevant and were ordered for full-text paper
screening. In total, eight studies12,17–23 were included in the diagnostic review of high-throughput NIPT,
seven studies18,20,22,24–27 were included in the clinical effectiveness review and 12 studies13,17,18,20–28 were
included in the review of implementation of high-throughput NIPT (with some overlap between studies).
Figure 1 shows a flow diagram outlining the screening process with reasons for exclusion of full-text
papers.
All studies except two8,28 were cohort studies. Most cohorts were reported in several papers and abstracts,
with considerable overlaps in data and reporting. For each cohort and each review we selected the paper
with the most up-to-date and complete data. Consequently, some papers were included in more than
one review and some papers (mostly conference abstracts with limited or outdated data) were not
Records identified through
database searching
(after deduplication)
(n = 3828) Unique records identified through
other sources (guidelines, trials,
systematic review registers,
websites)
(n = 93)
Full-text articles assessed for
eligibility
(n = 227)
Full-text articles excluded
(n = 182)
Reasons
• Not high-throughput NIPT, n = 123
• Ineligible population, n = 10
• Insufficient outcome data, n = 17
• Ineligible reference standard, n = 3
• Ineligible study design, n = 29
Records excluded
(n = 3694)
Studies included in the review
(from 45 reports)
(n = 14)
• Diagnostics, n = 8
• Effectiveness, n = 7
• Implementation, n = 12
Records identified
(n = 3921)
Records screened
(n = 3921)
FIGURE 1 Flow diagram: study selection process.
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included in any analysis. Table 1 presents an overview of these cohort studies, the publications associated
with each cohort and in which review the publications were included. Appendix 2 presents a list of all
included references.
Excluded studies
A list of full-text papers that were excluded, along with the reasons for their exclusion, is given in
Appendix 3. These papers were excluded because they failed to meet one or more of the inclusion criteria
in terms of the type of study, participants, test, reference standard or outcomes reported.
Results: assessment of diagnostic accuracy
Characteristics of the included studies
Table 2 presents the summary information of characteristics of the included diagnostic accuracy studies.
There were eight studies12,17–23 for the diagnostic review. All the studies were prospective studies and were
conducted in European countries. Four studies were conducted in England,12,17–19 three of which were
based in Bristol.12,17,18
The sample size (number of patients/samples analysed) of studies ranged from 282 to 18,383. Most
studies recruited pregnant women with a median gestational age of 10–28 weeks. Most participants were
of white European ethnicity. All studies used maternal plasma as their sample source. A robotic DNA
extraction instrument was employed in all studies. The studies used a number of robotic platforms such as
MDx BioRobot (Qiagen, Crawley, UK), MagNa Pure 96 (Roche Ltd, Rotkreuz, Switzerland), MagNA Pure
LC (Roche Ltd, Rotkreuz, Switzerland) and COBAS® AmpliPrep (Roche Ltd, Rotkreuz, Switzerland). For PCR,
all studies targeted at least two exons (generally exons 5 and 7) and used at least two controls for RHD
assay (RhD-positive DNA and RhD-negative DNA) except for the study by Wikman et al.,23 which targeted
only exon 4 and used glyceraldehyde 3-phosphate dehydrogenase (GAPDH) DNA as a control. The
reference standard used in all studies was cord blood serology, except for Akolekar et al.,19 which did not
describe the reference standard. Inconclusive results were reported in all but two studies.21,22 Appendix 4
presents further details of included studies.
Risk of bias of the included studies
Each of the eight full-text papers was assessed for risk of bias using a modified version of the QUADAS-2
tool containing 14 items. Table 3 presents a summary of the results for the risk of bias across all studies in
the four main domains: patient selection, index test, reference standard, and flow and timing. Appendix 5
presents results of quality assessment for the individual studies. Despite some gaps in reporting, most studies
were considered to have a low risk of bias for these four domains. NIPT as an automated procedure was
deemed to have a limited risk of human error, and multiple controls were used for RHD assays in all studies
except one.23 Cord blood serology was the reference standard in all studies. The index test of NIPT was
conducted independently of the reference standard and the results of one were considered unlikely to
influence the results of the other, so the risk of incorporation bias was considered low.
It appears that most studies prospectively recruited consecutive samples from clinical practice. Only three
studies stated that multiple pregnancies were included.17,22,23
Multiple pregnancies can pose specific challenges for NIPT (e.g. twin fetuses may have discordant RhD
status). Excluding them from the analyses may have introduced patient selection bias, although it was
deemed unlikely that this bias would substantially affect diagnostic accuracy estimates. Only three studies
stated that their diagnostic threshold was prespecified during the conduct of the screening programme.12,17,20
None of the studies reported whether or not there were any adverse events from the index test or
reference standard.
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TABLE 1 Overview of included cohorts and studies
Cohort
(country)
Number of
full-text
papers
Number of
conference
abstracts
Papers included in review
Diagnostic accuracy
(full-text paper)
Clinical effectiveness
(full-text paper)
Implementation (full-text
paper) Linked conference abstracts
UK (Bristol) 3 6 Chitty et al., 2014;12
Finning et al., 2008;17 and
Soothill et al., 201518
Soothill et al., 201518 Finning et al., 2008;17
and Soothill et al., 201518
Chitty et al., 2011;29 Chitty et al., 2012;30
Daniels et al., 2012;31 Finning et al.,
2015;32 Finning et al., 2014;33 and Ford
and Soothill, 201634
UK (London) 2 0 Akolekar et al., 201119 None Oxenford et al., 201328 None
Denmark 4 5 Banch Clausen et al.,
201420
Banch Clausen et al.,
2014;20 Banch Clausen
et al., 2012;24 and
Damkjaer et al., 201227
Banch Clausen et al., 2014;20
Banch Clausen et al., 2012;24
Clausen et al., 2013;13 and
Damkjaer et al., 201227
Banch Clausen 2012;35,36 Dziegiel 2012;37
Banch Clausen et al., 2011;38 and
Steffensen et al., 201239
The
Netherlands
2 10 Thurik et al., 201521 de Haas et al., 201225 de Haas et al., 2012;25
and Thurik et al., 201521
Veldhuisen et al., 2014;40 Veldhuisen
et al., 2013;41 Thurik et al., 2014;42,43
Scheffer et al., 2013;44 van der Schoot
et al., 2005;45 de Haas et al., 2012;46
de Haas et al., 2013;47 Grootkerk-Tax
et al., 2006;48 and van der Ploeg et al.,
201549
Spain 1 0 Grande et al., 201322 Grande et al., 201322 Grande et al., 201322 None
Sweden 2 10 Wikman et al., 201223 Tiblad et al., 201326 Wikman et al., 2012;23
and Tiblad et al., 201326
Wikman et al., 2012;50 Wikman et al.,
2011;51 Wikman 2013;52 Wikman et al.,
2010;53 Tiblad et al., 2010;54 Tiblad et al.,
2012;55 Neovius et al., 2014;56 Tiblad
2012;57 and Neovius et al., 201658
Total 8 7 12 31
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TABLE 2 Characteristics of the diagnostic accuracy studies
Study Location DNA extraction tool
Gestational age
(weeks) at time of
NIPT, median (range)
Sample
sizea
RhD-positive
fetuses
RhD-negative
fetuses
Inconclusive
test results
Akolekar et al.,
201119
UK (London) MDx BioRobot (Qiagen, Crawley, UK) 12.4 (11–14) 586 410 176 84
Banch Clausen
et al., 201420
Denmark QIAsymphony SP (Qiagen, Hilden, Germany);
MagNA Pure LC (Roche Ltd, Rotkreuz, Switzerland);
MagNA Pure Compact Instrument (Roche Ltd,
Rotkreuz, Switzerland)
25 (23–28) 12,668 7830 4838 274
Chitty et al.,
201412
UK (Bristol) MDx BioRobot (Qiagen, Crawley, UK) 19 (5–35) 4913 2890 2023 393
Finning et al.,
200817
UK (Bristol) MDx BioRobot (Qiagen, Crawley, UK) 28 (8–38) 1869 1156 713 64
Grande et al.,
201322
Spain COBAS® AmpliPrep (Roche Ltd, Rotkreuz,
Switzerland)
24–26 282 186 96 NR
Soothill et al.,
201518
UK (Bristol) MDx BioRobot (Qiagen, Crawley, UK) 15–17 (mostly) 499b 315 184 61
Thurik et al.,
201521
The
Netherlands
MagNa Pure 96 (Roche Ltd, Rotkreuz, Switzerland) 26 18,383b 11,283 7100 NR
Wikman et al.,
201223
Sweden MagNA Pure LC (Roche Ltd, Rotkreuz, Switzerland) 8–40 3291c 2073 1218 13
NR, not reported.
a Number of blood samples unless otherwise specified.
b Number of participants.
c Excludes pre 8 weeks’ gestation pregnancies.
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Two studies19,21 were judged as having a high risk of bias. Akolekar et al.19 stated that the targeted RhD-negative
women were selected from a database; however, it was unclear whether or not this selection was performed on
a random basis. The study recruited a large proportion of people with African ethnicity (19.3%), and so it may
not be representative of the general population of pregnant women in the UK. This, combined with the fact
that RHD variant analyses were not performed, may have contributed to the larger than average proportion of
inconclusive results (15%). Akolekar et al.19 excluded inconclusive results from their analyses, thereby potentially
inflating their diagnostic accuracy estimates. Characteristics of the reference standard were also poorly reported.
Thurik et al.21 excluded multiple pregnancies from their analysis and only 80% of participants received a
reference standard. Reasons why cord blood serology was not performed in a significant proportion of the
study population were not reported. The study also stated that their prediction algorithm was judged daily
and adjusted as needed, and it was likely that this introduced bias in the diagnostic accuracy estimates
(the authors reported the estimated impact of these changes on their diagnostic accuracy results).
The results of the studies were considered broadly applicable to the use of high-throughput NIPT for
nationwide screening purposes in the UK, except for two studies.19,23 The test used by Wikman et al.23
targeted only exon 4, unlike all other included studies, which targeted at least two exons (5, 7 and/or 10).
It is generally advocated that a combination of exons 5 and 7 is targeted to discriminate the pseudogene
RHDφ, which is particularly present in individuals of African origin.6,59 In addition, most participants in
Wikman et al.23 received NIPT in the first trimester of pregnancy. There is evidence to suggest that NIPT is
less accurate before around 11 weeks’ gestation. These potential issues may have negatively affected the
diagnostic accuracy of the test. Although it was a UK study, Akolekar et al.19 recruited a significantly
higher proportion of patients with African ethnicity (19.3%) than the population of pregnant women in
the UK (3%).60 As patients with black African ethnicity may be harder to diagnose, because of the high
prevalence of RHDφ in this population, this may limit the applicability of the study’s findings to the UK
population of pregnant women.
Overall, the majority of included studies were judged as having a low risk of bias, but two studies,
Akolekar et al.19 and Thurik et al.,21 were judged as having a high risk of bias.
Meta-analyses of diagnostic accuracy
This section presents the results of the meta-analyses of the diagnostic accuracy studies. One key issue
when considering the diagnostic accuracy of NIPT is how women with inconclusive test results are
handled. It is expected that, in the UK, such women will be treated as having a positive test with no
TABLE 3 Risk of bias and applicability of findings of included studies
Study
Risk of bias Applicability concerns
Patient
selection
Index
test
Reference
standard
Flow and
timing
Patient
selection
Index
test
Reference
standard
Akolekar et al., 201119 High High Unclear Unclear High Low Unclear
Banch Clausen et al., 201420 Low Low Low Low Unclear Low Low
Chitty et al., 201412 Low Low Low Low Low Low Low
Finning et al., 200817 Low Low Low Low Low Low Low
Grande et al., 201322 Low Low Low Low Low Low Low
Soothill et al., 201518 Low Unclear Low Low Low Low Low
Thurik et al., 201521 Low High Low High Low Low Low
Wikman et al., 201223 Low Low Low Low Unclear High Low
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further testing. Although this was the policy in the three high-quality studies performed in Bristol, data on
inconclusive tests were not reported in two studies.21,22
Given these differences we considered four approaches to the diagnostic analysis:
1. women with inconclusive tests treated as test positive (including Thurik et al.21 and Grande et al.22 studies)
2. women with inconclusive tests treated as test positive (excluding Thurik et al.21 and Grande et al.22 studies)
3. excluding all women with inconclusive test results
4. studies conducted in Bristol only.12,17,18
This last analysis is likely to represent the most plausible results for UK practice, assuming that the methods
used in Bristol are retained nationwide.
In all analyses, women whose NIPT was conducted at or before 11 weeks’ gestation were excluded when
possible because of concerns that the diagnostic accuracy is poorer before 11 weeks and that the test
should not be conducted before then (see Subgroup analyses). Some tests were performed between 8 and
11 weeks’ gestation in two studies,17,23 most women were tested between 8 and 12 weeks’ gestation in
Wikman et al.23 and < 8% of tests were performed before 11 weeks in Finning et al.,12 but it was not
possible to remove those women from the analysis.
In diagnostic analyses it is conventional to report results in terms of sensitivity (women who correctly test
positive) and specificity (women who correctly test negative). NIPT is highly accurate and the focus should
be on women with an incorrect test result, so in these analyses results are presented in terms of the FPRs
(women incorrectly testing positive and so offered unnecessary anti-D) and FNRs (women incorrectly
testing negative and so at risk of sensitisation, as they do not receive anti-D treatment).
A summary of all the results of the bivariate meta-analyses of FPRs and FNRs is presented in Table 4.
It can be seen that results are broadly consistent across the four scenarios. NIPT is very accurate among
women with a RhD-positive fetus: only 2–4 in 1000 of such women will have a negative test result and so
be at risk of sensitisation as a result of not being offered anti-D. NIPT is slightly less accurate among
women with a RhD-negative fetus: between 1.3% and 5.7% of such women will test positive (depending
on the analysis performed) and so may be offered NIPT unnecessarily. If women with inconclusive test
results are excluded from analyses, the FPR was 1.3%, rising to 3.9–4.4% if women with inconclusive test
results are treated as having tested positive. This suggests that the main cause of test error is treating
women with an inconclusive NIPT result as if they had tested positive.
Assuming that 60% of RhD-negative women have a RhD-positive fetus, about 0.5% of women have a
conclusive, but incorrect, positive test result. About 0.1–0.2% of women have a false-negative test result.
We consider the results of each analysis in more detail in the following sections.
TABLE 4 Bivariate meta-analyses of FPRs and FNRs
Analysis case
Number
of studies
FNR (at risk of sensitisation) FPR (unnecessary anti-D)
Estimate (%) 95% CI Estimate (%) 95% CI
Inconclusive tests treated as test positive
(including Thurik et al.21 and Grande et al.22)
8 0.34 0.15 to 0.76 3.86 2.54 to 5.82
Inconclusive tests treated as test positive
(excluding Thurik et al.21 and Grande et al.22)
6 0.38 0.15 to 0.94 4.37 2.79 to 6.78
Excluding all women with inconclusive test
results
8 0.35 0.15 to 0.82 1.26 0.87 to 1.83
Studies conducted in Bristol only 3 0.21 0.09 to 0.48 5.73 4.58 to 7.16
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Considering inconclusive results as test positive
Figure 2 shows forest plots of FNRs and FPRs when counting an inconclusive test result as being test
positive. The results of these figures are slightly different from those in Table 4, because the figure shows
separate analyses of FPR and FNR, rather than a full bivariate analysis.
There was some evidence of inconsistency across studies. The I2-statistic for heterogeneity was 75% for the
FNR and 99% for the FPR. It should be noted that these high heterogeneities are, in part, a consequence
of the high accuracy of the test and the large size of the studies (and consequent small within-study
variance, because I2 increases as the average within-study variance declines). They do not necessarily
0 1 2 3 4
FNR (%)
Estimates with 95% CI
Finning 200817
Akolekar 201119
Wikman 201223
Grande 201322
Banch Clausen 201420
Chitty 201412
Soothill 201518
Thurik 201521
Pooled
Study
0.26 (0.09 to 0.76)
1.46 (0.67 to 3.16)
1.11 (0.74 to 1.66)
0.27 (0.03 to 2.51)
0.14 (0.08 to 0.25)
0.13 (0.04 to 0.37)
0.32 (0.06 to 1.78)
0.08 (0.04 to 0.15)
0.23 (0.08 to 0.37)
FNR (95% CI)
(a)
0 2 64 108 12
FPR (%)
Estimates with 95% CI
Finning 200817
Akolekar 201119
Wikman 201223
Grande 201322
Banch Clausen 201420
Chitty 201412
Soothill 201518
Thurik 201521
Pooled
Study
6.03 (4.51 to 8.03)
6.82 (3.94 to 11.54)
1.81 (1.20 to 2.72)
1.55 (0.36 to 6.43)
2.73 (2.31 to 3.23)
4.98 (4.04 to 6.13)
7.61 (4.59 to 12.37)
2.21 (1.89 to 2.58)
3.57 (2.61 to 4.53)
FPR (95% CI)
(b)
FIGURE 2 Forest plots of (a) FNR and (b) FPR when counting an inconclusive test result as being test positive.
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indicate any clinically meaningful differences between studies. The heterogeneity in FPRs is likely to be a
consequence of differing reporting and handling of inconclusive tests.
Figure 3 shows the results of each study, the results of the bivariate analysis (black circle) and the summary
HSROC curve (black curve) for this analysis. As for other analyses, this is presented in terms of FPR and FNR
rather than sensitivity and specificity. This plot shows the consistency of false-negative results, except for
two outlying studies.19,23 The Wikman et al.23 study performed most NIPT in the first trimester, earlier than
other studies. As discussed later (see Subgroup analyses), the timing of NIPT may have an impact on the
FNR. The studies are less consistent in FPRs. This is most probably because the studies have different
numbers of inconclusive test results and different methods of handling such results. As women with an
inconclusive result are treated as RhD positive, women with an inconclusive result but a RhD-negative fetus
will have a false-positive result. There may also be some heterogeneity because of differences in the
threshold used and how different testing machines operated.
When excluding the two studies that did not report numbers of inconclusive tests,21,22 the results were
broadly similar, as seen in Table 4. The forest plots of FPR and FNR for this analysis are given in Appendix 6.
Excluding inconclusive results
We considered the diagnostic accuracy of NIPT, excluding all inconclusive test results, to identify the
‘optimal’ diagnostic accuracy in which a test result is obtained for every woman. This analysis excluded
women who were difficult to diagnose, so it may overestimate diagnostic accuracy. Forest plots for FNR
and FPR are shown in Figure 4.
Excluding women with inconclusive test results has no meaningful impact on false-negative results (as those
women are always assumed to have a positive result). It does, however, considerably reduce the FPR. The
FPR, at 1.2%, is low but still considerably higher than the FNR. This suggests that NIPT is more accurate in
20
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FIGURE 3 Hierarchical summary receiver operating characteristic and bivariate analysis when counting an
inconclusive test result as being RhD positive.
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women with a RhD-positive fetus than in those with a RhD-negative fetus. There was some evidence of
heterogeneity across studies. The I2-statistic for heterogeneity was 75% for the FNR and 99% for the FPR.
The ROC plot with bivariate and HSROC analyses is given in Appendix 6.
Bristol studies
We performed a subgroup meta-analysis of only the high-quality studies based in Bristol12,17,18 in order to
assess the most likely performance of NIPT in the UK. We excluded the study by Akolekar et al.19 (based in
London but with NIPT run in Bristol) from this analysis on the grounds of it having a high risk of bias, as it
was not primarily intended to assess NIPT screening and because of the limited applicability of recruited
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FIGURE 4 Forest plots of (a) FNR and (b) FPR excluding women with inconclusive test results.
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participants. A higher proportion of people with African ethnicity (19.3%) in this study means that it may
not be representative of the general population of pregnant women in the UK.
In this analysis, women with an inconclusive test result were treated as having a positive result, in line with
the practice in the studies.
As observed in Table 4 and Figure 5, the three Bristol studies have a slightly lower FNR and a higher FPR
than other studies. This suggests that the Bristol high-throughput NIPT approach in which the MDx Bio
Robot machine is used may be using a different test threshold from other countries, which further
minimises false-negative findings, with a consequent increase in the FPR. This may explain some of the
heterogeneity observed in previous analyses.
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FIGURE 5 Forest plots of (a) FNR and (b) FPR for the Bristol studies.
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If inconclusive tests results were excluded from the Bristol studies, the summary FNR was 0.263% (95% CI
0.13% to 0.56%) and the FPR was 1.474% (95% CI 0.82% to 2.63%). This confirms that most
false-positive results arise from treating women with an inconclusive test result as being test positive.
Inconclusive test results
As seen in Table 4, treating women with inconclusive test results as if they had a positive test has a
substantial impact on diagnostic accuracy. Knowing the incidence of inconclusive test results is therefore
important when determining diagnostic accuracy. Table 5 summarises the rates of and reasons for
inconclusive test results across included studies. When reported, the most common reasons for
inconclusive results were the presence of a maternal/fetal RHD variant.
These results show that there is considerable variation in the rates of inconclusive tests across studies. The
most likely cause for this variability is differences in how NIPT was conducted (e.g. different numbers and
types of exons considered). However, even in the studies in which tests were conducted in Bristol using the
same test, there is considerable unexplained variation. Differences in the characteristics of study populations
(e.g. different proportions of people of black African ethnicity) may also explain some of this variation.
TABLE 5 Inconclusive test results in the included studies
Study Location
RhD-positive
fetuses (%)
Inconclusive
test results (%)
RhD-positive
fetuses in
women with
inconclusive
test results (%)
Reported reasons for
inconclusive results (number
of cases)
Akolekar et al.,
201119
UK
(London)
70.0 14.3 85.7 Insufficient DNA (n= 5); RHD
variant (n= 44); NR (n= 40)
Banch Clausen
et al., 201420
Denmark 61.8 2.2 66.8 Maternal weak D (n= 93);
maternal silent RHD variant
(n= 38); high level of maternal
background DNA (n= 29);
technical problems (n= 19);
maternal DVI (n= 14); weak
PCR signal (n= 13); suspected
maternal RHD positive (n= 3);
no reported cause (n= 65)
Chitty et al.,
201412
UK (Bristol) 58.8 7.0 76.6 NR
Finning et al.,
200817
UK (Bristol) 61.9 3.4 54.7 Insufficient DNA (n= 30);
suspected maternal RHD gene
(n= 25); failure to extract DNA
from plasma (n = 1)
Grande et al.,
201322
Spain 66.0 NR NR NR
Soothill et al.,
201518
UK (Bristol) 63.1 12.2 77.0 NR
Thurik et al.,
201521
The
Netherlands
61.4 NR NR Maternal RHD variant (n = 55);
fetal variant (n= 45); weak
PCR signals (n= 70); incorrect
blood sample (n= 11)
Wikman et al.,
201223
Sweden 63.0 0.4 38.5 RHD variant (n= 14); no
second sample (n= 18, of
which 13 were spontaneous
abortions and miscarriages)
NR, not reported.
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We performed a meta-analysis to estimate average rates of inconclusive test results. The results of this
analysis are shown in Table 6. Based on these results, we would estimate that 6.7% of women in the UK
would have an inconclusive test result, but this is subject to considerable uncertainty.
Table 5 also shows that, in general, most women with an inconclusive test result have a RhD-positive fetus
(and it is more common than in the general population) and so treating all women with inconclusive test
results is reasonable, if no further testing is possible. However, there are still many women with a
RhD-negative fetus who would receive anti-D unnecessarily.
Subgroup analyses
We considered the effect of the timing of NIPT on its diagnostic accuracy. Figure 6 shows the FNRs plotted
by gestational age at time of high-throughput NIPT. It suggests that FNRs after 11 weeks’ gestation were
consistent, irrespective of timing, but that FNRs were higher before 11 weeks’ gestation. Figure 7 shows
the FPRs plotted by gestational age at time of high-throughput NIPT. There was no obvious pattern from
this figure. Only one study12 examined test performance at multiple time points. Figure 8 shows the FPRs
and FNRs at different times for this study. It indicates that FNRs were higher before 11 weeks’ gestation
and were generally stable after 11 weeks’ gestation. We did not perform any formal statistical analyses on
the timing data (such as a metaregression) because the relationship appears to be a step change in
accuracy, rather than a linear trend over time. These results together suggest that NIPT is insufficiently
accurate before around 11 weeks’ gestation (i.e. in first trimester) but is accurate at any time after the end
of the first trimester.
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FIGURE 6 False-negative rate by gestational age at time of NIPT.
TABLE 6 Meta-analyses of inconclusive results
Studies included Estimated inconclusive rate (%) 95% CI (%)
All reporting inconclusive tests 4.0 1.5 to 10.3
Bristol studies12,17,18 only 6.7 3.7 to 11.7
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We also considered the impact of the timing of high-throughput NIPT on the number of inconclusive test
results (Figure 9). Despite the data from Wikman et al.23 being heterogeneous, there appears to be a trend
that the percentage of inconclusive results for this test reduces as the gestational age increases from
11 weeks. This is most obvious in the Chitty et al.12 study, which reported numbers of inconclusive tests
at different times.
We were unable to conduct any subgroup analysis based on ethnicity, as the relevant data were not
reported in any publication. As all studies were conducted in Europe, numbers of participants of non-white
ethnicity were few. Any diagnostic analysis of non-white ethnicities may therefore not give reliable results.
Because each country used a different machine to perform NIPT, a subgroup analysis by type of NIPT
method was not feasible, as it would be confounded by study location. We have considered a subgroup
analysis including the Bristol-based studies only, as reported in Meta-analyses of diagnostic accuracy.
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FIGURE 7 False-positive rate by gestational age at time of NIPT.
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FIGURE 8 False-negative rate against FPR for Chitty et al.12 study.
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Sensitivity analyses
We performed two post hoc SAs. The first excluded the two studies considered to have a risk of bias19,21
and the second excluded the Wikman et al.23 study, as this included a substantial number of women with
NIPT performed before 11 weeks’ gestation. Bivariate meta-analyses as in Table 4 were performed
excluding these studies. The results are presented in Appendix 6.
Excluding the two studies that were considered to have high risk of bias had limited impact on the FPRs
and FNRs and does not alter any conclusions. Excluding the Wikman et al.23 study marginally reduced the
FNRs, which is consistent with the finding that the FNR is higher before 11 weeks’ gestation. It also slightly
increased the FPR when counting inconclusive test results as positive. This is because there were few
inconclusive tests in the Wikman et al. study (see Table 5). None of the SAs meaningfully alters any of the
conclusions of these meta-analyses.
Results: assessment of clinical effectiveness
Characteristics of the included studies
Table 7 presents a summary of the characteristics of the seven studies included in the review of clinical
effectiveness studies. All studies were observational and conducted in European countries, including
Denmark, the Netherlands, Spain, the UK and Sweden. The sample size of studies ranged from 284 to
15,126. All participants were RhD-negative pregnant women and most participants were white European.
Most studies recruited women with a gestational age median of 10–26 weeks. Three studies reported
using routine antenatal anti-D prophylaxis (RAADP) at between 28 and 30 weeks.
Only two studies compared women receiving NIPT to controls.20,26 One study26 compared patients
undergoing NIPT with routine management with no NIPT and routine postnatal anti-D prophylaxis only
(historical control). The other comparative study20 reported data on anti-D compliance in a small subgroup
of participants from one region in Denmark, comparing participants receiving NIPT with those receiving
no NIPT.
Risk of bias of the included studies
The results of the quality assessment of the two comparative studies are given in Appendix 7. In summary,
both studies had significant limitations. Tiblad et al.26 was considered as having a serious risk of bias,
primarily owing to concerns about patient selection, confounding and missing data. Banch Clausen et al.20
was considered as having a critical risk of bias across all outcomes because of concerns about patient
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FIGURE 9 Inconclusive results by test timing.
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TABLE 7 Characteristics of effectiveness studies
Study Location Study dates
Sample
sizea
Gestational
age at time of
NIPT (weeks)
Routine antenatal
anti-D prophylaxis Comparator
Banch Clausen et al., 201420 Denmark: one region January–June 2010 591 Median 25 250–300 µg at 29 weeks Postnatal anti-D only
(n= 109)
Banch Clausen et al., 201224 Denmark: nationwide January–June 2010 2312 Median 25 250–300 µg at 29 weeks None
Damkjaer et al., 201227 Denmark: one hospital June–September 2010 239 Mean 27 250–300 µg at 29 weeks None
de Haas et al., 201225 The Netherlands: nationwide July 2011–January 2012 15,126b Mean 26 250 µg at 30 weeks and
after birth
None
Grande et al., 201322 Spain: Barcelona February 2010–October 2011 284 Range 24–26 NR None
Soothill et al., 201518 England: three NHS trusts in
south-west England
April–September 2013 529 Range 15–26 500 or 1500 µg (timing
NR)
None
Tiblad et al., 201326 Sweden: Stockholm area September 2009–March 2012
(reference cohort: 2004–8)
8347c Median 10
(range 3–40)
250–300 µg at
28–30 weeks
Postnatal anti-D only
(historical control)
(n= 18,546)
NR, not reported.
a Number of blood samples undergoing NIPT unless otherwise specified.
b Number of participants undergoing NIPT.
c Number of pregnancies undergoing NIPT.
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selection and lack of adjustment for potential confounders. The generalisability of these two studies to the
UK context was limited given that participants in the control group did not receive RAADP.
The remaining five studies reported non-comparative effectiveness data for women receiving NIPT only.
We did not perform a formal quality assessment of these studies for clinical effectiveness, as we
considered the evidence from non-controlled studies to be of poor quality.
Results of studies on clinical effectiveness
Studies reported various clinical effectiveness outcomes, including sensitisation rate, NIPT uptake, rates
of women receiving antenatal and postpartum anti-D prophylaxis and number of women avoiding
unnecessary anti-D immunoglobulin use. We performed a narrative synthesis owing to the considerable
heterogeneity in outcomes and study designs.
Sensitisations
One study reported data on the incidence of sensitisation (defined as having developed anti-D antibodies
after the first trimester) and haemolytic disease of the newborn infant. Tiblad et al.26 compared targeted
routine antenatal anti-D in the first trimester with routine care (postnatal anti-D only, historical control) in
the Stockholm region, Sweden. The study reported that the incidence of RhD sensitisation in the cohort
that underwent high-throughput NIPT was 0.26% (95% CI 0.15% to 0.36%, n = 8347), compared with
0.46% (95% CI 0.37% to 0.56%, n = 18,546) in the historical control cohort. The absolute risk difference
in the incidence of sensitisation was 0.20%. The high-throughput NIPT for targeted antenatal anti-D was
associated with a significant risk reduction in sensitisation (unadjusted RR 0.55, 95% CI 0.35 to 0.87)
compared with historical controls. An updated analysis by Neovius et al.58 found an adjusted odds ratio of
0.41 (95% CI 0.22 to 0.87). In addition, this study reported one case of severe haemolytic disease
diagnosed soon after birth in a nulliparous mother who did not receive routine anti-D prophylaxis.
Non-invasive prenatal testing uptake
Rates of NIPT uptake are presented in Table 8. Seven studies reported on uptake rates of NIPT
screening.18,20,22,25–27 Uptake rates ranged from 70% to > 95% across the studies. In the pilot study
conducted by Soothill et al.18 in three maternity services in the south west of England, only 70% of eligible
women joined the study in the initial 6 months. The larger English study conducted by Chitty et al.12
reported that 88% of the 3069 participants consented to receive RHD genotyping. The only country that
reported nationwide NIPT screening uptake data was the Netherlands, where > 95% of eligible women
underwent fetal RHD genotyping. The studies generally noted that uptake is likely to increase over time if
a nationwide screening programme is implemented.
TABLE 8 Uptake of NIPT
Study Country Rates of NIPT uptake, % (n/N)
Banch Clausen et al., 201420 Denmark 84.2 (581/690)
Chitty et al., 201412 England 88 (372/3069)
Damkjaer et al., 201227 Denmark 90 (215/239)
de Haas et al., 201225 The Netherlands > 95 (15,126/approximately 15,750)
Grande et al., 201322 Spain 94 (284/302)
Soothill et al., 201518 England 70 (approximately) (numbers not reported)
Tiblad et al., 201326 Sweden 89 (8374/9380)
DOI: 10.3310/hta22130 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 13
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Saramago et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
27
Antenatal anti-D prophylaxis uptake
Rates of women receiving antenatal anti-D uptake according to NIPT uptake are presented in Table 9. Four
studies reported uptake rates of RAADP in women who accepted NIPT and received a positive result, ranging
from 86% to 96.1%.20,26,27,49 One study reported nationwide data in women receiving RhD genotyping in
the Netherlands, where 96.1% of approximately 18,383 women received antenatal prophylaxis anti-D.
TABLE 9 Uptake routine antenatal and postpartum anti-D prophylaxis according to NIPT uptake
RAADP % (n/N) Source Country
1. Uptake of RAADP with no
NIPT (current practice)
99 (n= 5276) receiving at least
one injection; 87.5% (n= 5276)
receiving the correct dose at the
correct time; 90%a (NR/5276)
receiving all injections at correct
doses
bUK anti-D audit8 UK
100 (10/10) Soothill et al., 201518 England
2. Uptake of RAADP in those
who refuse NIPT
0 (0/23) Damkjaer et al., 201227 Denmark
80 (4/5) Soothill et al., 201518 England
3. Uptake of RAADP in those
who accept NIPT and receive a
positive result
93.2 (330/354) Banch Clausen et al., 201420 Denmark
86 (NR) Damkjaer et al., 201227 Denmark
90 (4590/5104) Tiblad et al., 201326 Sweden
96.1 (of approximately 18,383) van der Ploeg et al., 201549 The Netherlands
4. Uptake of RAADP in those
who accept NIPT and receive an
inconclusive result
100 (5/5) Soothill et al., 201518 England
5. Uptake of RAADP in those
who accept NIPT and receive a
negative result
6 (1/18) Soothill et al., 201518 England
5 (5/95) Grande et al., 201322 Spain
Postnatal routine anti-D uptake
6. Uptake of postnatal anti-D
with no testing
98.4 (91.6% had the correct dose
at the correct time) (NR/3392)
bUK anti-D audit8 UK
95.7 (66/69) Banch Clausen et al., 201420 Denmark
7. Uptake of postnatal anti-D in
those who refuse NIPT
> 99 (NR) Damkjaer et al., 201227 Denmark
8. Uptake of postnatal anti-D in
those who accept NIPT and
receive a positive result
99.7 (353/354) Banch Clausen et al., 201420 Denmark
99.3 (151/152) Damkjaer et al., 201227 Denmark
92 (of approximately 18,383) van der Ploeg et al., 201549 The Netherlands
9. Uptake of postnatal anti-D in
those who accept NIPT and
receive an inconclusive result
No data N/A N/A
10. Uptake of postnatal anti-D in
those who accept NIPT and
receive a negative result
0 (0/227) Banch Clausen et al., 201420 Denmark
0 (0/85) Damkjaer et al., 201227 Denmark
0.087 (2/NR) Banch Clausen et al., 201224 Denmark
0 (NR) Soothill et al., 201518 England
N/A, not applicable; NR, not reported.
a Full compliance (correct dose, correct time) with single-dose regime. A total of 99% received at least one dose.
b Although this study did not meet the selection criteria for this review (no NIPT), it is included here for informative
purposes.
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Tiblad et al.6 reported a slightly lower rate, with 90% of 5104 women with a positive NIPT result receiving
RAADP. Further data on uptake of RAADP in women who received a negative result (two studies),18,22 those
who received an inconclusive result (one study)18 and those who refused NIPT (two studies)18,27 were limited.
None of the included studies reported whether or not all women who received antenatal anti-D prophylaxis
received the intended dosage at the intended time, or what proportion of women received additional anti-D
owing to a potentially sensitising event.
Postpartum anti-D prophylaxis uptake
Rates of women receiving postpartum anti-D uptake according to NIPT uptake are presented in Table 9.
Three studies reported uptake of postnatal anti-D prophylaxis in women who accepted NIPT and received
a positive result, ranging from 92% to 99.7%.20,27,49 One study reported nationwide data in women
receiving RhD genotyping in the Netherlands, where 92% of approximately 18,383 women received
postnatal prophylaxis anti-D. A subgroup analysis by Banch Clausen et al.20 (including a total of 690
pregnancies) found a slightly higher uptake of postnatal anti-D among women who received NIPT (99.7%,
353/354) than in those who did not undergo NIPT (95.7%, 66/69). Another Danish study reported a
similar rate among women who received NIPT (99.3%, 151/152).27 None of the included studies reported
whether or not all women who received postpartum anti-D prophylaxis received the intended dosage at
the intended time.
Reduction in anti-D use
Three non-comparative studies reported outcome measures relating to anti-D doses administered.
Soothill et al.18 reported a significant 6% reduction per month of anti-D administration (95% CI 4% to 8%,
Poisson regression) within 6 months in the three maternity services in the south-west of England. The total
use of anti-D doses fell by about 29%, corresponding to 35% of RhD-negative women not receiving anti-D
in their pregnancy unnecessarily. Similar results were also observed in Banch Clausen et al. study,20 which
reported that, of 12,668 pregnant women, 4706 (37.1%) avoided unnecessary anti-D administration within
2 years of prenatal RHD screening programme. The study by Grande et al.22 reported that, of 95 women
carrying a RhD-negative fetus, five requested anti-D administration; unnecessary anti-D administration was
therefore avoided in 95% of women carrying a RhD-negative fetus.
Adverse events
None of the studies reported any data on adverse events of either NIPT or antenatal anti-D administration.
In particular, there were no data on adverse reactions (such as allergic reactions) to anti-D, on transmission
of blood-borne diseases, or on social consequences of NIPT (such as revealing false paternity). No studies
reported data on health-related quality of life and patients’ anxiety associated with NIPT.
Simulation study of clinical effectiveness
As seen in the review of clinical effectiveness (see Results: assessment of clinical effectiveness), very limited
comparative evidence on the clinical outcomes of NIPT has been reported. In order to better understand
the probable consequences of implementing NIPT, and basing anti-D administration on its results, we
performed a simulation study.
The parameters of this simulation study are drawn primarily from the systematic reviews of diagnostic
accuracy and clinical effectiveness. Prevalence and diagnostic accuracy parameters are derived from the
three high-quality Bristol-based studies12,17,18 whenever possible to best represent the UK population. Data
on compliance with NIPT and anti-D are drawn from a recent audit of antenatal anti-D administration in
the UK, or papers in the clinical effectiveness review, favouring UK-based results whenever available. Some
important parameters, such as incidence of sensitisation with and without anti-D, were not reported in any
papers included in the diagnostic accuracy or clinical effectiveness reviews. To inform other parameter
estimates for this simulation, we conducted an additional literature search to identify relevant systematic
reviews of antenatal anti-D prophylaxis. Four relevant reviews61–64 were identified. These reviews provided
data on the probability estimates of the events used in the simulation study, including sensitisation and
compliance rates. These reviews are summarised in Appendix 8.
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Table 10 summarises the parameter estimates used in the simulation and gives their source. All these
parameter estimates assume the current practice of offering antenatal anti-D at around 28 weeks and
offering postpartum anti-D on the basis of a cord blood test (assumed to be 100% accurate). We assume
that there are no adverse consequences of administering anti-D. We note that this simulation considers
only women who would be eligible for NIPT at the time it would be received. Women who might not
receive NIPT, for example because the father is confirmed as RhD negative, are excluded.
The simulation study assumes that these input probabilities are accurate and does not account for any
uncertainty in their estimation. Therefore, results of the simulation study should be considered illustrative
of the probable consequences of the use of NIPT and not definitive estimates of effect.
The results of the simulation study are summarised in Table 11. These results are subject to a Monte Carlo
error of approximately ± 0.002%.
These results show that using NIPT leads to a substantial reduction in antenatal anti-D prophylaxis use,
from 99% of RhD-positive women (i.e. assuming 99% compliance) to 65.9%. This decline is similar in
magnitude to that observed by Soothill et al.18 This is a consequence of the substantial drop in unnecessary
anti-D administration in women with RhD-negative fetuses, from 39% of women to 5.7%. Using the NIPT
approach means that about 1.2% of women miss out on potentially beneficial prophylaxis, mainly because
of non-compliance, compared with 0.6% with universal anti-D administration.
TABLE 10 Probability estimates, derived from published data, that were used in the simulation study
Probability Estimate (%) Source
RhD-positive fetus 60.7 Bristol-based diagnostic studies12,17,18
RhD-positive fetus (with inconclusive NIPT) 70.7 Bristol-based diagnostic studies12,17,18
False-negative NIPT 0.21 Diagnostic meta-analysis (of the Bristol studies)
Inconclusive NIPT 6.7 Bristol-based diagnostic studies12,17,18
False-positive test (if conclusive) 1.5 Diagnostic meta-analysis (of the Bristol studies)
Compliance with antenatal anti-D (without NIPT)
(received at least one dose of anti-D)
99 UK NHS Blood and Transplant, 2013 Audit of
Anti-D Immunoglobulin Prophylaxis8
Uptake of NIPT 96 de Haas et al., 201225 (clinical effectiveness review)
Compliance with postpartum anti-D 99 UK NHS Blood and Transplant, 2013 Audit of
Anti-D Immunoglobulin Prophylaxis8
Compliance with antenatal anti-D (if NIPT
refused or missed)
80 Soothill et al., 201518 (clinical effectiveness review)
Compliance with antenatal anti-D (if NIPT
inconclusive)
99 Soothill et al., 201518 (clinical effectiveness review)
Uptake of antenatal anti-D in women with
negative NIPT
6 Soothill et al., 201518 (clinical effectiveness review)
Compliance with postpartum anti-D after NIPT
process
99 No data, assumed same as without NIPT
Sensitisation with antenatal anti-D and
postpartum anti-D
0.35 Pilgrim et al., 200962 (HTA report)
Sensitisation with only postpartum anti-D 0.95 Pilgrim et al., 200962 (HTA report)
Sensitisation with no anti-D 10.7 Pilgrim et al., 200962 (HTA report) and Crowther
and Middleton65
Subsequent pregnancy in sensitised women 62 Used by Chitty et al., 2014,12 no source given
Death of RhD-negative fetus in sensitised women 5 Used by Chitty et al., 2014,12 no source given
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Because sensitisation is rare, very few additional women will be sensitised if NIPT is used. Assuming that all
women still receive a postnatal cord blood test and anti-D if required, NIPT will result in about three extra
sensitisations per 100,000 women. If cord blood testing is not performed, then there will be approximately
13 extra sensitisations per 100,000 women. These increases are small compared with the total number of
sensitisations attributable to failure of anti-D treatment (around 284 per 100,000 women) and compared
with not using antenatal anti-D at all (around 641 per 100,000).
The use of NIPT is unlikely to have any meaningful impact on mortality in subsequent pregnancies. Even if
postpartum anti-D is never given to women with a negative NIPT result, only approximately five extra
deaths will occur per 1 million RhD-negative women.
This simulation assumes that women who do not receive NIPT, for whatever reason, would still be offered,
and generally receive, antenatal anti-D. As a SA we consider the impact of a strategy of requiring NIPT as a
prerequisite to antenatal anti-D, or, equivalently, of assuming that women who do not comply with NIPT
would not comply with the whole antenatal anti-D immunisation process. These results are shown in
Table 12.
These results show that anti-D administration rates will be further reduced (to 62.7%) if women who do
not receive NIPT do not receive antenatal anti-D. The number of women who miss out on potentially
beneficial anti-D will rise to 3.2%. This means that there will be more sensitisations: an extra 15 per
100,000 women if postpartum cord blood testing continues or 28 per 100,000 if it is withdrawn.
This simulation study suggests that the use of NIPT to determine antenatal anti-D use will substantially
reduce the number of women receiving anti-D unnecessarily and so is likely to be beneficial, provided that
the cost of the test does not outweigh this saving. The use of NIPT could also reduce the use of anti-D
administration after potentially sensitising events during pregnancy, in women with a negative test result.
The additional number of sensitisations compared with a universal offering of antenatal anti-D is very
small, provided that care is taken to ensure that women who do not receive NIPT are still offered, and
receive, anti-D.
TABLE 11 Results of the simulation study
Outcome Treatment approach
Percentage
of women
Antenatal anti-D given Universal anti-D 99
Based on NIPT 65.9
Unnecessary anti-D given (RhD-negative
fetus)
Universal anti-D 38.9
Based on NIPT 5.7
Anti-D not given (RhD-positive fetus) Universal anti-D 0.6
Based on NIPT 1.2
Sensitised during or after pregnancy Postpartum/emergency anti-D only 0.641
Universal anti-D 0.281
Based on NIPT with postpartum anti-D 0.284
Based on NIPT with no postpartum anti-D for test negatives 0.294
Deaths in subsequent pregnancies Postpartum/emergency anti-D only 0.0198
Universal anti-D 0.0086
Based on NIPT with postpartum anti-D 0.0091
Based on NIPT with no postpartum anti-D for test negatives 0.0091
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The results suggest that if a woman receives a conclusive NIPT, then test cord blood testing could
potentially be withdrawn and postpartum prophylaxis offered on the basis of NIPT. This conclusion
depends on whether or not the increase in sensitisations (approximately 13 per 100,000 RhD-negative
women) is considered ethically acceptable and cost-effective.
Results: assessment of implementation
Characteristics of included studies
Table 13 presents a summary of the characteristics of the 12 studies13,17,18,20–28 included in the review of
implementation of high-throughput NIPT. Most of these were also included in the diagnostic accuracy
and/or clinical effectiveness reviews. These studies were conducted in five countries: Denmark, the UK,
Spain, the Netherlands and Sweden. Fetal RhD screening programmes were implemented nationally in the
Netherlands and Denmark and regionally in England, Sweden and Spain. Most included studies were large
cohort studies that reported implementation data as well as diagnostic accuracy data. One study was a
UK-based survey (London). The number of included women ranged from 282 to 18,383.
Results of implementation studies
Table 14 presents a summary of implementation data for high-throughput NIPT. All the large cohort
studies reported high diagnostic accuracy of high-throughput NIPT (see Meta-analyses of diagnostic
accuracy) and suggested that high-throughput RhD genotyping of fetuses in all RhD-negative women was
feasible. These studies reported high compliance with anti-D immunoglobulin administration and moderate
to high compliance with NIPT (see details in Results of studies on clinical effectiveness).
One UK study18 conducted in the south west of England stated that it is feasible to implement routine
cell-free fetal DNA fetal blood grouping in RhD-negative women in the NHS. This study also stated that the
requirements of patient information, patient consent, sample handling, sample transfer and implementation
of the changed management were all successfully met.
TABLE 12 Results of the simulation study assuming that women who do not receive NIPT are not offered anti-D
Outcome Treatment approach
Percentage
of women
Antenatal anti-D given Universal anti-D 99
Based on NIPT 62.7
Unnecessary anti-D given (RhD-negative
fetus)
Universal anti-D 38.9
Based on NIPT 4.5
Anti-D not given (RhD-positive fetus) Universal anti-D 0.6
Based on NIPT 3.2
Sensitised during or after pregnancy Postpartum/emergency anti-D only 0.641
Universal anti-D 0.281
Based on NIPT with postpartum anti-D 0.296
Based on NIPT with no postpartum anti-D for test negatives 0.309
Deaths in subsequent pregnancies Postpartum/emergency anti-D only 0.0198
Universal anti-D 0.0086
Based on NIPT with postpartum anti-D 0.0096
Based on NIPT with no postpartum anti-D for test negatives 0.0096
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A number of studies reported issues related to the implementation of prenatal RhD screening programmes.
For example, Banch Clausen et al.20 stated that the challenges to the implementation of the prenatal RhD
screening programme were related to programme anti-D prophylaxis compliance. Another study by Banch
Clausen et al.24 noted that there may be challenges in logistics concerning the transportation of samples
from remote sites to testing laboratories and in getting results back to the correct general practitioner.
The UK-based survey28 investigated 290 women’s preferences and information needs for routine
implementation of NIPT. A total of 92.1% women agreed that NIPT should be offered but only 75.9%
stated that they would accept the test. Women preferred having the test when it was most accurate, even if
later in pregnancy. The study revealed that women’s current knowledge of rhesus blood groups and anti-D
administration was limited, which could be a barrier to implementation. Although women may agree to
extra appointments for NIPT, health professionals recruited from one London hospital thought that this may
be impractical. The data from this survey showed that women hold positive views regarding the introduction
of routine fetal RhD genotyping using cell-free fetal DNA. Given women’s limited knowledge of rhesus
blood groups and anti-D administration, the authors stated that developing information leaflets and health
professional training will be critical for successful implementation. They stated that this work will be
important for the development of policies and guidelines on the introduction of fetal RhD genotyping into
routine care.
TABLE 13 Study characteristics of implementation studies
Study Location Study dates Sample sizea
Gestational age
(weeks) at time
of NIPT, median
(range)
Finning et al., 200817 England: Birmingham
and Sheffield centre of
the National Blood
Service
NR 1869 28 (8–38)
Soothill et al., 201518 England: south west,
three NHS trusts
April–September 2013 526 15–17 (mostly)
Oxenford et al.,
201328
England: four hospitals
(Birmingham, London,
Newcastle, Sunderland)
NR 289 (270 survey
respondents,
19 interviews/
focus groups)
> 12
Banch Clausen et al.,
2014;20 Banch
Clausen et al., 2012;24
Banch Clausen et al.,
2013;13 and Damkjaer
et al., 201227
Denmark: nationwide,
five regions
2010–11 14,547 25 (73% between
23 and 28)
de Haas et al.,
2012;25 Thurik et al.,
201521
The Netherlands:
nationwide
July 2011–January 2012 18,383b 26
Grande et al., 201322 Spain: Barcelona, six
maternity care units
February 2010–October 2011 282 24–26
Wikman et al.,
2012;23 and Tiblad
et al., 201326
Sweden: Stockholm,
83 maternity care
centres, six delivery
units
September 2009–March 2012
(reference cohort: 2004–8)
8374c 8–40
NR, not reported.
a Number of blood samples undergoing NIPT unless otherwise specified.
b Number of participants undergoing NIPT.
c Number of pregnancies undergoing NIPT.
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TABLE 14 Summary of implementation studies
Screening
programme
(country) Study
Details of screening
programme General results Issues to implementation Authors’ practical advice
Authors’ research
recommendation
Denmark Banch Clausen
et al., 201420
National programme
delivered in five regions in
Denmark
Very good screening accuracy
(see diagnostic review).
False-negative results were
mainly because of poor DNA
yields or handling errors.
False-positive results were a
result of contamination and
genetic variants. Inconclusive
results were because of weak D
genotypes. High compliance
with anti-D/moderate
compliance with NIPT (see
effectiveness review)
The challenges to implement
the prenatal RHD screening
programme are related to
programme anti-D prophylaxis
compliance
Implement external quality
assurance programmes as well
as regular in-house testing to
optimise effectiveness of the
screening programme
Postnatal prophylaxis should be
based exclusively on the result
from the prenatal RHD
screening. An increased effort to
improve anti-D prophylaxis
compliance is important to
further reduce the number of
RhD immunisations
Issuing focused statements to
GPs may avoid sending samples
from early pregnancy, which may
help reduce false-negative results
Increase information given
directly to pregnant women, GPs,
midwives and obstetricians and
systems, such as a reminder
system integrated into the GPs’
software, which may help to
increase women’s compliance
with the programme
None
Banch Clausen
et al., 201224
Earlier report on Danish
screening programme
As above There may be challenges in
the logistics concerning the
transportation of samples
from remote sites to testing
laboratories and in getting
results back to the correct GP
Cord blood typing continues to
ensure that postnatal anti-D is
given if NIPT compliance is poor.
RhD testing should be based on
a single sample
Long-term follow-up is
required to assess clinical
effects of NIPT screening
Clausen et al.,
201313
Paper focused on issues
around transportation of
blood samples in the
Danish screening
programme
Total DNA declines over time
from sampling. Fetal DNA was
not generally affected over time
from sampling
Not applicable. The paper did
not consider implementation
of the screening programme
as a whole
The aim should be for a
transportation time of up to
4 days and no more than 7 days
None
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Screening
programme
(country) Study
Details of screening
programme General results Issues to implementation Authors’ practical advice
Authors’ research
recommendation
Damkjaer et al.,
201227
Earlier report on Danish
screening programme,
focused on compliance
issues
Compliance with NIPT was
around 90%, improving over
time
No additional implementation
issues reported
For GPs:
1. Higher level of physician
information regarding
antenatal RHD screening and
targeted anti-D prophylaxis
2. Use of new maternity reports
with separate text boxes for
information on antenatal
RHD screening and the
injection of anti-D, which
standardises the
communication between
departments
For midwives:
1. Increased attention to
documentation in the
maternity report
2. Obligatory disclosure to the
patient of the information
letter from the Danish
National Board of Health at
the first meeting with the
midwife
3. For patients: Encouragement
to make an appointment
with their GP at 25 weeks’
gestation for blood sample
collection for antenatal RhD
screening
For obstetricians:
1. To give extra antenatal
prophylaxis in case of
potentially sensitising events
and to register whether or
not extra doses are given
None
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TABLE 14 Summary of implementation studies (continued )
Screening
programme
(country) Study
Details of screening
programme General results Issues to implementation Authors’ practical advice
Authors’ research
recommendation
UK (Bristol) Finning et al.,
200817
Two regions in England
(Birmingham and
Sheffield), centres of the
National Blood Service for
routine ABO and RhD
blood grouping and
antibody screening
Very good diagnostic accuracy
(see review). Inconclusive results
were often a result of
substantial maternal DNA, for
example because samples were
old
No issues to implementation
were reported. The modest
apparent increase in risk of
sensitisation in false-negative
women might be offset by
an increased uptake of
prophylaxis among mothers
who have been correctly
identified as carrying a
RhD-positive fetus
If the policy on routine antenatal
prophylaxis were changed to a
single dose of anti-RhD
immunoglobulin given at
30 weeks’ gestation in
RhD-negative women, then
RHD genotyping testing at
28 weeks would be suitable
Commencement of anti-D
treatment at 30 weeks’
gestation, rather than 28 weeks’,
has been considered an option
in the UK. Anti-D could be
avoided after sensitising event in
test-negative women. Treating
inconclusive results as positive
seems to be the best approach
Testing only samples that are
< 7 days old would increase
logistical issues of transport
over large geographic areas
but would reduce the risk of
false-negative results
Feasibility trials on testing
maternal blood samples
obtained during the earlier
stages of pregnancy are
required
Soothill et al.,
201518
Three maternity services in
the south west of England
29% drop in use of anti-D at a
cost reduction of £60,000 per
year
It is possible to implement
routine cffDNA fetal blood
grouping in RhD-negative
women in the NHS
The requirements of patient
information, patient consent,
sample handling, sample
transfer and implementation
of the changed management
were all successfully met
This service should be extended
to the whole of the UK, because
it has led to a more targeted use
of anti-D. The cost of the tests
seems to be covered by the
resulting savings in the use of
anti-D immunoglobulin.
Continued use of anti-D in
women who can be shown to
have RhD-negative fetuses may
be unethical
Further research on
high-throughput NIPT to
improve the test accuracy
and reduce the inconclusive
rates is required
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Screening
programme
(country) Study
Details of screening
programme General results Issues to implementation Authors’ practical advice
Authors’ research
recommendation
UK (London) Oxenford et al.,
201328
Survey conducted in one
hospital in London, UK
This study investigated
women’s preferences and
information needs for routine
implementation of NIPT.
Around 290 women included:
92.1% agreed that NIPT should
be offered. Only 75.9% said
they would accept the test.
Women preferred having the
test when most accurate, even
if later in pregnancy
Women hold positive views
regarding the introduction of
routine fetal RhD genotyping
using cffDNA but women’s
current knowledge of rhesus
blood groups and anti-D
administration was found to
be limited
Although women may agree
to extra appointments for the
test, health professionals
(n= 13) all thought that this
may be impractical
Developing information leaflets
and health professional training
will be critical for successful
implementation
None
Spain Grande et al.,
201322
Six health centres of
Barcelona-West health
district in Spain
High diagnostic accuracy (see
diagnostic review). False-negative
results were mainly related to
specific DNA extraction methods,
prolonged storage time before
sample processing and early
gestational age
No issues to implementation
were reported
High-throughput NIPT of exons
5, 6, 7 and 10, before 28 weeks’
gestation in their mixed
population should be considered
for further clinical application
None
The
Netherlands
Thurik et al.,
201521
One region in the
Netherlands
Discordant test results were
mainly caused by RhD variant
genes and weak PCR signals
and the ‘vanishing twin’
phenomenon
No issues to implementation
were reported
Discordant positive results due to
co-twin demise would have
greater clinical impact in other
non-invasive prenatal tests. The
authors therefore advised
documenting a vanishing twin
at any early pregnancy scan
and counselling against NIPT.
False-positive findings will have
little impact in NIPT, as the test
causes only unnecessary anti-D use
Prospective studies in
pregnancies with a
vanishing twin will be
required to test whether or
not discrepant NIPT results
may be compatible with a
vanishing co-twin as a
source of a third genomic
cell line
de Hass et al.,
201225
Earlier report on the
Netherlands screening
programme
Compliance with NIPT
screening was around 95%.
The FPR was 1.1%
It is possible to guide both
antenatal and postnatal anti-D
immunoprophylaxis by fetal
RHD screening in maternal
blood obtained at 27 weeks’
gestation. No further issues
relating to implementation
were reported
None stated A longer period of
evaluation based on local
analyses of cord blood
testing is required
continued
D
O
I:
1
0
.3
3
1
0
/h
ta
2
2
1
3
0
H
E
A
L
T
H
T
E
C
H
N
O
L
O
G
Y
A
S
S
E
S
S
M
E
N
T
2
0
1
8
V
O
L
.
2
2
N
O
.
1
3
©
Q
u
e
e
n
’s
P
rin
te
r
a
n
d
C
o
n
tro
lle
r
o
f
H
M
S
O
2
0
1
8
.
T
h
is
w
o
rk
w
a
s
p
ro
d
u
ce
d
b
y
S
a
ra
m
a
g
o
e
t
a
l.
u
n
d
e
r
th
e
te
rm
s
o
f
a
co
m
m
issio
n
in
g
co
n
tra
ct
issu
e
d
b
y
th
e
S
e
cre
ta
ry
o
f
S
ta
te
fo
r
H
e
a
lth
a
n
d
S
o
cia
l
C
a
re
.
T
h
is
issu
e
m
a
y
b
e
fre
e
ly
re
p
ro
d
u
ce
d
fo
r
th
e
p
u
rp
o
se
s
o
f
p
riva
te
re
se
a
rch
a
n
d
stu
d
y
a
n
d
e
xtra
cts
(o
r
in
d
e
e
d
,
th
e
fu
ll
re
p
o
rt)
m
a
y
b
e
in
clu
d
e
d
in
p
ro
fe
ssio
n
a
l
jo
u
rn
a
ls
p
ro
vid
e
d
th
a
t
su
ita
b
le
a
ck
n
o
w
le
d
g
e
m
e
n
t
is
m
a
d
e
a
n
d
th
e
re
p
ro
d
u
ctio
n
is
n
o
t
a
sso
cia
te
d
w
ith
a
n
y
fo
rm
o
f
a
d
ve
rtisin
g
.
A
p
p
lica
tio
n
s
fo
r
co
m
m
e
rcia
l
re
p
ro
d
u
ctio
n
sh
o
u
ld
b
e
a
d
d
re
sse
d
to
:
N
IH
R
Jo
u
rn
a
ls
Lib
ra
ry,
N
a
tio
n
a
l
In
stitu
te
fo
r
H
e
a
lth
R
e
se
a
rch
,
E
va
lu
a
tio
n
,
T
ria
ls
a
n
d
S
tu
d
ie
s
C
o
o
rd
in
a
tin
g
C
e
n
tre
,
A
lp
h
a
H
o
u
se
,
U
n
ive
rsity
o
f
S
o
u
th
a
m
p
to
n
S
cie
n
ce
P
a
rk
,
S
o
u
th
a
m
p
to
n
S
O
1
6
7
N
S
,
U
K
.
3
7
TABLE 14 Summary of implementation studies (continued )
Screening
programme
(country) Study
Details of screening
programme General results Issues to implementation Authors’ practical advice
Authors’ research
recommendation
Sweden Wikman et al.,
201223
83 maternity care centres
in the Stockholm area,
Sweden
NIPT had high diagnostic
accuracy with > 99% sensitivity
and specificity. Before 8 weeks’
gestation, fetal RhD genotype
could not be reliably
determined (see diagnostic
accuracy review)
Fetal RHD detection in early
pregnancy in a routine clinical
setting is feasible and
accurate. No further issues
relating to implementation
were reported
This screening programme can
be included in the routine
antenatal care management
and will not require any extra
appointment for maternal
blood sampling
NIPT should not be performed
before 8 weeks’ gestation.
Maternal DNA levels may be too
large after 4 days’ storage for
reliable testing in first trimester
The cost-effectiveness of
fetal RHD screening
combined with targeted
antenatal Rh prophylaxis
will be an important area
for further research
Tiblad et al.,
201326
See Wikman et al., 201223 RhD immunisation rate was
0.26% in the screening cohort
and 0.46% in historical controls
(see effectiveness review)
Using first-trimester screening
significantly reduces the
incidence of new RhD
immunisation but test
sensitivity is lower than for
later screening
No further advice given Cost-effectiveness of
first-trimester screening
should be evaluated
cffDNA, cell-free fetal DNA; GP, general practitioner.
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Several studies offered practical advice for implementing high-throughput NIPT. For example, Finning
et al.17 stated that if the policy on routine antenatal prophylaxis were changed to a single dose of anti-RhD
immunoglobulin given at 30 weeks’ gestation in RhD-negative women, then RhD genotyping testing at
28 weeks would be suitable. This study also suggested that treating inconclusive results as positive seems
to be the best approach to minimise the risk of not treating women with a RhD-positive fetus. Another
recent UK (Bristol) study18 stated that this service should be extended to the whole of the UK, because it
has allowed the use of anti-D in a more targeted way and the cost of the tests seems to be offset by the
resulting savings in the use of anti-D. This study also stated that continued use of anti-D in women who
can be shown to have RhD-negative fetuses may be unethical. Banch Clausen et al.24 recommended
continuing cord blood typing in practice to ensure that postnatal anti-D is given if NIPT compliance is poor.
Damkjaer et al.27 suggested improvement in relevant knowledge on prenatal RhD screening among
general practitioners and midwives in Denmark.
Clausen et al.13 focused on issues around transportation of blood samples in the Danish screening
programme and suggested that the aim should be for a transportation time of up to 4 days and no more
than 7 days. Wikman et al.23 noted that testing before 8 weeks may be inappropriate because of the
instability of samples and consequent difficulties of transportation.
In summary, the findings from these studies suggest that high-throughput NIPT for fetal RhD screening in
all RhD-negative women is feasible. They also suggest that effective education, particularly for pregnant
women but also for general practitioners and midwives, on the role of NIPT and the importance of anti-D
immunisation is important. Any nationwide NIPT screening programme will require careful logistical
management to ensure that blood samples are transported to laboratories and tested quickly and that
results are reliably returned to general practitioners and midwives. NIPT could be carried out at any time
between 25 and 28 weeks, preferably as part of an existing antenatal appointment. Anti-D, if required,
should be administered as a single dose at around 30 weeks.
Clinical effectiveness summary and conclusions
Diagnostic accuracy
Eight studies12,17–23 were included in the diagnostic review of high-throughput NIPT. There were three
studies based in Bristol (UK).12,17,18 The majority of included studies were judged as having a low risk of bias.
Meta-analyses found that high-throughput NIPT had very good diagnostic accuracy. In the primary
analyses, in which women with inconclusive test results were treated as if positive, the summary FNR
(women at risk of sensitisation) was 0.34% (95% CI 0.15% to 0.76%) and the FPR (women needlessly
receiving anti-D) was 3.86% (95% CI 2.54% to 5.82%).
The three high-quality studies performed at Bristol,12,17,18 which were most representative of UK practice,
had a lower FNR of 0.21% (95% CI 0.09% to 0.48%), with a consequently higher FPR of 5.73% (95% CI
4.58% to 7.16%). This difference may be partly because the NIPT used in Bristol had a different test
threshold to other countries to further reduce false-negative results.
The FPR found is mostly a consequence of treating women who have an inconclusive test result
(approximately 7% of non-invasive prenatal tests in the UK) as if they had a positive test. Excluding these
women from analysis gave a lower FPR of 1.26% (95% CI 0.87% to 1.83%). It may therefore be possible
to reduce the FPR by further targeted testing of women with an initially inconclusive result.
The diagnostic accuracy performance of high-throughput NIPT varied by gestational age. The data suggest
that high-throughput NIPT is insufficiently accurate before around 11 weeks’ gestation (i.e. in first
trimester) but is accurate at any time after the end of the first trimester. One study12 also suggested that
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the number of inconclusive results may decline over time. Hence, NIPT cannot be recommended before the
second trimester and may be best performed later in the second trimester.
Clinical effectiveness
Seven studies18,20,22,24–27 were included in the clinical effectiveness review. Only two studies had a control
group. All studies were judged as having a high risk of bias. As all except one were conducted in non-UK
countries, the generalisability of their findings to the UK setting is limited because of variations in national
guidelines and health policies between countries (e.g. prescription of RAADP). One large prospective
cohort study26 reported that use of high-throughput NIPT for targeted antenatal anti-D prophylaxis was
associated with a significant risk reduction in sensitisation (adjusted odds ratio 0.41, 95% CI 0.22 to 0.87)
compared with historical controls (routine management, postpartum anti-D only).
Uptake rates of NIPT were reported in seven studies, ranging from 70% in a pilot study conducted in
England to > 95% in an established national programme in Denmark. Uptake rates of RAADP in women
who accepted NIPT and received a positive result were moderate to high, ranging from 86% to 96.1%
(four studies). Uptake rates of routine postnatal anti-D prophylaxis in women who accepted NIPT and
received a positive result were reported in three studies and were generally high, ranging from 92%
to 99.7%.
Three non-comparative studies evaluated changes in anti-D use following the implementation of NIPT. All
found that the use of NIPT reduced the total use of anti-D immunoglobulin doses, which fell by 29% in
one UK study18, because around 35% of RhD-negative women avoided receiving anti-D unnecessarily.
As the quality of the clinical effectiveness evidence was limited, we performed a simulation study, based
on the findings of our reviews, to assess the probable clinical consequences of implementing NIPT. Its
results were broadly consistent with the review evidence. It suggested that NIPT, when compared with
offering anti-D to all RhD-negative women, would substantially reduce the use for anti-D from 99% of
women to 65.9%. The number of women receiving anti-D unnecessarily would fall from 38.9% to 5.7%.
The number missing out on potentially beneficial anti-D (because of a false-negative test result or
non-compliance) depends on the compliance rate but could increase from 0.6% to between 1.2% and 3.1%.
The impact of NIPT on sensitisation rates (compared with universal anti-D use) also depends on compliance.
Sensitisation rates may increase by 3–15 sensitisations per 100,000 women if postpartum cord blood testing
is continued, or 13–28 per 100,000 women if cord blood testing is withdrawn and postpartum anti-D given
on the basis of the NIPT result. Ensuring that women who do not receive NIPT are still offered, and receive,
antenatal anti-D will minimise the number of additional sensitisations.
Implementation
Twelve studies were included in the review of implementation. Most of the included studies were large
cohort studies reporting implementation data along with diagnostic accuracy data, although one study
was a UK-based survey. As most studies were conducted in non-UK countries, the generalisability of their
findings to the UK settings is limited because of variations in national guidelines and health policies
between countries. All the large cohort studies suggested that high-throughput RhD genotyping of fetuses
in all RhD-negative women was feasible and should be recommended. A number of studies reported issues
of implementation such as those relating to programme anti-D prophylaxis compliance. Some studies
emphasised the importance of short transport times of samples and the need for good management of
transporting samples. Some studies also identified the need for greater knowledge of NIPT among
physicians, midwives and pregnant women.
Conclusions
High-throughput NIPT for fetal RhD status is an accurate diagnostic test, if performed after 11 weeks’
gestation. It has a FNR (women remain at risk of sensitisation) of around 0.2% and a FPR (women receive
unnecessary anti-D) of around 5.7%. The test gives an inconclusive result in around 7% of women in the
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UK. Owing to limited evidence, the accuracy of NIPT in non-white women and multiple pregnancies is
unclear. Treating inconclusive tests as if they were positive is the cause of most false-positive results. Giving
antenatal anti-D immunoglobulin on the basis of NIPT, rather than to all RhD-negative women, will reduce
the use of anti-D and largely eliminate unnecessary use of anti-D in women who do not need it because
they have a RhD-negative fetus. Some women will, however, continue to receive anti-D unnecessarily
because of an inconclusive test result.
Although the evidence was limited, it appears that using NIPT will lead, at worst, to only a small increase
in the number of sensitisations compared with universal use of anti-D. The simulation suggested that
achieving high compliance with both NIPT and antenatal anti-D (particularly in women who do not receive
NIPT) is important in order to achieve good clinical effectiveness and to reduce the sensitisation rate.
It may be clinically reasonable to withdraw postpartum cord blood testing and base postpartum anti-D
administration on the results of NIPT. All large implementation studies suggested that high-throughput
NIPT in all RhD-negative women was feasible and should be recommended. Key issues of implementation
include ensuring anti-D prophylaxis compliance, effective management of transporting samples and greater
knowledge of NIPT among physicians, midwives and pregnant women.
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Chapter 4 Systematic review of existing
cost-effectiveness evidence
This chapter provides an overview of the existing cost-effectiveness evidence for the use of high-throughputNIPT for rhesus D status in RhD-negative women not known to be sensitised to the RhD antigen. We
assessed the relevance of these data to inform UK practice and the current assessment, as set out in the NICE
scoping documentation.66 For each cost-effectiveness study we describe the manner in which NIPT is assumed
to impact on the care pathway and summarise how existing cost-effectiveness studies have characterised
the impact of NIPT on routine antenatal care costs, routine antenatal anti-D immunoglobulin administration,
management of potentially sensitising events and postnatal administration of anti-D immunoglobulin. The
findings from the review informed the development of a new decision-analytic model, reported in Chapter 5.
Methodology of the cost-effectiveness review
Searches
In addition to the searches conducted for the review of clinical evidence (see Chapter 3), the following
databases were searched up to December 2015 for cost-effectiveness evidence: NHS EED, EconLit and
IDEAS database via Research Papers in Economics (RePec). The bibliographies of relevant studies were also
searched. Citations of identified studies were searched for any relevant publications published after the
initial search.
Selection criteria
A broad range of studies was considered in the review, including economic evaluations conducted
alongside trials, modelling studies and analyses of administrative databases. Only full economic evaluations
that compared two or more options and considered both costs and consequences (i.e. cost-minimisation,
cost-effectiveness, cost–utility and cost–benefit analyses) were included in the review.
Study selection
Relevant studies were then selected in two stages. Titles and abstracts identified by the search strategy
were examined independently by two researchers (PS and SG) and screened for possible inclusion.
Disagreements were resolved by discussion. Full texts of the potentially relevant studies were obtained.
Two researchers (PS and SG) examined these independently for inclusion or exclusion, and disagreements
were resolved by discussion.
Data extraction
One reviewer (PS) independently extracted details from full-text studies on objectives, setting, population,
comparators, analytical approach, data on costs and outcomes (short- and long-term) and main results/
conclusions. Another reviewer (SG) checked extracted data and disagreements were resolved by discussion.
Critical appraisal
A quality appraisal was carried out using the checklist of Drummond and Jefferson.67 This checklist
evaluates the extent to which each review result provides detail on different aspects, such as study design,
data collected and their use in the economic evaluation and analysis and interpretation of results. One
reviewer (PS) independently assessed the quality of all included studies according to all these domains. The
quality assessment was checked by another reviewer (SG). Any disagreements were resolved by consensus.
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Results of the review of existing cost-effectiveness evidence
Quantity of research available
Number and type of studies included
The initial search of economic databases identified a total of 31 references. After the initial screening of
titles and abstracts, 10 were considered to be potentially relevant and were ordered for full-text paper
screening. Of those, seven met the selection criteria and were included in the review.58,68–73 A flow diagram
of the selection process is reported in Figure 10.
Number and type of studies excluded
A list of full-text papers that were excluded is given in Appendix 9. These papers were excluded because
they failed to meet one or more of the inclusion criteria, including lack of full-text publications and
ineligible study design.
Characteristics of included studies
The characteristics of the seven studies are summarised in Table 15. The large majority of studies specified
the target population as being unsensitised RhD-negative pregnant women or RhD-negative pregnant
women not known to be sensitised to the RhD antigen. Macher et al.70 and Hawk et al.72 stated that their
analysis considered RhD-negative pregnant women but they were not clear about women’s sensitisation
status at study entry. Only two studies68,73 explicitly stated that a high-throughput NIPT method was being
used for the comparative assessment, although for the other studies this was considered implicit, as the
test diagnostic performance was considered similar to the high-throughput studies. One study71 explicitly
focused on providing NIPT to all RhD-negative women, as the test for sensitisation was conducted only if
the NIPT result was positive.
Most studies58,68,71–73 evaluated the cost-effectiveness of introducing NIPT in the management pathway of
RhD-negative pregnant women compared with alternative strategies. These studies explored a range of
alternative strategies to prevent sensitisation. Except for Szczepura et al.68 and Macher et al.,70 two strategies
were common across the studies: (non-targeted) RAADP at around 28–30 weeks to every (unsensitised)
RhD-negative pregnant women; and use of NIPT for fetal RhD typing with prophylaxis guided by test results
(targeted RAADP) for RhD-negative pregnant women. Duplantie et al.71 also explored the immunological
Potentially relevant
articles identified and
screened for retrieval
(n = 31)
Full papers excluded
(n = 3)
Papers rejected at the
abstract stage
(n = 8)
Papers rejected at the
title stage
(n = 13)
Total abstracts
screened
(n = 18)
Total full papers
screened
(n = 10)
Total full papers
accepted
(n = 7)
FIGURE 10 Assessment of cost-effectiveness: summary of study selection and exclusion.
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TABLE 15 Cost-effectiveness study characteristics
Study Objectives
Setting/
perspective Population Analytical approach Diagnostic comparators Outcomes Main results
Szczepura
et al., 201168
Cost-effectiveness
analysis of NIPT
implementation in
England and Wales
English and
Welsh NHS
Unsensitised
RhD-negative
pregnant
women
Economic analysis of NIPT
implementation. For each
scenario a threshold
analysis was performed to
identify the circumstances
under which NIPT might
be considered cost saving
compared with RAADP
Two scenarios compared:
1. Assumed that all
RhD-negative women will
routinely receive NIPT at
approximately 28 weeks and
that RAADP will be withheld
if a RhD-negative fetus is
identified (prophylactic
anti-D for potentially
sensitising events assumed
withheld); postpartum testing
and anti-D prophylaxis
assumed to be unaffected
2. Assumed that, in addition to
scenario 1, postdelivery
blood cord serology and
FMH test will be withheld if
NIPT result has identified a
RhD-negative fetus
Costs (including NIPT
royalty fees), additional
sensitisations/year
Analysis performed did
not support routine
implementation of NIPT in
England and Wales for
unsensitised RhD-negative
pregnant women. Net
financial benefit of
implementing mass NIPT
as an add-on (while
maintaining current
postnatal testing) was
found to be negligible in
England and Wales. NIPT
implementation is unlikely
to produce important
clinical benefits: the
number of sensitisations
was estimated not to fall
appreciably and the
sensitisations are expected
to rise if NIPT sensitivity is
below 99.9%
continued
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TABLE 15 Cost-effectiveness study characteristics (continued )
Study Objectives
Setting/
perspective Population Analytical approach Diagnostic comparators Outcomes Main results
Benachi et al.,
201269
Cost-minimisation
analysis of NIPT on
the costs of managing
RhD-negative
pregnant women,
whether or not they
are sensitised
French NHS Unsensitised
RhD-negative
pregnant
women
A prospective follow-up
of RhD-negative women
during their pregnancy
Four scenarios compared:
1. RAADP at 28–32 weeks’
gestation
2. RAADP and additional
300-µg anti-D administration
at 28 weeks’ gestation
3. NIPT performed during
the first trimester in order
to detect women not at risk
(i.e. carrying a RhD-negative
fetus)
4. NIPT performed during the
third trimester in order to
offer RAADP only to women
carrying a RhD-positive fetus
For strategies 3 and 4
systematic (i.e. to all) and
targeted (i.e. conditional on
test results) newborn infant
serology scenarios were
explored
Costs, except for
potentially sensitising
events; no clinical
outcomes were
considered in the
analysis
NIPT performed early
during pregnancy (i.e. end
of first trimester and
beginning of second
trimester) was found to be
cost saving compared with
RAADP during the third
trimester
Macher et al.,
201270
Cost-minimisation
analysis of NIPT
(multiplex real-time
PCR assay for fetal
cell-free DNA) in the
plasma of pregnant
women
Andalusian
government,
Spain
RhD-negative
pregnant
women
An analysis of feasibility
of routine RhD status
determination into the
clinical setting using NIPT
targeted towards two
exons of the RHD gene
and one exon of SRY
gene
No diagnostic comparators were
presented
Three ways of detecting fetal
RhD using NIPT were compared:
1. Exon 5
2. Exon 7
3. SRY
Testing was performed on
RhD-negative women in
weeks 10–28 of pregnancy.
The consequences of test
results were not explored
Test accuracy; cost of
assay per sample
The routine determination
of fetal RhD status using
NIPT is feasible. The use of
multiplex real-time PCR
allows the improvement
of the response of the
laboratory, saving time and
reagent costs and opening
the door to a complete
automatisation of the
process
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Study Objectives
Setting/
perspective Population Analytical approach Diagnostic comparators Outcomes Main results
Duplantie
et al., 201371
Cost-effectiveness
analysis of strategies
to prevent RhD
alloimunisation
Public health-care
system of Quebec,
Canada
Unsensitised
RhD-negative
pregnant
women
Computer-based
simulation model with
virtual population of
10,000 RhD-negative
pregnant women
1. Two decision trees:
2. Applied to the first
pregnancy of a
RhD-negative woman
3. Applied to an eventual
second pregnancy in
55% of those women
Four scenarios compared:
1. Systematic prophylaxis:
RAADP at around 28 weeks’
gestation (recommended by
the Canadian guidelines)
2. NIPT at around 12 weeks’
and/or at 28 weeks’
gestation. RAADP and
postpartum anti-D withheld
for RhD-negative fetus result
3. Immunological determination
of the father’s Rh type
4. Mixed screening:
immunological determination
of the father’s Rh type,
followed, if the result is
positive, by NIPT at around 15
weeks’ gestation. RAADP and
postpartum anti-D withheld
for RhD-negative fetus result
Prophylactic anti-D for
potentially sensitising events
not discussed but assumed
withheld for a RhD-negative
fetus result in scenarios
2 and 4
Clinical:
1. Number of babies
without haemolytic
disease
2. Number of
surviving infants
Economic:
1. Cost per 10,000
pregnancies
2. Cost per number
of babies without
haemolytic disease
3. Cost per number
of surviving babies
Outcomes obtained
for first and second
pregnancies
The four proposed
strategies for prevention
and treatment of
sensitisation were found to
be similar in terms of their
effectiveness. In terms of
cost-effectiveness, two
options were found to be
superior: RAADP and
immunological Rh typing of
the father. NIPT was found
not to be a cost-effective
option unless its cost is
lowered
RAADP remained the
preferred option for the
prevention of maternal
sensitisation
continued
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TABLE 15 Cost-effectiveness study characteristics (continued )
Study Objectives
Setting/
perspective Population Analytical approach Diagnostic comparators Outcomes Main results
Hawk et al.,
201372
Cost-effectiveness of
NIPT for targeted
prophylaxis
US health system
(Medicaid and
Medicare)
RhD-negative
women
Decision tree model using
a decision tree structure
comparing three relevant
scenarios
Three scenarios compared:
1. RAADP at 28 weeks’
gestation and postpartum
prophylaxis guided by cord
blood typing (current
approach in most of
the USA)
2. Non-invasive fetal RhD
typing performed early in
pregnancy (first trimester
assumed) with prophylaxis
(i.e. for potentially sensitising
events, RAADP and
postpartum anti-D
administration) guided by
test results
3. No screening or prophylaxis
Costs per RhD
woman, morbidity
and mortality
attributable to
haemolytic disease
Non-invasive fetal RhD
testing was not found to
provide any economic
benefit for the management
of RhD-negative women.
RAADP and postpartum
prophylaxis guided by cord
blood typing remained the
most cost-beneficial option
for the management of
RhD-negative women
Neovius et al.,
201658
Cost-effectiveness of
first-trimester NIPT for
targeted antenatal vs.
no RAADP or vs.
non-targeted RAADP
Swedish health
service
Unsensitised
RhD-negative
pregnant
women
Decision-analytic model
based on a population-
based cohort study.
Markov model with
cohort simulation and
three health states: ‘not
sensitised’, ‘sensitised
during pregnancy’ or
‘sensitised from start of
pregnancy’
Three scenarios compared:
1. First-trimester NIPT followed
by targeted RAADP at
29 weeks’ gestation as well
targeted postpartum anti-D
2. Historical comparators of no
RAADP, only postpartum
anti-D in case of a
RhD-positive baby
3. Non-targeted RAADP and
postpartum anti-D
prophylaxis guided by cord
blood typing
Screening, pregnancy,
delivery and future
pregnancies related
costs, additional costs
per sensitisation
averted
NIPT for targeted RAADP
was found to be cost
saving as well as more
effective than no RAADP.
Introduction of targeted
prophylaxis was expected
to save money, reduce
sensitisations and avoid
unnecessary exposure of
pregnant women to a
plasma product in short
supply
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Study Objectives
Setting/
perspective Population Analytical approach Diagnostic comparators Outcomes Main results
Teitelbaum
et al., 201573
Cost-effectiveness of
non-invasive fetal RhD
determination
Canadian NHS Unsensitised
RhD-negative
pregnant
women
Decision-analytic
modelling – decision trees
to model costs and
benefits of targeted vs.
RAADP in Alberta over
1 year
Two scenarios compared:
1. RAADP for all unsensitised
pregnant women – including
the administration of anti-D
at 28 weeks’ gestation, at
any potentially sensitising
event and post partum for
women whose infants were
found to be RhD positive
after delivery (current
standard of care in Canada)
2. All RhD-negative women
undergo NIPT for RhD
genotyping at 12 weeks’
gestation. If the fetus is
found to be RhD negative,
no prophylactic anti-D
administration is required.
Women with a RhD-positive
fetus receive anti-D at
28 weeks’ gestation, at
any potentially sensitising
event and post partum
Number of women
sensitised in 1 year,
doses of anti-D
administered per
pregnancy in 1 year,
cost per pregnancy
Implementation of a
programme of targeted
anti-D prophylaxis using
NIPT was found to be both
feasible and cost saving
with no increase in the risk
of sensitisation. With
higher sample throughput
(i.e. in a national
programme) the cost per
patient was expected to
decrease owing to
economies of scale
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determination of the father’s RhD type to target RAADP. Most studies considered the introduction of NIPT at
a single time point, usually at first routine antenatal care appointment occurring between 8 and 12 weeks’
gestation. Benachi et al.69 compared alternative timings of NIPT by considering the cost consequences of
performing NIPT during the first and the third gestation trimesters. With the exception of the Duplantie
et al.71 study, for which insufficient information is provided, all cost-effectiveness studies evaluated the
consequences of introducing NIPT in terms of avoiding RAADP but also in terms of the impact it had on
postpartum treatment.
Three studies58,68,73 aimed to evaluate the short-term costs and consequences of sensitisation in RhD-negative
women. Duplantie et al.71 and Hawk et al.,72 however, estimated long-term outcomes relating to morbidity
and mortality attributable to haemolytic disease of the fetus and/or newborn infant. Furthermore, two
studies58,71 explicitly considered in their analysis women’s first and subsequent pregnancies, presenting
cost-effectiveness results for each scenario.
Benachi et al.69 and Macher et al.70 are cost-minimisation studies, as no health outcomes were considered,
restricting their analysis to an evaluation of the impact of the test on the costs of managing the target
population. A variety of cost components were considered across these two studies, such as anti-D
immunoglobulin, genotyping, antibody testing.
The cost-effectiveness studies evaluated different strategies in different health systems, including England
and Wales, Canada, Sweden and the USA. Except for Sweden, where only postpartum administration of
anti-D (conditional on having a RhD-positive baby) is recommended, current guidance for the prevention of
sensitisation in these countries is routine prophylactic administration of anti-D, with further prophylactic
doses for potentially sensitising events and post partum. The two cost-minimisation studies69,70 evaluated
the cost implications of introducing NIPT in the French and Spanish (namely the Andalusia region)
health-care settings. Current guidance on the prevention of sensitisation in these countries was not clearly
stated. Macher et al.70 focused mainly on addressing questions relating to the accuracy and implementation
of different NIPT methodologies into current clinical practice in Spain.
Quality of included studies
A summary of the results of the quality appraisal of the seven included studies is provided in Table 16.
Study design
All studies stated their research question and provided a rationale for it. Most studies failed to clearly
mention which economic approach was being taken; the ones that did only partially justified their choice.
Five of the seven studies were cost-effectiveness analyses using a decision-analytic modelling approach,
typically based on a decision tree. Most of these restricted their assessment to the more short-term outcome
of sensitisation, although Duplantie et al.71 and Hawk et al.72 explicitly dealt not only with sensitisations, but
also with a broader outcome set, such as the impact on infant health and/or on subsequent pregnancies.
The remaining two studies were cost-minimisation studies, with no evidence cited to support this approach.
None of the studies considered any adverse effects associated with the provision of NIPT or the administration
of anti-D immunoglobulin. None of the studies considered the clinical effectiveness and/or cost-effectiveness
of NIPT in ethnic minority groups. Except for one study,68 most studies were not explicit in considering
that most NIPT performance assessments have been undertaken in white European populations and, thus,
its reliability in minorities is still to be fully demonstrated. Overall justifications and descriptions of the
alternatives being compared were generally clear, with most studies comparing more than two alternative
scenarios. The viewpoint of the analyses was mentioned in most studies and implicitly justified by the public
health systems in which the studies were conducted.
Data
Studies utilised evidence on costs and/or effects from a variety of sources. Sources for the diagnostic
accuracy of NIPT Fetal RhD genotyping were based mainly on diagnostic studies aimed at verifying test
performance, including three studies58,69,70 that considered evidence collected from subjects in the underlying
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TABLE 16 Quality assessment of studies included in the economic review using the checklist of Drummond
and Jefferson67
Criteria
Study
Szczepura
et al.,
201168
Benachi
et al.,
201269
Macher
et al.,
201270
Duplantie
et al.,
201371
Hawk
et al.,
201372
Neovius
et al.,
201658
Teitelbaum
et al.,
201573
Study design
The research question is stated Yes Yes Yes Yes Yes Yes Yes
The economic importance of
the research question is stated
Yes Yes Yes Yes Yes Yes Yes
The viewpoint(s) of the analysis
are clearly stated and justified
Yes Yes No Yes Partial Yes No
The rationale for choosing
alternative programmes or
interventions compared is
stated
Yes Yes Yes Yes Yes Yes Yes
The alternatives being
compared are clearly described
Yes Yes Yes Yes Yes Yes Yes
The form of economic
evaluation used is stated
Partial Partial No Yes Partial Yes Partial
The choice of form of economic
evaluation is justified in relation
to the question addressed
No No No Partial No Partial No
Data collection
The source(s) of effectiveness
estimates used are stated
Yes N/A N/A Yes Yes Yes Yes
Details of the design and results
of the effectiveness study are
given (if based on a single study)
No N/A N/A No No Yes No
Details of the methods of
synthesis or meta-analysis of
estimates are given (if based on
a synthesis of a number of
effectiveness studies)
No N/A N/A N/A N/A N/A No
The primary outcome
measure(s) for the economic
evaluation are clearly stated
Yes No No Partial Partial Yes Yes
Methods to value benefits are
stated
N/A N/A N/A No No No N/A
Details of the subjects from
whom valuations were
obtained are given
N/A N/A N/A N/A N/A N/A N/A
Productivity changes
(if included) are reported
separately
No No No No No No No
The relevance of productivity
changes to the study question
is discussed
N/A N/A N/A N/A N/A N/A N/A
Quantities of resource use are
reported separately from their
unit costs
Yes Yes Yes Yes No Yes Yes
Methods for the estimation of
quantities and unit costs are
described
Yes No Yes Yes Partial No Partial
continued
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cohort studies. These types of observational studies are inherently prone to bias and tools exist to appraise
them [e.g. Standards for Reporting Diagnostic accuracy studies,74 Quality Assessment of Diagnostic Accuracy
Studies (QUADAS)75 or the more recent update QUADAS-214]. To our knowledge, these tools were not used
to appraise the study findings. Sources for the effectiveness of anti-D immunoglobulin varied across the
different studies and were not based on systematic reviews but mainly on jurisdiction-specific sensitisation
estimates. Studies that considered broader outcomes associated with sensitisation (i.e. haemolytic disease
and impact of future pregnancies) populated these parameters with relevant published evidence.76–78
Three studies reported the methods of collecting health-care resource use data and the unit costs applied
to them. The majority specified the currency and price date; however, almost all failed to provide details on
whether or not any price and currency conversion adjustments were made. One study72 did not report unit
costs and quantities separately. No study valued health benefits or examined changes in productivity or its
associated costs.
Two key aspects in these studies were the unit cost of the diagnostic test itself and the cost of the anti-D
immunoglobulin treatment. The cost of NIPT varied significantly across studies from approximately €20.0070
(2012 prices) to US$45072 (2013 prices) per sample, with some including blood type, RhD determination
and antibody screen. The NIPT cost range in the studies that explicitly stated that a high-throughput
method was being assessed varied from £16.2568 (2011 prices) to CA$34.4573 (2015 prices). This may
indicate that studies reporting a high unit cost for NIPT71,72 were not based on a high-throughput process.
The majority of studies that provided a reference for the NIPT cost figures obtained these from the
government58,71,73 or from laboratory genetic test companies.72 A relevant consideration in relation to
the cost of NIPT is whether or not the test is also subject to additional royalty fees that could affect the
unit cost. For the majority of studies it is not clear if this fee was already included in the diagnostic test unit
cost. Only the study by Szczepura et al.68 explicitly considered this aspect by exploring the robustness of
the results by varying the fee from zero to £46.50, the latter cost being the unit cost of a commercial
TABLE 16 Quality assessment of studies included in the economic review using the checklist of Drummond
and Jefferson67 (continued )
Criteria
Study
Szczepura
et al.,
201168
Benachi
et al.,
201269
Macher
et al.,
201270
Duplantie
et al.,
201371
Hawk
et al.,
201372
Neovius
et al.,
201658
Teitelbaum
et al.,
201573
Currency and price data are
recorded
Yes No Yes Yes Partial Yes Partial
Details of currency of price
adjustments for inflation or
currency conversion are given
No No No No No Partial No
Details of any model used are
given
No No No Yes Yes Yes Yes
The choice of model used and
the key parameters on which it
is based are justified
N/A N/A N/A Partial Partial No Partial
Analysis and interpretation of results
Time horizon of costs and
benefits is stated
No No No Partial No Yes No
The discount rate(s) are stated No No No N/A No Yes No
The choice of discount rate(s) is
justified
N/A N/A No N/A N/A Yes N/A
N/A, not applicable.
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testing kit including the royalty fee. Significant variation was also found in the unit costs per dose of anti-D
immunoglobulin, which varied from £33.5068 (2011 prices) to US$462.0072 (2013 prices). None of the
studies considered the potential for further costs associated with the introduction of NIPT in terms of
additional antenatal care appointments or counselling with regard to test implications.
Analysis and interpretation of results
The two cost-minimisation studies69,70 took a simple approach and evaluated direct medical costs
associated with the management of the RhD-negative pregnant women. Of the five cost-effectiveness
studies, only one58 explicitly stated the time horizon of costs and benefits and the discount rate used in the
analysis. Uncertainty was assessed in the majority of studies58,71–73 using deterministic sensitivity and
scenario analysis. Only one of these58 reflected the need to jointly consider uncertainty in all parameter
inputs through probabilistic methods.
Except for Szczepura et al.,68 all cost-effectiveness studies mentioned the timing for when NIPT was offered
to pregnant women. This was generally assumed across studies to happen at around 12 weeks’ gestation
(typically at first routine antenatal care appointment). This assumption was largely supported by the fact
that sufficiently high test diagnostic accuracy levels were expected at that stage of the pregnancy. Benachi
et al.69 found that greater cost savings were possible when NIPT was given in the first trimester than in the
third trimester owing to the avoidance of costs associated with the management of potentially sensitising
events in the intervening period. Their analysis shows that NIPT early in pregnancy (first trimester) was a
cost-reduction strategy in comparison with performing the test later in pregnancy (third trimester), saving,
on average, €38.00 per patient (2012 prices).
Teitelbaum et al.73 and Szczepura et al.68 were the only two research studies that, in their analyses,
factored in the issue of NIPT fetal RhD genotyping producing inconclusive results and therefore performing
SA over the inconclusive rate. Their analyses assumed that inconclusive test results would be treated as
positive test results and, thus, women were assumed to receive RAADP.
Generally, the cost-effectiveness studies highlighted that the main limitations of their analysis were the
external validity of the results, the uncertainty over the cost of the test and the associated royalty fee, the
cost of clinically managing sensitisations, the fact the ethnic background of the target population had not
been fully accounted for and the impact of this on the reliability of test assays.
Results of included studies
In terms of conclusions, conflicting results were reported across the existing economic studies. Three
studies68,71,72 reported NIPT fetal RhD genotyping not to be cost-effective or of no economic benefit. Hawk
et al.72 and Szczepura et al.68 reported that the main factor driving these factors was the cost of the test
itself (i.e. the clinical and economic benefits were not sufficient to offset the additional costs of the test).
Szczepura et al.68 also stated that the implementation of NIPT in the clinical pathway of the RhD-negative
pregnant woman was not expected to produce important clinical benefits. Supporting this was an
estimation of the potential rise in the number of sensitised women if NIPT sensitivity fell below 99.9%.
Two studies58,69 reported that NIPT is cost saving compared with no RAADP (i.e. compared with
postpartum anti-D only). Only one study73 found NIPT for targeted RAADP to be cost saving compared
with non-targeted RAADP, which also estimated no increase in the risk of sensitisation if NIPT were to be
used. Duplantie et al.71 found that targeting of RAADP based on the immunological RhD typing of the
father is cost-effective compared with the use of NIPT.
Overall, the quality of the included studies’ findings is uncertain because of a lack of reporting of the
validity of the diagnostic accuracy outcomes used. Furthermore, although SA exercises were generally done
over some key parameters, the degree of uncertainty in the cost-effectiveness estimates is generally
difficult to establish.
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Relevance to the NHS and current decision problem
One of the key aspects of this review is to address how relevant study assumptions and findings are to
the UK. None of the study approaches and findings reviewed was considered to be generalisable to the
decision problem as set out in the NICE scope for the current diagnostic assessment. The scope for this
decision problem includes an evaluation of the introduction of NIPT at different gestation points, the
impact of the test result on the administration of anti-D immunoglobulin treatment routinely and post
partum, and the impact of sensitisation on infant health and/or on subsequent pregnancies. Only one68
of the seven economic studies reviewed directly relates to the UK. This study, however, did not explicitly
explore how the introduction of NIPT could impact on costs relating to potentially sensitising events.
In addition, it assumed that postpartum testing and treatment would be unaffected by NIPT results.
Furthermore, no assessment of the timing of NIPT or any consideration of the impact on subsequent
pregnancies was undertaken. Therefore, limited UK-specific information exists that explicitly relates to the
decision problem as specified in the scope for this diagnostic appraisal. Although some studies are from
Canada and the USA, countries in which similar guidance to that in the UK exists on the prevention of
sensitisation, relevance to the UK and generalisability of findings can be questioned, as there are crucial
health-care system differences and differences in how anti-D immunoglobulin policies have been
implemented over recent decades.
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Chapter 5 Independent economic assessment
Overview
A de novo independent economic model was developed to assess the cost-effectiveness of high-throughput
NIPT to identify fetal rhesus D status in women who are RhD negative and not known to be sensitised to
the RhD antigen. The conceptualisation and development of the de novo model was informed by existing
economic modelling studies described in Chapter 4, Methodology of the cost-effectiveness review and
the independent economic model used to inform NICE technology appraisal (TA)156 on the clinical and
cost-effectiveness of RAADP.62 The model provides a framework for the synthesis of diagnostic accuracy
reported in Chapter 3 with a range of other relevant parameters required to establish cost-effectiveness.
A decision-analytic model using a decision tree cohort approach was developed to estimate, based on best
available data, the costs and health outcomes of the relevant testing and treatment strategies. The model
was made up of two main elements: (1) an identification part reflecting the diagnostic performance and
costs of the alternative identification strategies and (2) a treatment part that evaluated the subsequent
costs and outcomes [expressed in quality-adjusted life-years (QALYs)] of alternative care pathways. The
treatment part of the model was based closely on the economic model for NICE TA156 developed by
researchers at the School of Health and Related Research (ScHARR), University of Sheffield.62 This model
was kindly provided on request and was subsequently modified and updated to accommodate all the
required changes for the cost-effectiveness assessment of the introduction of high-throughput NIPT in
pregnant RhD-negative women’s clinical pathway, as outlined in Appendix 10.
The decision model is populated using the results from the systematic clinical review on the diagnostic accuracy
of high-throughput NIPT as described in Chapter 3 and other relevant parameters required to provide a link
between the diagnostic accuracy of a given identification strategy, the impact on subsequent treatment
decisions and the ultimate effect on health outcomes and costs. The determination of the RhD status of fetuses
through high-throughput NIPT may impact the administration of anti-D immunoglobulin prophylactically
following potentially sensitising events, routinely and at birth. Routine prophylactic anti-D immunoglobulin may
be avoided by RhD-negative women who are indicated to be carrying a RhD-negative fetus. The use of fetal
RhD status testing may also prevent further testing (i.e. FMH) as well as the administration of prophylactic
anti-D immunoglobulin after a potentially sensitising event where the test result indicates a RhD-negative fetus.
In addition, high-throughput NIPT for fetal RhD status determination may impact postpartum testing (i.e. cord
blood typing and FMH) and postpartum anti-D immunoglobulin administration. As high-throughput NIPT is
not a perfect test, women who receive inconclusive or false-positive test results will not avoid unnecessary use
of anti-D immunoglobulin and the costs and consequences of suboptimal use of anti-D immunoglobulin
prophylaxis in women who receive false-negative results need to be accounted for.
The following sections outline the decision problem and the structure of the model and also provide an
overview of the key assumptions and data sources used to populate the model.
Overall aims and objectives of the independent economic assessment
The cost-effectiveness assessment of the use of high-throughput NIPT to identify fetal rhesus D status had
the following overall main objectives:
l To produce a de novo cost-effectiveness model assessing the cost-effectiveness of high-throughput NIPT
to identify fetal RhD status in RhD-negative women not known to be sensitised to the RhD antigen.
l To assess the impact of alternative scenarios related to the timing of the test and the impact of the test
on the use of antenatal anti-D immunoglobulin prophylaxis for sensitising events and postdelivery
testing and postpartum anti-D immunoglobulin administration.
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Intervention and comparator pathways
Current NICE clinical guidance on antenatal care7 recommends that women be offered testing for blood
group and rhesus D status in early pregnancy. All pregnant women identified as RhD-negative would be
tested for the presence of RhD antibodies. Women identified as RhD-negative and found not to have
RhD antibodies are not yet sensitised and form the population for this appraisal. In these women, anti-D
immunoglobulin is recommended, both as prophylaxis and following potential sensitising events, to
prevent sensitisation occurring.2
Routine antenatal anti-D prophylaxis is recommended to be given as two doses at weeks 28 and 34 of
pregnancy, or as a single dose between 28 and 30 weeks. Supplementary doses of anti-D immunoglobulin
should also be administered prophylactically after a potentially sensitising event.2,8 Potentially sensitising
events include those that may lead to FMH, such as medical interventions (e.g. chorionic villus sampling,
amniocentesis or external cephalic version), terminations, late miscarriages, antepartum haemorrhage and
abdominal trauma. Following a potential sensitisation event, the recommended minimum dosage of anti-D
immunoglobulin increases with gestational age (i.e. a higher dose for > 20 weeks’ gestation), and FMH
testing is used to inform the actual dose after 20 weeks’ gestation.
Following birth, RhD typing should be performed on a cord blood sample to determine the RhD status of
the baby. If the baby is confirmed to be RhD positive, it is recommended that previously non-sensitised
RhD-negative pregnant women receive anti-D immunoglobulin within 72 hours following delivery, with
the actual dose guided by FMH results. This represents the pathway and current clinical practice of the
management of RhD-negative pregnant women not known to be sensitised.
The intervention technology of this assessment is high-throughput NIPT for fetal rhesus D status. By
analysing cell-free fetal DNA in the plasma of RhD-negative pregnant women, high-throughput NIPT is able
to predict fetal RhD genotype. High-throughput NIPT for fetal RhD status may enable prophylactic anti-D
immunoglobulin to be withheld from women who are RhD-negative and carrying a RhD-negative fetus.
These women could avoid unnecessary treatment with anti-D immunoglobulin, along with the potential risk
associated with blood products. The results of NIPT could impact on the care pathway in the following ways:
1. For women in whom the high-throughput NIPT indicates the presence of a RhD-negative fetus:
¢ avoidance of RAADP
¢ avoidance of prophylactic anti-D immunoglobulin and FMH tests following potentially
sensitising events
¢ avoidance of cord serology testing, fetal maternal haemorrhage test and administration of anti-D
immunoglobulin following delivery.
2. For women in whom the high-throughput NIPT indicates the presence of a RhD-positive fetus:
¢ avoidance of cord serology testing in favour of routine FMH testing and postpartum anti-D
immunoglobulin following delivery.
Model structure
Modelling methodology and scope
A decision-analytic model using a decision tree structure simulates the experience of a hypothetical cohort
of RhD-negative pregnant women not known to be sensitised to the RhD antigen, with and without the
introduction of high-throughput NIPT for fetal RhD status. A pregnant woman enters the model after
having been identified as RhD-negative and not yet sensitised based on the results of tests from bloods
drawn either at first contact with the doctor or midwife (the date at which pregnancy is reported or
established) or at the booking appointment (8–12 weeks’ gestation). All further contacts between the
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woman and the health service are informed by the recorded test results. At the routine 16-week visit the
woman is informed about her RhD status, whether or not she is sensitised and how these results impact
on further management. If the woman contacts the health service following any potentially sensitising
event she may be offered anti-D immunoglobulin and, if after 20 weeks’ gestation, a FMH test. Women
provided with RAADP receive it at either or both of the routine visits at 28 and 34 weeks’ gestation. At
delivery, a sample of cord blood may be taken and the baby’s RhD status established to guide the use of
FMH tests and the administration of postpartum anti-D immunoglobulin.
All high-throughput NIPT are assumed to be performed early enough to determine the use of RAADP at
28 weeks’ gestation. Figure 11 shows the current schedule of routine antenatal care appointments and the
potential placement of NIPT.
In addition to the first contact/8–12 weeks’ gestation booking appointment, the points of routine
contact at which blood could be drawn for NIPT are the 16-week visit and 18- to 20-week scan (at which
outstanding routine screening tests are offered). Other opportunities may include attendance to receive the
Potential placement of 
high-throughput NIPT within
routine antenatal care
Current provision
of RAADP
Healthy pregnant woman
First contact with a
health-care professional
Booking appointment and
arranging screening
16 weeks
Anomaly scan at 18 to 20
weeks
28 weeks
34 weeks
31 weeks for nulliparous
women only
25 weeks for nulliparous
women only
3
1
2
4
5
7
8
6
9
FIGURE 11 Excerpt from NICE schedule of appointments in routine antenatal care. © NICE 2016. All rights reserved.
Schedule of Appointments in Routine Care.79 Available from: http://beta.pathways.nice.org.uk/pathways/antenatal-
care/schedule-of-appointments-in-routine-antenatal-care. NICE guidance is prepared for the National Health Service
in England, and is subject to regular review and may be updated or withdrawn. NICE has not checked the use of its
content in this report to confirm that it accurately reflects the NICE publication from which it is taken.
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whooping cough vaccine and the routine 25 weeks’ gestation visit for first pregnancy only. Once the
results of any high-throughput NIPT are known, they will be communicated to the woman and recorded
with the potential to inform all further contacts and decisions regarding testing and treatment. We assume
that RAADP and management for potentially sensitising events would be subsequently offered only to
women in whom the test result indicates that their fetus is RhD positive and in whom the test result is
inconclusive. For women in whom the high-throughput NIPT result is inconclusive, the existing care
pathway will remain unchanged and they would receive the same management as women for whom the
results of NIPT indicate a RhD-positive baby. We assume that provision of NIPT can be incorporated into
routine antenatal care without requiring additional visits (to undertake the test or to communicate the
results of test). Similarly, in the base case we do not model additional resources within existing antenatal
care appointments to draw blood.
As previously mentioned, the model may be separated into two main elements: (1) an identification part
reflecting the diagnostic performance and costs of the alternative identification strategies and (2) a
treatment part evaluating the subsequent costs and outcomes (expressed in QALYs) of alternative care
pathways. The main aim of the first model element is to divide the cohort according to fetal RhD status
and treatment administered (i.e. routine anti-D immunoglobulin, FMH tests and anti-D immunoglobulin
for potentially sensitising events, cord serology, FMH tests and postnatal anti-D immunoglobulin). This
determines when receipt of anti-D immunoglobulin is appropriate (true positive in terms of NIPT result and/or
postnatal cord serology and inconclusive result but pregnant with RhD-positive fetus), when avoidance of
anti-D immunoglobulin is appropriate (true negative in terms of NIPT result), when anti-D immunoglobulin is
unnecessary (false positive or inconclusive in terms of NIPT result and carrying a RhD-negative fetus) and
when avoidance of anti-D immunoglobulin is potentially harmful (false negative in terms of NIPT result).
Aspects such as the diagnostic test performance (including inconclusive results and results at different
gestation timings), compliance with high-throughput NIPT and anti-D immunoglobulin treatment and the
effectiveness of anti-D immunoglobulin all inform the estimation of the probability of sensitisation for each
of these groups. The second model element (i.e. the treatment part) considers the short- and long-term
consequences of sensitisations (i.e. fetal or neonatal death, minor and major development problems of the
child) for the first, second, third and subsequent pregnancies. Costs and utilities are then evaluated for the
different components and for each of the alternative pathways.
Four alternative ways in which the use of high-throughput NIPT may impact on the existing postpartum
care pathway were considered.
1. NIPT postpartum scenario 1 (PP1): postpartum cord blood typing and FMH testing would continue to be
performed, as per current guidelines, in all women regardless of the fetal RhD status identified through
high-throughput NIPT.
2. NIPT postpartum scenario 2 (PP2): postpartum cord blood typing, FMH testing (and by implication
anti-D immunoglobulin) would be withheld if high-throughput NIPT of fetal RhD status identifies a
RhD-negative fetus but would continue to be performed if high-throughput NIPT was inconclusive or
had identified a RhD-positive fetus.
3. NIPT postpartum scenario 3 (PP3): postpartum cord blood typing would be performed if high-throughput
NIPT of fetal RhD status identifies a RhD-negative fetus. FMH testing and postdelivery anti-D
immunoglobulin would be administered if high-throughput NIPT was inconclusive or identifies a
RhD-positive fetus.
4. NIPT postpartum scenario 4 (PP4): postpartum cord blood typing not performed in any women. FMH
testing and postdelivery anti-D immunoglobulin administered if high-throughput NIPT was inconclusive
or had identified a RhD-positive fetus.
The impact that postdelivery testing has on the cost-effectiveness results is explored using separate
scenarios in the model. In reality, these four separate scenarios actually represent separate and distinct
testing and management strategies and, hence, could also be considered to represent relevant strategies
that should be directly compared in the cost-effectiveness assessment.
INDEPENDENT ECONOMIC ASSESSMENT
NIHR Journals Library www.journalslibrary.nihr.ac.uk
58
The cost-effectiveness of high-throughput NIPT is determined by comparing with current practice (i.e. no
use of high-throughput NIPT), which comprises (1) RAADP and supplementary anti-D immunoglobulin
(as required based on potentially sensitising events) offered to all RhD-negative pregnant women and
(2) further postpartum anti-D immunoglobulin offered to all RhD-negative women whose baby’s RhD
status is confirmed to be positive after cord blood typing.
A schematic representation of the model is provided in Figure 12a and b. Note that this figure does not
provide a comprehensive representation of all components being considered in each alternative strategy,
including the postpartum scenarios. The four postpartum scenarios for how the introduction of NIPT could
impact on the use of cord serology, fetal maternal haemorrhage tests and anti-D immunoglobulin use
following delivery are detailed in Table 17.
The model considers the total number of children who would be born to each RhD-negative woman in order
to capture the effect of any sensitisation on all subsequent pregnancies based on national fertility rates. We
assume that the consequences of sensitisation do not affect the pregnancy in which it occurs (with respect
to treatments and tests administered, management and health outcomes of the resultant RhD-positive baby)
but rather only subsequent pregnancies. Under current practice, a woman who is sensitised during
pregnancy will be identified at the start of her next pregnancy, when she will be tested for antibodies to
the RhD antigen. As a consequence of having been sensitised, the woman will be subject to more intense
antenatal care in all subsequent pregnancies (see Cost of management of sensitisation) and any further
RhD-positive fetuses are at risk of adverse health consequences (see Cost of high-throughput non-invasive
prenatal testing and Cost of management of sensitisation). First and subsequent pregnancies together with
long-term consequences of sensitisations, in terms of costs and utilities, are evaluated with a yearly cycle and
a lifetime horizon. This lifetime horizon includes the full life expectancy of any fetus lost as a consequence of
sensitisation. The decision model follows a NHS perspective, and all costs and effects are discounted at a
rate of 3.5% each year. The main outcomes of interest within the model are the total lifetime costs and total
lifetime QALYs for each of the alternative pathways. Other outcomes recorded in the model include:
l number of sensitisations and the associated costs
l number of affected fetuses following sensitisation
l number of fetuses lost and associated QALY loss
l cost per life-year gained.
What alternative scenarios have been modelled?
In addition to the five alternative pathways compared in the base-case analysis, we compare the inclusion
of the high-throughput NIPT at specific gestational ages. These are determined based on available data
that show how the diagnostic accuracy of the test varies with gestational age. The timing of the test is
important not only in terms of diagnostic performance but also in terms of the cost of managing
potentially sensitising events. Although the majority of these are thought to occur in the third trimester
(weeks 29–40), any that occur prior to the use of the high-throughput NIPT will incur the cost of anti-D
immunoglobulin for all women regardless of fetal RhD status. We further explore the impact of variation in
compliance with anti-D immunoglobulin.
Under current guidance, more recent data on RAADP coverage indicate an uptake of approximately
99.0% in women who are still pregnant at 28 weeks and where the father is not established as RhD
negative.8 In addition, postpartum anti-D immunoglobulin current uptake is believed to be also close to
100%.8 However, data relating to the uptake of routine and postpartum anti-D immunoglobulin in the
presence of fetal RhD status identification are scarce (see Chapter 3). Finally, we consider alternative
scenarios for the proportion of women in whom the NIPT result is inconclusive. The rate of inconclusive
results may reach > 14% and these are typically managed as RhD-positive results (see Chapter 3, Results:
assessment of diagnostic accuracy). However, women in whom the high-throughput NIPT result is
inconclusive are likely to differ systematically from those in whom the test result is positive, with ethnicity
being the most important factor.
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FIGURE 12 Decision-analytic model schematic representation of RhD-negative pregnant women pathways. (a) No high-throughput NIPT and RAADP (current practice, no test
and RAADP); and (b) high-throughput NIPT and targeted RAADP. (continued )
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FIGURE 12 Decision-analytic model schematic representation of RhD-negative pregnant women pathways. (a) No high-throughput NIPT and RAADP (current practice, no test
and RAADP); and (b) high-throughput NIPT and targeted RAADP.
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Model input parameters
This section provides a description of key model input parameters and the evidence used to inform these.
A full list of parameters and their characteristics is given in Table 23.
Target population
The number of pregnancies in RhD-negative women in England was estimated to be 99,225 per year.
This represents a cross-section of all pregnancies and the proportions of first, second, third and subsequent
pregnancies are used to characterise the total fertility rate of a typical RhD-negative woman. This estimate
was based on a birth rate of 12.2 per 1000 women per year80 and assumes that 15% of the population is
RhD negative.3
Proportion of RhD-positive babies born to RhD-negative women
The RhD status of babies does not depend solely on the zygosity of the mother but also of the father.
The RhD-negative gene is recessive. Following Mendel’s law on inheritance,81 if the father is homozygous
(i.e. he has two RhD-positive genes) all of his children will be RhD positive, but if he is heterozygous (i.e.
he has one RhD-positive gene and one RhD-negative gene) his children will have a 50% chance of being
RhD-negative. Therefore, as in the NICE TA156,62 the model assumes that the proportion of RhD-positive
babies born to RhD-negative women is a function of (1) the proportion of RhD-positive men (assumed
to be identical to the proportion of RhD-positive women, thus, the complement of the proportion of
RhD-negative women), (2) the proportion of heterozygous fathers and (3) the proportion of heterozygous
fathers having RhD-positive babies. Although the probability of having a RhD-positive baby in subsequent
pregnancies can be estimated conditional on knowledge of the RhD status of the first baby, we do not
split the cohort in this way. The use of high-throughput NIPT among RhD-negative women not yet
sensitised to the RhD antigen is not expected to be determined on the basis of the RhD status of previous
offspring. It is therefore unnecessary to split the cohort according to this characteristic and so we apply the
same overall rate of RhD-positive babies across all pregnancies. This equates to approximately 62%, as
described in Table 18.
Diagnostic accuracy of non-invasive prenatal testing
Data on the diagnostic accuracy of high-throughput NIPT are based on the meta-analyses summarised in
Chapter 3, Results: assessment of diagnostic accuracy. The base case utilises the pooled results for the
subgroup of UK (Bristol-based) studies in which inconclusive results are considered as test positive. These
were considered to be the most relevant to the English setting. Sensitivity, specificity (with 95% CIs) and
the correlation between these two test accuracy dimensions (on the log-odds scale) were used to inform
TABLE 17 Characteristics of the postpartum scenarios
Scenario High-throughput NIPT result Cord serology FMH test Postpartum anti-D
PP1 Any Yes Yes if CS+ As guided by CS and FMH test
PP2 T– No No No
T+, inc Yes Yes if CS+ As guided by CS and FMH test
PP3 T– Yes Yes if CS+ As guided by CS and FMH test
T+, inc No Yes Yes with additional dose per FMH test
PP4 T– No No No
T+, inc No Yes Yes with additional dose per FMH test
CS, cord serology.
‘–’ indicates a negative high-throughput NIPT result; ‘+’ indicates a positive high-throughput NIPT result; ‘inc’ indicates a
inconclusive high-throughput NIPT result.
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log-normal distributions within the decision model. Note that the correlation estimate for the UK (Bristol)
approach was based on only three studies (Table 19). SAs were performed based on pooled results from all
studies and when inconclusive results were not considered as test positive. In general, high-throughput NIPT
accuracy is consistently high across the different approaches to the diagnostic meta-analysis. The subgroup
of only UK studies shows a lower FNR and a slightly higher FPR than other scenarios.
Only one study12 extensively examined the test performance at multiple gestation time points. In scenario
analysis these results were used to assess the cost and consequences of introducing high-throughput NIPT
at different gestation ages (Table 20). We considered that high-throughput NIPT might be targeted at
more specific gestational ages from 11 weeks’ gestation and not after 24 weeks’ gestation, and thus,
in the model, we compared the diagnostic accuracy reported for 11–13 weeks, 14–17 weeks and
18–23 weeks (see Sensitivity analyses results).
TABLE 18 Probability of subsequent RhD-positive baby following the birth of a RhD-positive baby
Parameter
Mean
value
Standard
error Distribution Source/calculation
Total number of births 659,213 – – Office for National Statistics,
201382
Proportion of pregnancies
accounted for by Rh-negative
women (a)
15.0% – – NHS Digital, Hospital Episode
Statistics, 2013–143
Proportion of heterozygous
fathers (b)
55.0% 10.0% Normal Roman and Pernell, 200283
Proportion of heterozygous fathers
having RhD-positive babies (c)
50.0% – – Assumption
Proportion of RhD-positive babies in
Rh-negative women (first baby) (d)
61.6% – Uncertainty captured
from above (f)
Estimate based on information
above [ = (1 – a) – ((1 – a) × b × c)]
Probability that baby will be
RhD-positive in second, third
and subsequent pregnancies
61.6% – Uncertainty captured
from above (f)
Assumed the same as the
proportion of RhD-positive
babies in Rh-negative women
(first baby) (d)
TABLE 19 Summary results of alternative scenarios of high-throughput NIPT RhD diagnostic testing using
bivariate models
Pooled NIPT accuracy from bivariate
synthesis model
Sensitivity
(mean, 95% CI)
Specificity
(mean, 95% CI)
Correlation
between sensitivity
and 1 – specificity
(log-odds scale) Distribution
All studies (excluding inconclusive
results)
0.996
(0.991 to 0.999)
0.987
(0.981 to 0.991)
0.461 Log-normal
All studies (treating inconclusive results
as if testing positive)
0.997
(0.992 to 0.999)
0.962
(0.943 to 0.975)
–0.316 Log-normal
Only studies reporting inconclusive
resultsa (treating inconclusive results
as if testing positive)
0.996
(0.989 to 0.998)
0.957
(0.932 to 0.972)
–0.074 Log-normal
UK Bristol studies only (treating
inconclusive results as if testing positive)
0.998
(0.992 to 0.999)
0.942
(0.92 to 0.959)
–1.000 Log-normal
a Excluding Thurik et al.21 and Grande et al.22
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Non-invasive prenatal testing inconclusive results
In the UK studies that inform the base case for the decision model, the pooled proportion of inconclusive
NIPT results was 6.7%. Across all diagnostic studies that report the number of inconclusive results this
proportion is lower at 4.0%. The results of the diagnostic accuracy studies suggest that the probability of a
RhD-positive baby is higher among women in whom the high-throughput NIPT is inconclusive than in all
RhD-negative women (see Chapter 3, Inconclusive test results). In Proportion of RhD-positive babies born
to RhD-negative women, it was estimated that the probability of RhD-negative women having RhD-positive
babies in the first and subsequent pregnancies was 61.6%. In the presence of high-throughput NIPT
inconclusive results it is estimated that this probability is 70.1%, irrespective of the pregnancy. This
probability is slightly reduced (70.7%) if only UK studies are considered. These last two probabilities are
used to estimate the positive predictive value of NIPT, and in SA around the postpartum management of
women with inconclusive NIPT results (SA8).
Effectiveness of anti-D immunoglobulin
The introduction of high-throughput NIPT into the care pathway will be used to determine the level of
use of anti-D immunoglobulin. Anti-D immunoglobulin affects the rate of sensitisation in women carrying
RhD-positive fetuses and carries a potential risk of adverse effects as it is derived from blood products.
The costs and consequences of the introduction of high-throughput NIPT are therefore determined by:
l the efficacy of anti-D immunoglobulin in preventing sensitisation, as this determines the health and
cost implications for women from whom this is incorrectly withheld because of a false-negative
high-throughput NIPT result
l the costs and adverse effects associated with administration of anti-D immunoglobulin.
The clinical effectiveness and cost-effectiveness of RAADP in RhD-negative women has been previously
established in NICE TA4184 and most recently in NICE TA156.62 No new systematic reviews of RAADP with
studies not considered in TA156 were identified. We maintain consistency between the NICE TA process
and the diagnostics assessment of high-throughput NIPT for fetal rhesus D status by utilising the RAADP
TABLE 20 High-throughput NIPT RhD diagnostic test performance at multiple time points and when including and
excluding inconclusive test results
NIPT accuracy per gestational age (weeks)12
Sensitivity
(mean, standard error)
Specificity
(mean, standard error) Distribution
Treating inconclusive results as if testing positive
< 11 0.9685 (0.0079) 0.9440 (0.0123) Log-normal
11–13 0.9983 (0.0023) 0.9525 (0.0114) Log-normal
14–17 0.9967 (0.0045) 0.9534 (0.0141) Log-normal
18–23 0.9982 (0.0003) 0.9304 (0.0138) Log-normal
> 24 1.0000 (0.0010) 0.9574 (0.0076) Log-normal
Excluding inconclusive results
< 11 0.9615 (0.0079a) 0.9970 (0.0123a) Log-normal
11–13 0.9981 (0.0023a) 0.9884 (0.0114a) Log-normal
14–17 0.9963 (0.0045a) 0.9956 (0.0141a) Log-normal
18–23 0.9980 (0.0003a) 0.9847 (0.0138a) Log-normal
> 24 1.0000 (0.0010a) 0.9900 (0.0076a) Log-normal
a In the absence of information the standard errors were assumed to be the same as in the approach in which
inconclusive results were treated as positive results.
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efficacy estimated based on the same set of clinical effectiveness studies that were considered to be most
representative of the UK within NICE TA156. The parameter estimates applied in our base-case analyses are
based on the synthesis presented within NICE TA156. The impact of using alternative estimates reported in
a related publication by Turner et al.,63 published after NICE TA156 had been completed, is explored within
a separate SA. Evidence for the clinical effectiveness of the postpartum use of anti-D immunoglobulin was
sourced from a previous Cochrane review.65 The clinical effectiveness estimates of RAADP and postpartum
use of anti-D immunoglobulin reported across these separate sources are reported in Table 21.
National Institute for Health and Care Excellence technology appraisal on
routine antenatal anti-D prophylaxis
The NICE TA156 found 10 relevant studies that evaluated the clinical effectiveness of RAADP. These
studies varied in terms of their patient selection criteria and dosage regimens. Despite this apparent
heterogeneity across studies, overall consistency of results was obtained when synthesising relevant data
from different subsets of the evidence base. The result of a fixed-effect meta-analysis of two non-randomised
community-based UK studies that used a dosage regimen of 500 international units (IUs) at 28 weeks and
34 weeks were considered to be most relevant to the UK. Based on these results, the introduction of
RAADP, in addition to the use of anti-D immunoglobulin for potentially sensitising events and post partum,
was assumed to reduce the sensitisation rate from 0.95% (95% CI 0.18% to 1.71%) to 0.35% (95% CI
0.29% to 0.40%). These sensitisation rates are conditional on anti-D immunoglobulin treatment being
provided at potentially sensitising events also. This gives an odds ratio for the risk of sensitisation of
0.37 (95% CI 0.21 to 0.65) for RAADP compared with no RAADP and an absolute reduction in risk of
sensitisation in RhD-negative mothers at risk (i.e. of carrying a RhD-positive child) of 0.6%. These estimates
were used in the economic model, which informed the NICE TA156 and are also used to inform the
base-case analysis for the de novo model presented here.
Turner et al.63
Following the publication of the NICE TA156, Turner et al.63 revisited the effectiveness of RAADP for
preventing sensitisation in pregnant RhD-negative women. This publication used alternative meta-analytic
TABLE 21 Effectiveness of anti-D immunoglobulin when routinely administered and post partum
Source
Sensitisation, odds ratio (95% CI) Sensitisation rate, % (95% CI)
RAADPa
At birth, follow-up
up to 6 months,
with postpartum
anti-Db
(Baseline) no
RAADPa
RAADP
(pooled using
meta-analysis)
No RAADP and
no postpartum
anti-D
NICE TA15662 0.37
(0.21 to 0.65)
– 0.95
(0.18 to 1.71)
0.35
(0.29 to 0.40)
–
Turner et al.63 0.31
(0.17 to 0.56)
– 0.95c
(0.18 to 1.71)
0.40
(0.16 to 0.70)
–
Turner et al.,63
(single dosed)
0.42
(0.17 to 0.73)
– 0.95c
(0.18 to 1.71)
0.30
(0.16 to 0.53)
–
Turner et al.,63
(two dosee)
0.31
(0.09 to 0.65)
– 0.95c
(0.18 to 1.71)
0.31
(0.09 to 0.62)
–
fCrowther et al.65 – 0.08
(0.06 to 0.11)
0.95c
(0.18 to 1.71)
– 10.7
(8.0 to 13.8)
a Versus no RAADP, conditional on receiving postpartum anti-D immunoglobulin.
b Versus no postpartum anti-D immunoglobulin, conditional on no RAADP.
c Baseline sensitisation rate of no RAADP assumed the same.
d Single dose (1500 IU) at 28–30 weeks, conditional on receiving postpartum anti-D immunoglobulin.
e Two doses (500 IU) at 28 and 34 weeks, conditional on receiving postpartum anti-D immunoglobulin.
f Sensitisation 6 months after delivery, irrespective of ABO status.
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methods, which allow for the adjustment of both methodological limitations (internal biases) in the set of
studies to be combined and differences in study design relative to the research question of interest
(external biases). The impact of differences in dose regimen, follow-up times and study populations were
evaluated by clinical experts (‘assessors’) with knowledge of anti-D immunoglobulin prophylaxis, and the
impact of methodological flaws in the studies was evaluated by assessors with quantitative expertise.
Elicited evidence on the bias for each study was used to adjust the study effect estimates and standard
errors, while acknowledging uncertainty in the extent of bias.
After adjusting for differences in study quality and design, the pooled odds ratio for sensitisation was
estimated to be 0.31 (95% CI 0.17 to 0.56), with no evidence of heterogeneity (I2 = 0%). Pooled results
were similar to the ones obtained from the NICE TA156 meta-analysis, which included only two studies.
Thus, this result substantiated the already existing evidence on the effectiveness of RAADP in preventing
sensitisation of pregnant RhD-negative women. This odds ratio is applied in a SA for the de novo model
presented here.
Postpartum use of anti-D
Current anti-D immunoglobulin postpartum prophylaxis states that following a baby’s birth, ABO and
RhD typing should be performed on a cord blood sample. If the baby is confirmed to be RhD positive,
all RhD-negative, previously non-sensitised, women should receive a minimum of 500 IU of anti-D within
72 hours of delivery. Maternal samples should be tested for FMH and additional dose(s) given as guided by
FMH tests.2,7
A Cochrane systematic review was identified that assessed the effectiveness of anti-D immunoglobulin in
RhD-negative women who had given birth to RhD-positive babies.65 Data on six eligible studies, comparing
postpartum anti-D immunoglobulin prophylaxis with no treatment or placebo, were synthesised. The
estimated odds ratio for sensitisation 6 months after birth with postpartum anti-D immunoglobulin was
0.08 (95% CI 0.06 to 0.11). The estimated odds ratio for sensitisation in subsequent pregnancies with
postpartum anti-D immunoglobulin was 0.12 (95% CI 0.07 to 0.19). The former was estimated on five
studies with approximately 7500 participants and the latter was based on four studies with approximately
1000 patients. Thus, on the basis of a larger sample size we assumed the former estimate to be the most
representative of the effectiveness of postpartum anti-D immunoglobulin in the target population (reported in
the last row of results in Table 20). Estimated benefits of postpartum anti-D immunoglobulin administration
were observed irrespective of the ABO status of mother and child.
Potentially sensitising events
Following potentially sensitising events, the administration and dosage of anti-D immunoglobulin is
conditional to the pregnancy stage in which the event occurs. Current guidance7 recommends that only in
extraordinary sensitising events (such as ectopic pregnancy, molar pregnancy or therapeutic termination of
pregnancy) should anti-D immunoglobulin be administered at < 12 weeks’ gestation. A minimum dose of
250 IU of anti-D immunoglobulin within 72 hours of the event is recommended to be administered if it
occurs between 12 and 20 weeks’ gestation. For potentially sensitising events after 20 weeks’ gestation, a
minimum anti-D immunoglobulin dose of 500 IU should be administered within 72 hours, with additional
doses as guided by a test for FMH.
Evidence on the reported number of potentially sensitising events was found in the recent audit on anti-D
immunoglobulin prophylaxis.8 The probability of women having at least one (reported) potentially
sensitising event was estimated to be 15.5%. Of these, 69.3% women were estimated to have had a FMH
test and 95.8% women were estimated to have been treated with anti-D immunoglobulin following the
event. It was estimated that approximately 80% of these events happened after 20 weeks’ gestation. We
assume that these 80% of sensitising events are treated with the minimum required dose of 500 IU of
anti-D immunoglobulin. For the remaining 20% of events (pre 20 weeks’ gestation events), we assumed
that women received the minimum required dose of 250 IU of anti-D immunoglobulin.
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The audit on anti-D immunoglobulin prophylaxis8 also provided information on the type of potentially
sensitising event. It was estimated that the probability of women having a miscarriage (including stillbirth
and intrauterine death) was 4.7%. We assumed that these fetal deaths were not a consequence of
sensitisation and they are incorporated in the model only to adjust the amount of postpartum health
resource consumption following delivery.
In contrast to women in whom the high-throughput NIPT result indicates that their fetus is RhD positive,
women in whom the test shows that the fetus is RhD negative will not be offered prophylactic anti-D
immunoglobulin treatment and will not be subject to FMH testing. This is an issue particularly for the false
negatives (RhD-negative women with a RhD-positive fetus but for whom the test result was negative), as
these women will, at most, receive only postpartum treatment. For women with false-negative NIPT results
who receive only postpartum anti-D immunoglobulin, the model assumes a rate of sensitisation of 0.95%.
This is likely to be an underestimate, as it includes receipt of anti-D immunoglobulin for potentially
sensitising events. However, the only other estimate for the rate of sensitisation without RAADP is that
based on no anti-D immunoglobulin at all, including no postpartum treatment (10.7%), which is likely to be
a large overestimate, as the majority of events occur at birth (see Table 20). The true rate of sensitisation is
likely to lie between 0.95% and 10.7%, but it appears reasonable that this rate will be closer to 0.95%.
Compliance with routine antenatal anti-D prophylaxis and postpartum anti-D
immunoglobulin
The National Comparative Audit of Blood Transfusion 2013 on Anti-D Immunoglobulin Prophylaxis8
reported that, out of all eligible women, 99% received at least one RAADP injection. Full compliance
(i.e. correct dose at the correct time) was found to be higher in the single-dose regime (90%) than in the
two-dose regime (59%). In addition, the audit shows that a very high proportion of eligible women
(98.4%) received postpartum anti-D immunoglobulin prophylaxis. Finally, for documented potentially
sensitising events, it showed that approximately 96% of eligible women having these events received
anti-D immunoglobulin.
Following the recent audit findings, within the de novo economic model it has been assumed that
compliance with RAADP is 99.0%. This value was assumed for the base case and subject to scenario
analysis, assuming a rate of 87.5% (i.e. the proportion receiving the correct dose at the correct time).
Evidence from the audit points to higher compliance with the single-dose regimen than with the two-dose
regimen for a number of reasons (e.g. cost, manufacturer supply, etc.) and there is a move towards the
use of the single dose, over the two dose, with its market share reaching approximately 93%.8 Thus, we
did not adjust the compliance rate across RAADP regimen. In the model it has been also assumed that
postpartum anti-D immunoglobulin compliance rate is 98.4%, again following evidence from the recent
audit.8 This value was subject to scenario analysis by assuming a rate of 91.6% (i.e. the proportion
receiving the correct dose at the correct time).
Compliance with non-invasive prenatal testing given routine antenatal anti-D
prophylaxis and postpartum anti-D immunoglobulin
The evidence for compliance with high-throughput NIPT is scarce, particularly in health systems in which the
test is introduced after RAADP guidance is in place (see Chapter 3, Results: assessment of clinical effectiveness).
In the absence of such evidence, and based on the already high rates of compliance assumed for current
practice (99.0% for RAADP and 98.4% of women received at least one dose of anti-D immunoglobulin at
RAADP and post-partum, respectively), we subsequently assume that the use of high-throughput NIPT has no
additional impact on compliance. Therefore, it has been assumed that RAADP and postpartum anti-D
immunoglobulin compliance is 99.0% and 98.4%, respectively, the same as in the no high-throughput
NIPT scenarios.
Sensitisation outcomes
As for the independent economic model developed for NICE TA156 on RAADP, the current economic
model considered a set of input parameters directly related to the consequences of sensitisation towards
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the fetus and the newborn infant, namely the implications of haemolytic disease. Three of these model
input parameters were key to an appropriate representation of the possible health states, namely (1) the
fetal loss rate per RhD-negative women at risk (i.e. carrying a RhD-positive baby), (2) the proportion of
babies affected by haemolytic disease that resulted in minor developmental problems (these include, for
instance, myopia, squint or delay in language and fine motor skills) and (3) the proportion of babies
affected by haemolytic disease that resulted in major developmental problems (these include, for instance,
severe permanent neurodevelopmental delay, such as cerebral palsy). Given the long-term consequences
of these two last parameters, it was also important to consider the average duration of minor development
problems and the life expectancy of an individual with major development problems.
A pragmatic literature search was performed to identify evidence sources for the outcomes associated with
haemolytic disease of the fetus and newborn infant, in addition to the ones found in the NICE TA156.
The literature review focused particularly on the anti-D immunoglobulin systematic reviews64,65,85 and the
high-throughput NIPT diagnostic accuracy studies (see Chapter 3, Results: assessment of clinical effectiveness)
as potential sources of data associated with the consequences of sensitisation. Apart from the study
published by Finning et al.,17 no other relevant evidence was found. Evidence from this study relating to the
proportion of fetal or neonatal deaths (5%) and to the proportion of babies affected with mild/severe
development problems (5%) was used to populate the model. In the absence of more recent data for
parameters relating to the proportion of babies affected with minor development problems and the duration
of these problems and relating to the life expectancy of people with major developmental problems, we used
the same evidence as NICE TA156 with updated costs. It should be noted that owing to the small number of
haemolytic disease-related events, the corresponding model estimates are subject to considerable uncertainty.
In the absence of more recent or relevant data, the health-related quality of life evidence used relating to
the utilities of minor (0.85) and major (0.42) development problems and the associated uncertainty was
assumed to be the same as those used in NICE TA156.62
Cost of high-throughput non-invasive prenatal testing
For the base-case analysis the cost of high-throughput NIPT per sample was estimated to be (confidential
information has been removed). This unit cost takes into account consumables, staffing, equipment, indirect
costs and overhead costs. This is the company’s estimated cost of testing at full capacity, that is, dealing with
at least 100,000 samples. An estimated royalty payment of (confidential information has been removed) of
the test cost is assumed to be added to the unit cost of the test, bringing the base-case estimate of the cost
of the test to (confidential information has been removed). The cost of high-throughput NIPT is discounted
according to the pregnancy number in which it is being performed, accounting for an expected median
time between pregnancies of around 3.2 years. The unit cost per sample may, however, fluctuate, as it is a
function of capacity and predicted level of usage of each testing machine annually. The cost applied in the
base-case analysis does not include transport costs for the delivery of blood samples for testing. Szczepura
et al.68 included a postage cost of £1.10 per sample in their analysis, although they recognised that the cost
would be much reduced if the existing NHS transport service system was to be used.
Cost of routine antenatal anti-D prophylaxis and of anti-D immunoglobulin
for potentially sensitising events and post partum
The cost of anti-D immunoglobulin was taken from the British National Formulary (BNF).86 Currently, two
brands [D-Gam® (Bio Products Laboratory Ltd, Elstree, Hertfordshire, UK) and Rhophylac®(CSL Behring LLC,
Kankakee, IL, USA)] and four doses (250-, 500-, 1500- and 2500-unit vials) are available. At current prices
the cost of anti-D immunoglobulin is £23.75 for D-Gam 250 IU, £33.75 for D-Gam 500 IU and £39.52 for
Rhophylac. Note that current market prices of anti-D immunoglobulin may vary with supply and demand.
Regional and local price negotiations exist that may make the cost anti-D immunoglobulin lower than the
values indicated above.
The cost of anti-D immunoglobulin for potentially sensitising events was estimated to be £31.69,
representing a weighted average of the cost of anti-D immunoglobulin 250 IU and 500 IU (minimum
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required) doses and their expected utilisation before and after 20 weeks’ gestation based on evidence
from a recent audit.8 The cost of RAADP was estimated to be £41.58, representing a weighted average of
single-dose (1500 IU) and two-dose (2 × 500 IU) regimens and their associated market share, 92.6% versus
7.4%, respectively.8 Similarly, the cost of anti-D immunoglobulin administered post partum was estimated
to be £35.69, which reflects the expected utilisation of ‘standard’ doses: 500 IU (66.3%) and 1500 IU
(33.7%).8 Costs applied in the current economic model were discounted according to the timing of the
pregnancy (the pregnancy number) in which the treatments are administered. As in NICE TA156,62 an
administration cost of anti-D immunoglobulin was set to £5.
Cost of postpartum health resources used
Following birth, in current practice a cord serology test should be performed to confirm the baby’s RhD
type. In addition, maternal blood samples should be tested for FMH. The costs, updated to 2015 prices,
for postpartum serology (£4.18) and associated phlebotomy (£3.32) were obtained from Szczepura et al.68
The cost of FMH testing was provided by personal communication with a NHS Blood and Transplant
Manager and estimated to be £128.10 (for test by flow cytometry, NHS Blood and Transport Red Cell
Immunohaemotology) (Erika Rutherford, NHS Blood and Transplant, 2016, personal communication). This
cost was subject to SA, as Szczepura et al.68 report a much lower value of £3.17 for a Kleihauer test (when
updated to 2015 prices). All costs were discounted according to the timing of the pregnancy in which the
resources were consumed.
Cost of management of sensitisation
The list of relevant interventions in the management of maternal and neonatal sensitisation was taken from
the previous NICE TA156.62 The proportion of individuals requiring each intervention, the estimated average
number of interventions required per individual and the estimated average number of days were considered
to be the same as in NICE TA15662 (Table 22). Utilisation of these resources was validated by our clinical
experts, who highlighted that no significant changes in clinical practice have occurred since 2009. Similarly,
the estimated annual costs for minor (£111) and major (£574) development problems was assumed to be
the same as in NICE TA156 but updated to 2015 prices. Unit costs were sourced from the NHS reference
costs 2014–15.87 The total average cost per sensitisation is estimated to be £3167. Note that, owing to the
multiplicity of factors affecting sensitisation and its management, the uncertainty associated with this
parameter was taken from NICE TA15662 and assumed to be substantial (standard error £700).
Model parameters and main assumptions
The parameters used within the de novo economic model, and their characteristics, as described in the
preceding sections, are outlined in Table 23. Costs refer to 2015 prices.
Within the model the following assumptions are consistent with NICE TA156:62
l Sensitisations do not affect the pregnancy in which they occur.
l Anti-D immunoglobulin used within one pregnancy has no effect on reducing sensitisations during the
next pregnancy.
l The proportion of RhD-negative women is based on the white European population given that this
group makes up > 90% of the population of England and Wales.
Furthermore, the following assumptions were made:
l The proportion of RhD-positive babies in Rh-negative women is the same irrespective of
pregnancy number.
l The probability of having a RhD-positive baby in the general population of Rh-negative women (61.6%) is
combined with the diagnostic accuracy results in terms of sensitivity and specificity (in which inconclusive
results are treated as test positive) to determine the number of Rh-positive babies in the model.
l The probability of having a RhD-positive baby in women with inconclusive test results is based on the
pooled probability in the study populations used to inform the diagnostic accuracy estimates.
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TABLE 22 Cost of management of sensitisation
Intervention
Management
element
Percentage of sensitised
mothers/babies
requiring intervention
Average number
required per
person
Average
days per
treatment
Unit cost of
intervention (£)
Total
cost (£)
Listed NHS Reference Costs 2014–1587
used for the unit costs
Management of
maternal
sensitisation
Blood tests, bilirubin,
monitoring, etc.
100 6 1 195 1172 Code NZ19B – Ante-Natal Major
Disorders with CC Score 0–1 – Regular
Day or Night Admissions
Doppler scanning 90 4 1 109 392 Code NZ21Z – Ante-Natal Standard
Ultrasound Scan – Outpatient Procedures
In utero transfusion 5 3 1 195 29 Code NZ19B – Ante-Natal Major
Disorders with CC Score 0–1 – Regular
Day or Night Admissions
Management of
the sensitised baby
Phototherapy 71 1 3 526 1121 Code PB04D; PB05C; PB06F; PB06M
(average) – Neonatal Diagnoses –
Non-elective Inpatients – Short Stay
Exchange transfusion 5 2 1 526 53 Code PB04D; PB05C; PB06F; PB06M
(average) – Neonatal Diagnoses –
Non-elective Inpatients – Short Stay
Neonatal follow-up
visits
10 2 1 526 105 Code PB04D; PB05C; PB06F; PB06M
(average) – Neonatal Diagnoses –
Non-elective Inpatients – Short Stay
Neonatal intensive
care unit
5 1 5 1176 294 Code XA01Z – Neonatal Critical Care,
Intensive Care – Critical Care
Total 3167
CC, Complication and Comorbidity.
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TABLE 23 Model parameters
Parameter Mean value
Standard
error Distribution Source/calculation
Discounting
Discount rate for utilities 3.5% – – NICE methods guidance88
Discount rate for costs 3.5% – – NICE methods guidance88
Target population characteristics
Population of England (a) 54,316,600 – – Office for National Statistics, Annual
Mid-year Population Estimates, 201489
Crude birth rate in England: all
births per 1000 population of
all ages (b)
12.18 – – Office for National Statistics, Births in
England and Wales, 201480
Proportion of pregnancies
accounted for by Rh-negative
women (c) – reiterated from
Table 17
15.0% – – NHS Digital, Hospital Episode
Statistics: NHS Maternity Statistics,
2013–143
Number of women requiring
treatment
99,225 – – Estimate based on information above
[ = (a × (b/1000) × c)]
Proportion of first pregnancies
proceeding to next pregnancy
91.4% – – Office for National Statistics, Birth
Summary Tables, England and Wales90 –
Characteristics of Mother 2, England
and Wales – Average 2009 to 2013
Proportion of second
pregnancies proceeding to next
pregnancy
40.5% – – Office for National Statistics, Birth
Summary Tables, England and Wales90 –
Characteristics of Mother 2, England
and Wales – Average 2009 to 2013
Proportion of third pregnancies
proceeding to next pregnancy
58.3% – – Office for National Statistics, Birth
Summary Tables, England and Wales90 –
Characteristics of Mother 2, England
and Wales – Average 2009 to 2013
Median time between
pregnancies (years)
3.17 – – Office for National Statistics, Birth
Summary Tables, England and Wales
201490 – Characteristics of Mother 2,
England and Wales, 2013
Compliance
Compliance with RAADP 99.0% 0.1% Beta NHS Blood and Transplant, National
Comparative Audit of Blood
Transfusion – 2013 Audit of Anti-D
Immunoglobulin Prophylaxis8
Compliance with RAADP if
high-throughput NIPT
performed
99.0% 0.1% Beta Assumed the same as compliance
with RAADP
Compliance with postpartum
Anti-D immunoglobulin (dose
of at least 500 IU given within
3 days of delivery)
98.0% 0.2% Beta NHS Blood and Transplant, National
Comparative Audit of Blood
Transfusion – 2013 Audit of Anti-D
Immunoglobulin Prophylaxis8
continued
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TABLE 23 Model parameters (continued )
Parameter Mean value
Standard
error Distribution Source/calculation
High-throughput NIPT inconclusive results
Proportion of high-throughput
NIPT inconclusive results: all
studies reporting inconclusives
6.7% 0.4% Beta Diagnostic accuracy review
(see Chapter 3)
Proportion of high-throughput
NIPT inconclusive results: UK
Bristol studies
4.0% 0.1% Beta Diagnostic accuracy review
(see Chapter 3)
Proportion of RhD-positive
babies in high-throughput NIPT
inconclusive results: all studies
reporting inconclusives
70.1% 0.7% Beta Diagnostic accuracy review
(see Chapter 3)
Proportion of RhD-positive
babies in high-throughput NIPT
inconclusive results: UK Bristol
studies
70.7% 0.3% Beta Diagnostic accuracy review
(see Chapter 3)
Sensitisation events
Probability of having at least
one potentially sensitising event
15.5% 0.5% Beta NHS Blood and Transplant, National
Comparative Audit of Blood
Transfusion – 2013 Audit of Anti-D
Immunoglobulin Prophylaxis8
Probability of performing a
FMH test given at least one
potentially sensitising event
69.3% 1.4% Beta NHS Blood and Transplant, National
Comparative Audit of Blood
Transfusion – 2013 Audit of Anti-D
Immunoglobulin Prophylaxis8
Probability of receiving anti-D
after having at least one
potentially sensitising event
95.8% 0.6% Beta NHS Blood and Transplant, National
Comparative Audit of Blood
Transfusion – 2013 Audit of Anti-D
Immunoglobulin Prophylaxis8
Probability of women having a
miscarriage (including stillbirth
and intrauterine death)
4.7% 0.3% Beta NHS Blood and Transplant, National
Comparative Audit of Blood
Transfusion – 2013 Audit of Anti-D
Immunoglobulin Prophylaxis8
Consequences of sensitisation
Fetal loss rate per woman at
risk
5.0% 1.0% Beta Finning et al. (2008)17 and the
previous NICE assessment (TA156)62
Proportion of babies affected
by HDN with minor
developmental problems
6.0% 2.0% Beta Previous NICE assessment (TA156)62
Duration of minor
developmental problems (years)
16 5 Beta Previous NICE assessment (TA156)62
Proportion of babies affected
by HDN with major
developmental problems
5.0% 1.0% Beta Finning et al. (2008)17 and the
previous NICE assessment (TA156)62
Life expectancy for person with
major developmental problems
59.5 Range
40–79
Uniform Previous NICE assessment (TA156)62
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TABLE 23 Model parameters (continued )
Parameter Mean value
Standard
error Distribution Source/calculation
Utilities
Utility for ‘normal’ person 0.88 0.02 Beta Previous NICE assessment (TA156)62
Utility for minor development
problems
0.85 0.02 Beta Previous NICE assessment (TA156)62
Utility for major development
problems
0.42 0.03 Beta Previous NICE assessment (TA156)62
Costs
Cost of high-throughput NIPT (Confidential
information has
been removed)
– – (Confidential information has been
removed)
Royalty fee of high-throughput
NIPT
(Confidential
information has
been removed)
– – (Confidential information has been
removed)
Cost of RAADP £41.58 – – BNF86 and NHS Blood and Transplant,
National Comparative Audit of Blood
Transfusion – 2013 Audit of Anti-D
Immunoglobulin Prophylaxis8 –
weighted average of single- and
two-dose anti-D regimen costs and
their market share
Cost of anti-D immunoglobulin
for potentially sensitising events
£31.69 – – BNF86 and NHS Blood and Transplant,
National Comparative Audit of Blood
Transfusion – 2013 Audit of Anti-D
Immunoglobulin Prophylaxis8 –
weighted average of dose anti-D
regimen cost and the likelihood of pre
and post 20 weeks events
Cost of postpartum anti-D
immunoglobulin
£35.69 – – BNF86 and NHS Blood and Transplant,
National Comparative Audit of Blood
Transfusion – 2013 Audit of Anti-D
Immunoglobulin Prophylaxis8 –
weighted average of dose anti-D
regimen cost and their market share
Cost of anti-D immunoglobulin
administration per RhD-negative
woman treated
£5.00 £2.00 Gamma Previous NICE assessment (TA156)62
Cost of postpartum blood cord
serology
£4.18 – – Szczepura et al.,68 updated to 2015
Cost of FMH testing £128.10 – – Provided by clinical experts
Cost of phlebotomy £3.32 – – Szczepura et al.,68 updated to 2015
prices
Cost of management of a
sensitised woman and
sensitised neonate
£3166.72 £700.00 Gamma Previous NICE assessment (TA156)62
Yearly cost of minor
developmental problems
£110.58 £35.00 Gamma Previous NICE assessment (TA156),62
updated to 2015 prices
Yearly cost of major
developmental problems
£573.72 £405.73 Gamma Previous NICE assessment (TA156),62
updated to 2015 prices
HDN, Haemolytic Disease of the Newborn.
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l All NIPT is performed early enough to determine the use of RAADP at 28 weeks’ gestation.
l Routine and prophylactic anti-D immunoglobulin is offered only to women whose NIPT result indicates
that their fetus is RhD positive or whose results are inconclusive.
l In women with an inconclusive NIPT result the existing care pathway is unchanged and they are treated
the same as women who test positive in terms of RAADP, anti-D immunoglobulin and associated tests.
l Women identified to receive RAADP will receive supplementary anti-D immunoglobulin at the minimum
dose required for any potentially sensitising events.
l Potentially sensitising events that involve fetal death were independent of previous sensitisation within
the same pregnancy.
l Women with false-negative test results but who are provided with cord serology and postpartum
anti-D immunoglobulin have a sensitisation rate of 0.95% despite forgoing anti-D immunoglobulin
treatment for potentially sensitising events.
l Compliance with RAADP is same with and without NIPT; similarly, compliance for postpartum anti-D
immunoglobulin is assumed to be the same with or without NIPT.
Analytic methods
In exploring the alternative means by which the introduction of high-throughput NIPT could impact on the
postpartum care pathway, we first present results for each postpartum scenario separately compared with
‘no test and RAADP’. Thereafter, we combine them and compare them directly in a full incremental analysis.
The decision-analytic model was evaluated using 10,000 Monte Carlo simulations to reflect the joint
uncertainty across all of the inputs according to the probability distributions assigned to each, as shown
in Table 22. All results are presented in terms of the average over 10,000 simulations, as these provide
an unbiased estimate of the expected model outcomes. The existing model non-linearity means that the
deterministic results are not an accurate estimate of the mean costs and QALYs in each strategy. This
non-linearity is likely to be attributable to the model being structured around the specificity and sensitivity
of NIPT and the rate of sensitisation, all characterised by skewed distributions and all with baseline values
close to the upper bound of 1 (sensitivity and specificity) or lower bound of 0 (rate of sensitisation). The
primary results are the total expected costs and expected QALYs for each alternative strategy. Population
net health benefits (NHBs) are used to summarise the cost-effectiveness results in addition to the
cost-effectiveness ratio. NHBs are calculated for cost-effectiveness thresholds of £20,000 and £30,000 as
shown in the equation below:
Net health benefit = QALYs −
Costs
Cost-effectiveness threshold
. (1)
For a given cost-effectiveness threshold, the strategy with the highest net benefit is the same strategy that
would be considered cost-effective when comparing incremental cost-effectiveness ratios (ICERs) against
the threshold. They are useful to summarise results when there are small differences in health between
strategies and when the new intervention may be less effective and less costly than current practice. In
these circumstances, ICERs can be very volatile and sensitive to small changes in the denominator. Further
to this, the ICER for a less costly and less effective new intervention actually represents the cost per QALY
gain of introducing current practice, and this can lead to some confusion in interpretation. The introduction
of the high-throughput NIPT is not expected to produce large differences in clinical outcomes and may
result in lower health outcomes than RAADP if the rate of sensitisations is increased.
Results are expressed per pregnancy and for the cross-section of 100,000 pregnancies, as described in
Target population. It should be noted that for the population-level results, the total number of pregnancies
is distributed across time and, therefore, not all test costs or consequences are experienced in year 1.
Results were initially calculated for the comparison of ‘no test and RAADP’ with ‘no test and no RAADP’ in
order to illustrate the impact of the adjustments made to the model used in NICE TA15662 and to establish
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the baseline comparability in terms of the cost-effectiveness of the current practice, ‘no test and RAADP’.
This was necessary because the benefits of a diagnostic test are reliant on there being a cost-effective
treatment available. The results of this analysis are shown in Appendix 10. Throughout the main body of
this diagnostic assessment report we omit the ‘no test and no RAADP’ strategy, as this is not relevant to
UK current practice.
Cost-effectiveness acceptability curves are used to show the probability that each alternative strategy is
cost-effective for a range of cost-effectiveness threshold. We also calculate the health consequences of the
total amount of parameter uncertainty in terms of the potential health benefits that could be gained if all
uncertainty were eliminated. This is the expected value of perfect information and it represents an upper
bound for the value of any further research to reduce parameter uncertainty. The maximum value of
further research was calculated as the difference between the expected value of basing a decision about
the use of NIPT on perfect information (i.e. with no probability of error) and the expected value of that
decision made on the basis of existing evidence (i.e. subject to uncertainty). This value is expressed in terms
for the cross-section of 100,000 pregnancies multiplied over 10 years, as the further research may inform
decisions beyond the immediate cohort of pregnancies considered in this model.
Uncertainty regarding the appropriate source of data, the appropriate assumptions or model structure and
other scenarios are explored using one- and two-way SA, as described further in Sensitivity analyses.
Base-case analysis
The set of main assumptions used in the base-case analysis are shown in Table 24.
Sensitivity analyses
A series of scenario analyses and SAs was also conducted. We focused on parameters and assumptions to
which we expected that the ICER would be the most sensitive and where the available evidence was
limited. The SAs are described in detail but also summarised in Table 24. We focus on the comparison of
current practice with the best performing postpartum scenario in all cases unless the results of the SA
TABLE 24 Main base-case assumptions
Parameter Assumption/evidence source
High-throughput NIPT accuracy Bivariate meta-analysis of UK (Bristol) studies, see Chapter 3; the diagnostic
test was assumed to be performed at first contact with health services
Effectiveness of RAADP (vs. no RAADP) Sensitisation rate = 0.35% (NICE TA15662)
Uptake of RAADP (with and without
high-throughput NIPT performed)
99.0% (NHS Blood and Transplant, National Comparative Audit of Blood
Transfusion – 2013 Audit of Anti-D Immunoglobulin Prophylaxis8)
Uptake of postpartum anti-D
immunoglobulin (with and without
high-throughput NIPT performed)
98.4% (NHS Blood and Transplant, National Comparative Audit of Blood
Transfusion – 2013 Audit of Anti-D Immunoglobulin Prophylaxis8)
High-throughput NIPT inconclusive results Inconclusive rate of 6.2% treated as positive test results
Cost of high-throughput NIPT Base-case unit cost of (confidential information has been removed) with a
(confidential information has been removed) royalty fee added: (confidential
information has been removed)
Cost of anti-D immunoglobulin Potentially sensitising event, £31.69; RAADP, £41.58; postpartum, £35.69
Cost of FMH test £128.10 (Erika Rutherford, Business Development Manager, Red Cell
Immunohaematology, NHS Blood and Transplant, 2016, personal
communication)
Further postpartum scenario on the
management of high-throughput NIPT
inconclusive results
Inconclusive results are treated post delivery as positive test results
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affect the rank order of postpartum scenarios or suggest that multiple postpartum scenarios could
potentially provide the highest NHB.
Sensitivity analysis 1
We explored alternative sources for the diagnostic performance of high-throughput NIPT. The base-case
analysis utilises the results from the UK (Bristol) studies, as these are thought to be most generalisable to a
UK setting. We also show the results utilising all available studies, regardless of geography. For lower
estimates of sensitivity, high-throughput NIPT is expected to result in more false-negative results, which
are associated with adverse health consequences in terms of additional sensitisations. For lower estimates
of specificity, high-throughput NIPT is expected to result in more false-positive results, which reduce the
amount of unnecessary anti-D immunoglobulin and associated management costs that is avoided.
Sensitivity analysis 2
We explored the use of high-throughput NIPT at different gestation periods. Performance results from a
recent UK study12 were used to assess the cost and consequences of introducing high-throughput NIPT
at 11–13 weeks, 14–17 weeks and 18–23 weeks. Note that the economic model does not incorporate
the timing of a potentially sensitising event and so a threshold analysis is performed to determine the
percentage of the costs that would have to occur prior to NIPT in order for the ICER to cross a threshold of
£20,000 per QALY.
Sensitivity analysis 3
The base-case analysis utilised the same rate of sensitisation with ‘no test and RAADP’ as was used in the
NICE TA156.62 Subsequent to NICE TA156 a further meta-analysis was performed by Turner et al.,63 which
suggests that anti-D immunoglobulin could be marginally more effective if all studies are taken into
account, reducing the rate of sensitisation with ‘no test and RAADP’ from 0.35% to 0.30%. The increased
efficacy of RAADP will increase the health costs associated with false-negative results of high-throughput
NIPT, as women will have incorrectly forgone a more effective treatment.
Sensitivity analysis 4
We explore the impact of an overall change in uptake of anti-D immunoglobulin. Lower uptake of RAADP
will reduce the cost savings possible from avoiding unnecessary RAADP but will also affect the health
consequences of additional sensitisations. However, we did not explore an effect of high-throughput NIPT
on uptake. The base-case analysis assumes that the introduction of high-throughput NIPT will not alter
the proportion of women who comply with the administration of anti-D immunoglobulin. Currently, few
women in the UK refuse RAADP, so there is little scope for an increase in uptake. We consider that it may
be possible that women who would refuse RAADP would also refuse high-throughput NIPT, but this should
not impact on the cost-effectiveness of NIPT, only on throughput. Although the clinical effectiveness review
identified studies that reported the rate of uptake of anti-D immunoglobulin among women provided with
high-throughput NIPT, none provided a comparison with what uptake would have been in those same
women without provision of high-throughput NIPT. We therefore assumed that women informed that they
are carrying a RhD-positive fetus would be no more or less likely to uptake anti-D immunoglobulin than
they would be if offered RAADP. Some women who are told that they are carrying a RhD-negative fetus
may still demand RAADP, and this cost is not incorporated in the model. We conduct a two-way SA in
which the uptake of RAADP is decreased or increased alongside the reduction of the uptake of postpartum
anti-D immunoglobulin.
Sensitivity analysis 5
The base-case analysis incorporates the rate of inconclusive high-throughput NIPT results found in the
UK (Bristol) studies.12,17,18 The rate of inconclusive results will vary according to the local population
demography because they are more likely in certain ethnic groups, such as in those of African ethnic
origin. The rate of inconclusive results may also vary if the operation of NIPT is different in a trial setting
compared with in routine use, for example if less time is spent on reprocessing initially inconclusive test
results. Increasing the rate of inconclusive test results when these are treated as test positive will increase
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the rate of false-positive results and reduce the specificity of NIPT. This will, in turn, reduce the amount of
unnecessary anti-D immunoglobulin and associated management costs that can be avoided through the
use of high-throughput NIPT.
Sensitivity analysis 6
We conduct a two-way SA in which the cost per dose of anti-D immunoglobulin therapy is varied
alongside the cost per high-throughput NIPT. The cost of high-throughput NIPT to the NHS is uncertain for
a number of reasons: (1) the unit cost varies by throughput and so will depend on the total uptake of
NIPT, (2) the unit cost of the test must be considered alongside other potential additional costs relating to
the transportation of blood samples for testing, to whether or not additional antenatal visits are required
to draw blood and to the delivery of test counselling and results and (3) the royalty fee charged to the
NHS in addition to the unit cost of the test is uncertain. The base-case analysis includes a test cost of
(confidential information has been removed) and a royalty fee of (confidential information has been
removed). The base case assumes that high-throughput NIPT can be incorporated in to routine antenatal
care without imposing further marginal costs to the NHS, which is likely to be favourable to any ‘test and
RAADP’ strategies. We calculate the threshold NHS cost per high-throughput NIPT at which the ICER for
any strategy incorporating NIPT falls below £20,000 and £30,000 per QALY. We also show how the ICER
varies as the cost per test is varied between £13.20 and £24.20. The cost of anti-D immunoglobulin
may be subject to discounts from the list prices utilised in the base-case analysis. We show how the
cost-effectiveness results vary to –20%, –10%, +10% and +20% of list price. The cost-effectiveness of
any high-throughput NIPT will be reduced as the price of anti-D immunoglobulin falls because the savings
from avoiding unnecessary RAADP will be lower.
Sensitivity analysis 7
Since the introduction of RAADP there has been a move from the two-dose to the single-dose regimen for
a variety of reasons, as indicated in the recent anti-D immunoglobulin prophylaxis audit. We conducted a
SA that assumes a 100% use of the cheaper of the two regimens, that is, the single dose.
Sensitivity analysis 8
A further alternative way in which the use of high-throughput NIPT may impact on the existing postpartum
care pathway is considered. This strategy, rather than grouping high-throughput NIPT inconclusive results
with positive results, regards them as distinct from those for whom NIPT indicated a RhD-positive fetus.
In this scenario postpartum cord blood typing would be performed if high-throughput NIPT of fetal RhD
status identifies a RhD-negative fetus or if the test result is inconclusive. FMH testing and postdelivery
anti-D immunoglobulin would be administered if a RhD-positive fetus is identified either in the positive test
result group or in the inconclusive test result group.
A summary of the SA performed is listed in Table 25.
Model validation
Pedro Saramago developed the model and Susan Griffin checked the model for errors. Comparisons across
strategies were done to identify inconsistencies. Comparisons with the previous NICE TA156 were also
done to identify the sources of any potential discrepancy.
Results of the independent economic assessment
This section reports the results of the de novo economic model developed to assess the cost-effectiveness
of high-throughput NIPT to identify fetal RhD status in women who are RhD-negative and not known to
be sensitised to the RhD antigen. The base-case results for the different postpartum strategies are shown
first, followed by the results of performing SA on key model input parameters. All results are based on the
probabilistic analysis. Detailed characteristics of each postpartum scenario are provided in Table 16.
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Base-case results
Table 26 presents the results for each postpartum testing scenario separately against current practice of
‘no test and RAADP’. Total costs, total QALYs, incremental costs and incremental QALYs are presented
together with incremental cost per QALY gained (ICER) and population NHBs at £20,000 and £30,000
threshold values. The results of the model suggest that for each additional sensitisation there is a loss of
approximately 0.9 QALYs. Any difference in QALYs between strategies is attributable wholly to the
difference in the number of sensitisations.
Non-invasive prenatal testing PP1 describes the use of NIPT to guide RAADP only, with all women
continuing to receive cord serology with FMH testing and postpartum anti-D immunoglobulin as required,
irrespective of NIPT result. This is estimated to reduce costs by £584,000 per 100,000 pregnancies and to
result in lower health benefits (0.5 QALYs) than current practice.
Non-invasive prenatal testing PP2 (NIPT PP2) describes the use of NIPT to guide both RAADP and
postpartum care to women who test positive or in whom the results are inconclusive, when cord serology
is provided only in these women to guide FMH testing and postpartum anti-D immunoglobulin as required.
This is estimated to reduce costs compared with current practice by approximately £671,000 but to result
in a loss of 19.1 QALYs per 100,000 pregnancies.
Non-invasive prenatal testing PP3 (NIPT PP3) describes the use of NIPT to guide RAADP and postpartum
anti-D immunoglobulin to women who test positive or inconclusive and when cord serology is used to
guide FMH testing and postpartum anti-D immunoglobulin as required only to women whom NIPT
TABLE 25 Summary of SA performed
Parameter Assumption/evidence source
High-throughput NIPT accuracy SA1: bivariate meta-analysis of all studies (see Chapter 3)
SA2: high-throughput NIPT performance assessed at different gestation periods,
using evidence from Chitty et al.12
Effectiveness of RAADP (vs. no RAADP) SA3: sensitisation rate= 0.30% (Turner et al.63)
Compliance with RAADP (with and
without high-throughput NIPT
performed)
SA4a: 87.5% (NHS Blood and Transplant, National Comparative Audit of Blood
Transfusion – 2013 Audit of Anti-D Immunoglobulin Prophylaxis8)
Compliance with postpartum anti-D
immunoglobulin (with and without
high-throughput NIPT performed)
SA4b: 91.6% (NHS Blood and Transplant, National Comparative Audit of Blood
Transfusion – 2013 Audit of Anti-D Immunoglobulin Prophylaxis8)
High-throughput NIPT inconclusive
results
SA5: pooled estimates for the sensitivity and specificity replaced with the
individual study results
Cost of high-throughput NIPT SA6a: varied between £13.20 and £24.20 (confidential information has been
removed)
Cost of anti-D immunoglobulin SA6b: all varied ± 20%
Cost of FMH test SA7: £3.17 (Szczepura et al.,68 updated to 2015 prices)
SA8:
Further postpartum scenario on the
management of high-throughput NIPT
inconclusive results
NIPT result
Cord
serology FMH test Postpartum anti-D
T– Yes Yes if CS+ As guided by CS and FMH test
T+ No Yes Yes with additional dose per FMH test
Inconclusive Yes Yes if CS+ As guided by CS and FMH test
CS, cord serology.
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indicates have a RhD-negative fetus. This is estimated to reduce costs compared with current practice by
£485,000 but to result in a loss of 0.5 QALYs per 100,000 pregnancies.
Non-invasive prenatal testing PP4 (NIPT PP4) describes the use of NIPT to guide both RAADP and
postpartum FMH testing and anti-D immunoglobulin to women who test positive or inconclusive and
when cord serology is not provided. This is estimated to reduce costs compared with current practice by
approximately £573,000 but results in a loss of 19.1 QALYs per 100,000 pregnancies.
All postpartum scenarios are cost saving but also less effective than no test and RAADP, placing them on
the south-west quadrant of the cost-effectiveness plane (Figure 13). The least effective strategies are those
that omit cord serology for women who test negative on NIPT. Without cord serology false negatives are
not picked up at delivery and are not provided with postpartum anti-D immunoglobulin. In the model, the
additional health gains are determined by the management of high-throughput NIPT false-negative
test results.
Owing to these NIPT strategies being less costly and less effective than no test and RAADP, the ICERs
calculated in Table 25 (and Figure 13) show the cost per QALY gained with current practice compared with
high-throughput NIPT. Hence, when the ICER is above the cost-effectiveness threshold this would support
the use of NIPT (no test and RAADP vs. NIPT PP1, ICER approximately £1,270,000 per QALY gained). The
cost-effectiveness threshold can be used to present results in terms of NHBs, in which case the comparison
is more straightforward, as the strategy with the highest NHB is preferred. All NIPT strategies have an
expected NHB higher than no test and RAADP, both at threshold values of £20,000 and £30,000.
Compared with no test and RAADP, NIPT PP1 has greater NHB (incremental NHB at £20,000 of
approximately 14; incremental NHB at £30,000 of approximately 16, vs. no test and RAADP).
TABLE 26 Incremental cost-effectiveness outcomes associated with high-throughput NIPT vs. other strategies
(base-case postpartum scenarios): probabilistic results
Strategies
Total
costs (£)
Total
QALYs
Incremental
costs (£)
Incremental
QALYs
ICER
(£/QALY
gained)
Population
NHB
(λ= £20,000)
Population
NHB
(λ= £30,000)
Current clinical practice
No test and RAADP 15,983,725 2,433,756 – – – 2,432,957 2,433,223
NIPT PP1
Test and RAADP
(T+ only) vs. no
test and RAADP
15,400,187 2,433,756 –583,538 –0.46 1,269,050 2,432,986 2,433,242
NIPT PP2
Test and RAADP
(T+ only) vs. no
test and RAADP
15,312,630 2,433,737 –671,095 –19.13 35,087 2,432,972 2,433,227
NIPT PP3
Test and RAADP
(T+ only) vs. no
test and RAADP
15,498,942 2,433,756 –484,783 –0.46 1,054,281 2,432,981 2,433,239
NIPT PP4
Test and RAADP
(T+ only) vs. no
test and RAADP
15,410,610 2,433,737 –573,114 –19.13 29,964 2,432,967 2,433,223
Estimates of ICERs shown relate to the comparison No test and RAADP vs. any strategy involving NIPT.
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The base-case analysis assumes no adverse health impacts from use of a blood-based product, such as
anti-D immunoglobulin. This is in line with the fact that widespread global use of anti-D immunoglobulin has
yet to produce evidence of any adverse consequences. We illustrate how sensitive the ICER is to changes in
these assumptions. Using the net benefit framework, it is possible to interpret the results of the SA around
the price of anti-D immunoglobulin in terms of health impact. An increase of 20% in the cost of anti-D
immunoglobulin represents a cost of £39.50 × 0.2 = £7.90. At a cost-effectiveness threshold of £20,000 per
QALY, this is equivalent to assuming a health cost of 7.9/20,000 = 0.0004 QALYs per administration, or a
loss of 3.5 hours of full lifetime health from every woman per dose of anti-D immunoglobulin they receive.
The incremental costs of introducing NIPT can be broken down into the cost of NIPT, the cost of managing
potentially sensitising events, the cost of RAADP, the cost of postpartum tests and anti-D immunoglobulin
and the cost consequences of sensitisations, and these are shown in Table 27. Although the added NIPT
cost is similar across strategies (at approximately £1,585,000 per 100,000 pregnancies) it is accumulated
over multiple pregnancies and so is affected by the performance of strategy in terms of the number of
sensitisations. Strategies with more sensitisations (NIPT PP2 and NIPT PP4) have marginally less test cost, as
sensitised women do not receive NIPT to guide RAADP in subsequent pregnancies (however, it is worth
noting that it is recommended that NIPT be used in women who are sensitised in order to guide antenatal
care). Similarly, all strategies save similar levels of costs from avoiding RAADP (approximately £1,544,000
per 100,000 pregnancies) and the management of potentially sensitising events (approximately £626,000
per 100,000 pregnancies). The NIPT strategies vary more markedly in their impact on postpartum testing
TABLE 27 Breakdown of incremental costs of high-throughput NIPT strategies vs. no test and RAADP
Cost item (£) NIPT PP1 NIPT PP2 NIPT PP3 NIPT PP4
NIPT cost 1,585,117 1,584,861 1,585,117 1,584,861
Potentially Sensitising Event management costs –626,165 –627,470 –626,165 –627,470
RAADP costs –1,544,149 –1,544,887 –1,544,149 –1,544,887
Postpartum test and anti-D costs –43 –152,771 98,712 –54,790
Sensitisation costs 1703 69,173 1703 69,173
Total incremental cost –583,538 –671,095 –484,783 –573,114
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and anti-D immunoglobulin costs. Here, NIPT PP1 is essentially the same as current practice, except for the
small reduction in costs attributable to increased sensitisations, which makes women ineligible for FMH
testing and anti-D immunoglobulin. NIPT PP2 decreases postpartum care costs by avoiding cord serology
for women who test negative, but this comes at an increased cost of managing sensitisations, as false
negatives are not picked up at delivery and women testing negative falsely are not provided with
postpartum FMH tests and anti-D immunoglobulin. NIPT PP3 increases postpartum care costs because,
although cord serology is avoided for those who test positive, this results in unnecessary use of FMH tests
and anti-D immunoglobulin among women who test false positive (which includes those who test
inconclusive but carry a RhD-negative baby). NIPT PP4 decreases postpartum care costs relative to current
practice by avoiding cord serology for all women and is a combination of NIPT PP2 and NIPT PP3. As might
be expected, the added cost of managing sensitisations and their associated health consequences is largest
for the strategies with more sensitisations (NIPT PP2 and NIPT PP4) and is very small for strategies NIPT PP1
and NIPT PP3 (approximately £1700 per 100,000 pregnancies).
The assumption that the results of NIPT can be used to avoid all costs associated with the management of
potentially sensitising events is favourable to NIPT and £626,000 represents the maximum cost saving in
this regard. If this cost saving is reduced to £52,000, that is, if 92% of potentially sensitising events occur
prior to the results of the NIPT being known, the ICER for no test and RAADP compared with NIPT PP1
would fall below £20,000 per QALY. The results of the audit indicate that 80% of potentially sensitising
events occur after 20 weeks’ gestation. This suggests that incorporating NIPT into routine antenatal care
when it would be provided in week 20 or earlier (see Figure 11 for schedule of appointments) could avoid
upwards of 80% of the cost of managing potentially sensitising events.
We calculated the probability that each strategy would be cost-effective compared with no test and
RAADP for each pair-wise comparison. NIPT PP1 and NIPT PP3 both have 99% probability of being
cost-effective at a threshold of £20,000 per QALY. NIPT PP2 and NIPT PP4 have a lower probability of
being cost-effective at £20,000 per QALY, at no higher than 73% compared with no test and RAADP.
Table 28 presents the fully incremental cost-effectiveness probabilistic results for high-throughput NIPT
versus other strategies. Fully incremental results do not compare each NIPT strategy with current practice
(i.e. no test and RAADP) but compare all NIPT scenarios simultaneously as competing alternative strategies.
In this table, strategies are ranked by total costs and total QALYs, with the cheapest strategy coming first
(NIPT PP2). Dominated strategies (those that have higher costs than more effective strategies) are in the
bottom rows of the table. Incremental costs, incremental QALYs and, consequently, the ICER are incremental
to the next cheapest, non-dominated strategy. This means that they represent the difference between the
strategy in the current row compared with the strategy in the row above, as the table is ordered from least
to most costly. The same applies to the incremental NHBs at £20,000 and £30,000 threshold values.
TABLE 28 Fully incremental cost-effectiveness outcomes associated with high-throughput NIPT vs. other strategies
(base-case postpartum scenarios): probabilistic results
Strategies
Total
costs (£)
Total
QALYs
Incremental
costs (£)
Incremental
QALYs
ICER
(£/QALY
gained)
Population
incremental
NHBs
(λ= £20,000)
Population
incremental
NHBs
(λ= £30,000)
NIPT PP2 15,312,630 2,433,737 – – – – –
NIPT PP1 15,400,187 2,433,756 87,557 18.67 4690 14 16
No test and
RAADP
15,983,725 2,433,756 583,538 0.46 1,269,050 –29 –19
NIPT PP4 15,410,610 2,433,737 – – Dominated – –
NIPT PP3 15,498,942 2,433,756 – – Dominated – –
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In NIPT PP2 cord serology is used to identify false-positive results, thereby avoiding unnecessary FMH
testing and anti-D immunoglobulin in these women, but this is withheld in women for whom NIPT
indicates a RhD-negative fetus. Using the negative results of high-throughput NIPT to rule out postpartum
cord serology, FMH and anti-D immunoglobulin (NIPT PP2 and NIPT PP4) has lower QALYs than no test
and RAADP, NIPT PP1 and NIPT PP3. Although there are further cost savings from avoiding postpartum
cord serology and anti-D immunoglobulin, the majority of sensitisations occur and can be prevented by the
administration of anti-D immunoglobulin at delivery. NIPT PP2 is the cheapest strategy and provides the
same QALYs as NIPT PP4. Hence, NIPT PP4 is dominated by NIPT PP2.
Providing cord serology to all women, as with NIPT PP1, will identify both the false-positive results (the small
number of false positives and the proportion of women with inconclusive results who are carrying
RhD-negative babies) and false-negative results. Although NIPT PP1 has higher costs than NIPT PP2 because
of the additional cord serology tests, these are offset somewhat by cost savings from avoiding sensitisations
in false negatives. Compared with NIPT PP2, NIPT PP1 is estimated to provide approximately 19 additional
QALYs per 100,000 pregnancies, at approximately £88,000 in additional costs, corresponding to an ICER of
around £5000 per QALY gained.
In NIPT PP3 cord serology is used to identify false-negative results but this is withheld in women with
inconclusive results or for whom NIPT indicates a RhD-positive fetus (in favour of FMH testing and anti-D
immunoglobulin). Compared with NIPT PP1, the QALY gain is not affected as the model assumes no
adverse health benefits from unnecessary use of anti-D immunoglobulin. As NIPT PP3 is more costly than
NIPT PP1, in the base case it is dominated by NIPT PP1.
No test and RAADP is more costly than NIPT PP1 and is the most effective strategy. The administration of
RAADP and supplementary anti-D immunoglobulin for potentially sensitising events among the false
negatives leads to an additional 0.5 QALYs per 100,000 pregnancies compared with NIPT PP1, at an
additional cost of £584,000. This means that the ICER for no test and RAADP compared with NIPT PP1 is
£1,270,000. Using high-throughput NIPT and performing cord serology irrespective of the result (NIPT PP1)
has higher NHB than any other strategy.
The decision uncertainty can be shown graphically with a cost-effectiveness acceptability curve. Figure 14
shows the cost-effectiveness acceptability curves for the different scenarios being compared (i.e. no test
and RAADP and alternative high-throughput NIPT scenarios – PP1 to PP4) in which we can depict the
probability that each strategy is cost-effective for a range of threshold values. When all strategies are
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simultaneously compared, for threshold values of £20,000 and £30,000, the highest probability of being
cost-effective is obtained by NIPT PP1 with 0.65 and 0.73, respectively. For the same threshold values, the
probability of NIPT PP2 being cost-effective is 0.30 and 0.22, respectively. NIPT PP1 is the alternative with
the highest probability of being cost-effective and also the expected cost-effective alternative for thresholds
above £10,000. An estimate of the maximum value of further research, the expected value of perfect
information, is estimated to be approximately £203,000 considering 10 years of cohorts of 100,000
pregnancies and using a cost-effectiveness threshold of £20,000 per QALY. If research to reduce uncertainty
in the model values would cost > £203,000 this suggests that it would not represent a good investment.
Sensitivity analyses results
Several SAs were carried out to assess the sensitivity of the base-case cost per QALY findings, as detailed in
Table 24. We assessed the impact of using pooled evidence from all relevant NIPT accuracy evidence rather
than UK Bristol studies only and, by using recent evidence from a UK study,12 assessed the performance of
high-throughput NIPT at different gestation periods. An analysis of the NIPT inconclusive results was also
performed by replacing the pooled estimates for the sensitivity and specificity with the individual study
results. SA was performed on the effectiveness of RAADP by using a different sensitisation rate pooled
from a larger number of studies. An assessment was also carried out for the uptake rates for RAADP and
postpartum anti-D immunoglobulin, with and without NIPT, decreasing these to the circumstances when
the correct dose at the correct time was administered according to recent evidence.8 In addition, we
analysed the impact of altering the cost of the diagnostic test and the cost of treatment, two key
components of this assessment as highlighted in the relevant literature. Finally, we have evaluated the
impact of reducing the cost of the FMH test and, under an alternative postpartum scenario, assessed the
management of high-throughput inconclusive results separately to the positive test results. The following
sections look closely at each of these analyses and provide interpretations of obtained results relative to
the base-case findings.
Sensitivity analysis 1: sensitivity analysis over the non-invasive prenatal testing
accuracy using all relevant evidence
Table 29 shows the results when diagnostic accuracy for high-throughput NIPT accuracy is based on all
available studies as opposed to UK (Bristol) studies only. This increases the pooled specificity by 2%,
although the pooled sensitivity levels are reduced by only 0.2% (see Chapter 3, Results: assessment of
diagnostic accuracy). Compared with the base case, the 2% reduction in false-positive results allows for
more avoidance of anti-D immunoglobulin and associated tests, reducing total costs across all NIPT
strategies by between £20,000 and £150,000 per 100,000 pregnancies. Total QALYs are marginally
affected by the small 0.2% increase in false negatives, with NIPT PP2 and NIPT PP4 being the most
affected, as these assume no use of cord serology post partum for women with negative results.
Compared with the base case, this results in a further loss of approximately 12 QALYs per 100,000
pregnancies. Compared with no test and RAADP, NIPT PP2 and NIPT PP3 are still found to be cost saving
(approximately £630,000–690,000 per 100,000 pregnancies) but NIPT PP3 is associated with a loss of
approximately 1 QALY per 100,000 pregnancies compared with a loss of 31 with NIPT PP2. NIPT PP1 and
NIPT PP3 are the only strategies to offer increased NHBs compared with no test and RAADP, with ICERs for
no test and RAADP of approximately £830,000.
Sensitivity analysis 2: sensitivity analysis over the non-invasive prenatal testing
accuracy at different timings using Chitty et al.12
Table 30 presents the results of providing high-throughput NIPT at different gestation periods. These are
based on the analysis by Chitty et al.12 (see Chapter 3, Results: assessment of diagnostic accuracy), with the
sensitivity and specificity repeated for information. In this analysis, only the diagnostic accuracy is varied
from the base-case values of 0.998 for sensitivity and 0.942 for specificity, which impacts on the
probability of sensitisation. The sensitivity estimate is least favourable at 14–17 weeks’ gestation and the
specificity estimate is least favourable at 18–23 weeks’ gestation, although these differences may be a
result of random chance rather than systematic variation between these time points. Although this analysis
does not directly take into consideration the impact of the test timing on the potential to avoid costs
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associated with the management of a potentially sensitising events, we estimate the threshold amount of
these costs that would have to occur prior to NIPT in order for the ICER to cross the threshold of £20,000
per QALY gained. Thus, results are shown only for the best NIPT strategy within each period.
As for the base case, the introduction of high-throughput NIPT results in lower health benefits than no test
and RAADP. This happens irrespective of the timing at which the test is carried out. The QALY loss is slightly
greater when performing NIPT at 14–17 weeks’ gestation because of the very small drop in sensitivity of
0.002, leading to more false negatives and a loss of approximately 1 QALY per 100,000 pregnancies compared
with current practice, rather than a loss of approximately 0.4 QALYs if NIPT is provided at 11–13 weeks’ or
18–23 weeks’ gestation. The cost saving is greatest at 14–17 weeks because of the increase in specificity, as
fewer false-positive results result in less unnecessary treatment.
The base-case results suggest that NIPT PP1 provides savings of £626,000 from avoiding the costs of
managing potentially sensitising events. The audit8 indicates that 80% of potentially sensitising events
occur after week 20. If NIPT PP1 is provided between 18 and 23 weeks’ gestation and £547,000 or 87%
of the cost of managing potentially sensitising events occurs prior to the test, the ICER for no test and
RAADP would fall below £20,000 per QALY gained. If NIPT PP3 is provided between 11 and 13 weeks’ or
14 and 17 weeks’ gestation, then approximately £598,000 or 95% of the cost of managing potentially
sensitising events would have to occur prior to the test in order for the ICER for no test and RAADP to fall
below £20,000 per QALY gained.
Sensitivity analysis 3: sensitivity analysis on the effectiveness of routine antenatal
anti-D prophylaxis using Turner et al.
Findings from Turner et al.63 estimated a pooled odds ratio estimate for sensitisation under RAADP (vs. no
RAADP, only postpartum anti-D immunoglobulin) of 0.31 rather than 0.37 as in NICE TA15662 (Table 31).
TABLE 29 Incremental cost-effectiveness outcomes associated with high-throughput NIPT vs. other strategies:
probabilistic results – all NIPT accuracy evidence
Strategies
Total
costs (£)
Total
QALYs
Incremental
costs (£)
Incremental
QALYs
ICER
(£/QALY
gained)
Population
NHB
(λ= £20,000)
Population
NHB
(λ= £30,000)
Current clinical practice
No test and
RAADP
15,983,725 2,433,756 – – – 2,432,957 2,433,223
NIPT PP1
Test and RAADP
(T+ only) vs. no
test and RAADP
15,353,678 2,433,756 –630,047 –0.76 829,196 2,432,988 2,433,244
NIPT PP2
Test and RAADP
(T+ only) vs. no
test and RAADP
15,291,035 2,433,725 –692,690 –31.13 22,253 2,432,961 2,433,215
NIPT PP3
Test and RAADP
(T+ only) vs. no
test and RAADP
15,351,238 2,433,756 –632,487 –0.76 832,406 2,432,988 2,433,244
NIPT PP4
Test and RAADP
(T+ only) vs. no
test and RAADP
15,286,779 2,433,725 –696,946 –31.13 22,390 2,432,961 2,433,216
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TABLE 30 Incremental cost-effectiveness outcomes associated with high-throughput NIPT at different timings vs. other strategies (postpartum scenarios): probabilistic results,
based on Chitty et al.12
Strategies Sensitivity Specificity
Total
costs (£)
Total
QALYs
Incremental
costs (£)
Incremental
QALYs
ICER
(£/QALY gained)
Population NHB
(λ= £20,000)
Population NHB
(λ= £30,000)
Current clinical practice – irrespective of NIPT timing
No test and RAADP – – 15,983,725 2,433,756 – – – 2,432,957 2,433,223
Best postpartum scenario when NIPT performed at 11–13 weeks’ gestation
NIPT PP1 (vs. no test and
RAADP)
0.9983 0.9525 15,378,009 2,433,756 –605,716 –0.39 1,536,731 2,432,987 2,433,243
Best postpartum scenario when NIPT performed at 14–17 weeks’ gestation
NIPT PP1 (vs. no test and
RAADP)
0.9967 0.9534 15,370,718 2,433,756 –613,007 –0.77 797,046 2,432,987 2,433,243
Best postpartum scenario when NIPT performed at 18–23 weeks’ gestation
NIPT PP1 (vs. no test and
RAADP)
0.9982 0.9304 15,429,067 2,433,756 –554,658 –0.36 1,529,418 2,432,984 2,433,242
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Compared with base-case results (see Table 25) the marginal reduction in the sensitisation rate (0.05%
less) brings minimal changes to the total costs and QALYs estimates, as expected. The increase in
effectiveness of RAADP provides reductions in total costs for all strategies and minor changes in the QALY
loss associated with NIPT.
Sensitivity analysis 4: sensitivity analysis on the uptake of routine antenatal anti-D
prophylaxis and postpartum anti-D immunoglobulin
In the base-case analysis our estimates of compliance are based on the use of anti-D immunoglobulin in
women who are eligible in terms of RhD status and ignorance of the father’s status, and who remain
pregnant, to receive RAADP. The National Comparative Audit of Blood Transfusion 2013 on Anti-D
Immunoglobulin Prophylaxis8 reported that, out of all RhD-negative women, 87.5% received the correct
dose at the correct time of RAADP. Furthermore, it reported that 91.6% received the correct dose at the
correct time of postpartum anti-D immunoglobulin prophylaxis. We made use of these estimates to provide
a lower bound for compliance with anti-D immunoglobulin. As for the base case, it was assumed that the
use of high-throughput NIPT does not influence the uptake with anti-D immunoglobulin, that is, the
uptake rate is the same irrespective of whether NIPT was previously accepted/administered.
Table 32 presents the incremental cost-effectiveness outcomes for each alternative scenario when different
RAADP and postpartum anti-D immunoglobulin uptake rates are used. As the SA does not impact on the
rank order of the alternative postpartum scenarios, the results are shown for NIPT PP1 only, that is, out of
the five alternatives being compared, the results for the best strategy are shown together with current
practice. Base-case results correspond to 99.0% and 98.4% uptake with RAADP and postpartum anti-D
immunoglobulin, respectively. Overall, the results are robust to reduced compliance and there is little
impact on incremental comparison between NIPT PP1 and no test and RAADP. The cost for all strategies is
increased if compliance with a cost-effective treatment, such as RAADP, is reduced, although the QALY
loss associated with additional sensitisations is slightly reduced.
TABLE 31 Incremental cost-effectiveness outcomes associated with high-throughput NIPT vs. other strategies
(postpartum scenarios): probabilistic results – pooled RAADP effectiveness, based on Turner et al.63
Strategies
Total
costs (£)
Total
QALYs
Incremental
costs (£)
Incremental
QALYs
ICER
(£/QALY
gained)
Population
NHB
(λ= £20,000)
Population
NHB
(λ= £30,000)
Current clinical practice
No test and
RAADP
15,923,756 2,433,774 – – – 2,432,978 2,433,243
NIPT PP1
Test and RAADP
(T+ only) vs. no
test and RAADP
15,339,945 2,433,773 –583,811 –0.50 1,164,285 2,433,006 2,433,262
NIPT PP2
Test and RAADP
(T+ only) vs. no
test and RAADP
15,252,388 2,433,755 –671,369 –19.17 35,018 2,432,992 2,433,246
NIPT PP3
Test and RAADP
(T+ only) vs. no
test and RAADP
15,438,716 2,433,773 –485,040 –0.50 967,307 2,433,001 2,433,259
NIPT PP4
Test and RAADP
(T+ only) vs. no
test and RAADP
15,350,384 2,433,755 –573,372 –19.17 29,906 2,432,987 2,433,243
INDEPENDENT ECONOMIC ASSESSMENT
NIHR Journals Library www.journalslibrary.nihr.ac.uk
86
Sensitivity analysis 5: sensitivity analysis on non-invasive prenatal testing
inconclusive results
The cost saving achievable by using the high-throughput NIPT to guide anti-D immunoglobulin will depend
on the rate of inconclusive test results, as for these women the current care pathway is unchanged. That
is, all inconclusive results are managed as if they were test positive and, hence, unnecessary anti-D
immunoglobulin continues to be provided in these women carrying a RhD-negative fetus. In order to
undertake a SA around the rate of inconclusives, we replaced the pooled estimates for the sensitivity and
specificity with the individual study results. Figure 15 shows how the specificity varies with the rate of
inconclusives within each study. In general, a higher rate of inconclusive results will lead to a larger
number of false positives and, correspondingly, a lower specificity. The cost saving achievable by using
high-throughput NIPT to guide anti-D immunoglobulin will depend on the rate of inconclusive test results,
as for these women the current care pathway is unchanged, that is, all inconclusive results are managed as
if they were test positive, and, hence, unnecessary antenatal anti-D immunoglobulin continues to be
provided in those women carrying a RhD-negative fetus.
One study produced no inconclusive results and no false-negative results and so we omitted this from the
SA.22 In general, the NHBs associated with the NIPT strategies fall as the rate of inconclusive results
increases, but at no point do the NHBs from NIPT PP1 or NIPT PP3 fall below those offered with no test
and RAADP. Figure 16 shows the NHBs for all of the NIPT strategies. When the rate of inconclusive results
is low, NIPT PP3 offers the highest NHB. This is because the amount of unnecessary postpartum FMH
testing and anti-D immunoglobulin is reduced when the number of false-positive results falls. When the
rate of inconclusives is high, NIPT PP1 is preferred. If the rate of inconclusives was very high, no test and
TABLE 32 Incremental cost-effectiveness outcomes associated with high-throughput NIPT vs. other strategies
(postpartum scenarios): different anti-D immunoglobulin uptake rates of RAADP and postpartum anti-D
immunoglobulin – probabilistic results of the two best strategies for each analysis are shown
Strategies
Total
costs (£)
Total
QALYs
Incremental
costs (£)
Incremental
QALYs
ICER
(£/QALY
gained)
Population
NHB
(λ= £20,000)
Population
NHB
(λ= £30,000)
RAADP at 99.0% and post partum at 98.4% (base case)
No test and
RAADP
15,983,725 2,433,756 – – – 2,432,957 2,433,223
NIPT PP1 (vs. no
test and RAADP)
15,400,187 2,433,756 –583,538 –0.46 1,269,050 2,432,986 2,433,242
RAADP at 87.5% and post partum at 98.4%
No test and
RAADP
16,060,984 2,433,733 – – – 2,432,930 2,433,198
NIPT PP1 (vs. no
test and RAADP)
15,477,810 2,433,733 –583,174 –0.41 1,430,198 2,432,959 2,433,217
RAADP at 99.0% and post partum at 91.6%
No test and
RAADP
16,029,705 2,433,743 – – – 2,432,941 2,433,208
NIPT PP1 (vs. no
test and RAADP)
15,446,384 2,433,742 –583,321 –0.43 1,360,214 2,432,970 2,433,227
RAADP at 87.5% and post partum at 91.6%
No test and
RAADP
16,101,601 2,433,721 – – – 2,432,916 2,433,185
NIPT PP1 (vs. no
test and RAADP)
15,518,619 2,433,721 –582,982 –0.38 1,532,578 2,432,945 2,433,204
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RAADP would be preferred. However, the rate would have to be much higher than that observed in the
set of studies underlying the evidence synthesis. Akolekar et al.91 and Wikman et al.23 diverge from the
remaining studies in terms of the number of false-negative results and sensitivity and this impacts on the
NHBs of the strategies that do not identify false negatives through cord serology (NIPT PP2 and NIPT PP4).
For these two strategies, the NHB falls below that offered by current practice when the results associated
with these two studies are used. Figure 17 shows how the NHBs for NIPT PP1 vary only with the rate
of inconclusives.
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FIGURE 15 Specificity by rate of high-throughput NIPT inconclusive results per study.
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FIGURE 16 Population NHBs for all NIPT strategies by rate of NIPT inconclusive results per study.
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Sensitivity analysis 6: sensitivity analysis on non-invasive prenatal testing and
Anti-D costs
The unit cost of NIPT is subject to some uncertainty as it depends on throughput (the total number of
samples per year) and the level of the royalty fee. The throughput determines how many machines must
be bought and at what capacity they are utilised. The base-case analysis assumed sufficient machines to
process all pregnancies in England in a given year. Further to this, the introduction of NIPT may impose
additional costs in routine antenatal care in terms or appointments and staff time. Similarly, the cost of
anti-D immunoglobulin may depart from the list price on the basis of negotiated discounts.
The results of a two-way analysis around these unit costs reported in Figure 18 show that the base case is
very sensitive to both the price of NIPT and the price of anti-D. The x-axis represents the range of anti-D
immunoglobulin cost from –20% to +20%. This increase/decrease in the cost of anti-D immunoglobulin is
applied to all occasions in which the treatment is administered and, thus, the RAADP cost shown is
indicative only, as the estimated costs of anti-D for potentially sensitising events and post partum, as
described in Cost of postpartum health resources used, are omitted. The y-axis represents the range of
costs per high-throughput NIPT from £17.60 to £28.60 [which may, for example (confidential information
has been removed)].
A price increase would raise the costs associated with all strategies that provide NIPT and does not affect
the ranking of the strategies. The postpartum strategy that provides the lowest NHB will be associated
with the lowest threshold cost, and the postpartum strategy that provides the highest NHB will be
associated with the highest threshold cost.
The threshold cost for NIPT PP1, the strategy with the highest NHB, is £24.64 (confidential information has
been removed). That is, raising the cost per high-throughput NIPT to £24.64 implies that NIPT PP1 no
longer offers the highest population NHB, switching to no test and RAADP. Similar results were found
when the cost-effectiveness threshold was £20,000 or £30,000. NIPT PP1 strategy is always preferred over
other postpartum strategies (PP2, PP3 or PP4). At no point would the price of anti-D immunoglobulin be
high enough to make the omission of postpartum anti-D immunoglobulin (NIPT PP2 and NIPT PP4) look
cost-effective.
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FIGURE 17 Population NHBs for NIPT PP1 by rate of NIPT inconclusive results per study.
FIGURE 18 (Confidential information has been removed.)
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Sensitivity analysis 7: sensitivity analysis over the fetal–maternal haemorrhage test cost
Reducing the cost of the FMH test to £3.17 (Szczepura et al.,68 updated to 2015 prices) halves the
estimated total costs of all strategies compared with the total costs of the base-case scenarios (Table 33).
Estimated total QALYs are similar to base-case findings. NIPT PP1 is now less cost saving than current
practice. This is explained by the use of the FMH test in the management of potentially sensitising events.
When the cost of the FMH test is reduced, the savings from avoiding the management of potentially
sensitising events are reduced. All NIPT strategies still reduce costs compared with no test and RAADP but
by a lesser amount. This causes the ICER for no test and RAADP compared with NIPT PP2 and NIPT PP4 to
fall below £20,000 per QALY.
Sensitivity analysis 8: sensitivity analysis on postpartum management of
inconclusive results
The postpartum scenarios specified in the decision problem applied cord serology, FMH testing and
postpartum anti-D immunoglobulin according to whether or not the results of NIPT were positive or
negative. In this regard, we grouped inconclusive results with NIPT positive results. However, in terms of
postpartum management, it may be worthwhile to regard those with inconclusive results as distinct from
those on whom NIPT indicates a RhD-positive fetus. This would allow cord serology to be provided to
women with negative results in order to identify false negatives and cord serology to be provided to
women with inconclusive results in order to identify false positives, but for it to be withheld in women in
whom NIPT indicates a RhD-positive fetus. This would result in total costs of £15,230,372 and 2,433,756
QALYs per 100,000 pregnancies. This postpartum approach would dominate all other NIPT strategies, and
the ICER for no test and RAADP compared with this strategy would be £1,638,356 per QALY gained.
Table 34 summarises the results of the base-case analysis and the key SAs.
TABLE 33 Incremental cost-effectiveness outcomes associated with high-throughput NIPT vs. other strategies
(postpartum scenarios): probabilistic results – FMH test cost reduced
Strategies
Total
costs (£)
Total
QALYs
Incremental
costs (£)
Incremental
QALYs
ICER
(£/QALY
gained)
Population
NHB
(λ= £20,000)
Population
NHB
(λ= £30,000)
Current clinical practice
No test and
RAADP
8,132,447 2,433,756 – – – 2,433,350 2,433,485
NIPT PP1
Test and RAADP
(T+ only) vs. no
test and RAADP
7,986,460 2,433,756 –145,987 –0.46 317,485 2,433,356 2,433,490
NIPT PP2
Test and RAADP
(T+ only) vs. no
test and RAADP
7,915,559 2,433,737 –216,888 –19.13 11,339 2,433,341 2,433,473
NIPT PP3
Test and RAADP
(T+ only) vs. no
test and RAADP
7,846,684 2,433,756 –285,763 –0.46 621,464 2,433,363 2,433,494
NIPT PP4
Test and RAADP
(T+ only) vs. no
test and RAADP
7,775,584 2,433,737 –356,862 –19.13 18,658 2,433,348 2,433,478
INDEPENDENT ECONOMIC ASSESSMENT
NIHR Journals Library www.journalslibrary.nihr.ac.uk
90
TABLE 34 Summary of base-case analysis and key SA results
Analysis
Total
Compared with no test and
RAADP (current practice)
Compared with next
best strategy
Cost (£) QALYs ICER (£) ICER (£) Comparator
Base case
No test and RAADP 15,983,725 2,433,756 – 1,269,050 NIPT PP1
NIPT PP1 15,400,187 2,433,756 1,269,050 4690 NIPT PP2
NIPT PP2 15,312,630 2,433,737 35,087 – –
NIPT PP3 15,498,942 2,433,756 1,054,281 – –
NIPT PP4 15,410,610 2,433,737 29,964 – –
SA1: bivariate meta-analysis of all studies
No test and RAADP 15,983,725 2,433,756 – 834,396 NIPT PP3
NIPT PP1 15,353,677 2,433,756 831,178 – –
NIPT PP2 15,291,034 2,433,725 22,255 – –
NIPT PP3 15,351,238 2,433,756 834,396 2123 NIPT PP4
NIPT PP4 15,286,779 2,433,725 22,391 – –
SA2: high-throughput NIPT performance assessed at different gestation periods (Chitty et al.12)
11–13 weeks’ gestation
No test and RAADP 15,983,725 2,433,756 – 1,536,731 NIPT PP1
NIPT PP1 15,378,008 2,765,228 1,165,229 3190 NIPT PP4
NIPT PP2 15,283,278 2,765,206 31,462 – –
NIPT PP3 15,420,079 2,765,228 1,084,295 – –
NIPT PP4 15,325,344 2,765,206 29,573 – –
14–17 weeks’ gestation
No test and RAADP 15,983,725 2,433,756 – 797,046 NIPT PP1
NIPT PP1 15,370,717 2,433,756 604,062 678 NIPT PP4
NIPT PP2 15,310,563 2,433,724 15,604 – –
NIPT PP3 15,409,227 2,433,756 566,114 – –
NIPT PP4 15,349,062 2,433,724 14,712 – –
18–23 weeks’ gestation
No test and RAADP 15,983,725 2,433,756 – 1,529,418 NIPT PP1
NIPT PP1 15,429,066 2,433,756 1,162,227 6209 NIPT PP2
NIPT PP2 15,334,643 2,433,741 31,744 – –
NIPT PP3 15,593,754 2,433,756 817,141 – –
NIPT PP4 15,499,308 2,433,741 23,691 – –
SA3: sensitisation rate (Turner et al.63)
No test and RAADP 15,923,756 2,433,774 – 1,164,285 NIPT PP1
NIPT PP1 15,339,945 2,433,773 1,164,285 4690 NIPT PP2
NIPT PP2 15,252,387 2,433,755 35,021 – –
NIPT PP3 15,438,716 2,433,773 970,788 – –
NIPT PP4 15,350,383 2,433,755 29,909 – –
continued
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TABLE 34 Summary of base-case analysis and key SA results (continued )
Analysis
Total
Compared with no test and
RAADP (current practice)
Compared with next
best strategy
Cost (£) QALYs ICER (£) ICER (£) Comparator
SA4: uptake with RAADP (with and without high-throughput NIPT performed)
Uptake of RAADP at 87.5%
No test and RAADP 16,060,984 2,433,733 – 1,430,198 NIPT PP1
NIPT PP1 15,477,810 2,433,733 1,430,198 4691 NIPT PP2
NIPT PP2 15,390,257 2,433,714 35,171 – –
NIPT PP3 15,576,545 2,433,733 1,188,057 – –
NIPT PP4 15,488,218 2,433,714 30,035 – –
Uptake of postpartum anti-D immunoglobulin at 91.6%
No test and RAADP 16,029,705 2,433,743 – 1,360,214 NIPT PP1
NIPT PP1 15,446,384 2,433,742 1,360,214 4691 NIPT PP2
NIPT PP2 15,358,829 2,433,724 35,137 – –
NIPT PP3 15,545,127 2,433,742 1,129,960 – –
NIPT PP4 15,456,798 2,433,724 30,006 – –
Uptake of RAADP at 87.5% and postpartum anti-D immunoglobulin at 91.6%
No test and RAADP 16,101,601 2,433,721 – 1,532,578 NIPT PP1
NIPT PP1 15,518,619 2,433,721 1,532,578 4692 NIPT PP2
NIPT PP2 15,431,068 2,433,702 35,216 – –
NIPT PP3 15,617,343 2,433,721 1,273,046 – –
NIPT PP4 15,529,017 2,433,702 30,072 – –
SA5: high-throughput NIPT inconclusive results rate
Please see Sensitivity analysis 5: sensitivity analysis on non-invasive prenatal testing inconclusive results
SA6: cost of high-throughput NIPT and anti-D immunoglobulin
Please see Sensitivity analysis 6: sensitivity analysis on non-invasive prenatal testing and Anti-D costs
SA7: cost of FMH test
No test and RAADP 8,132,446 2,433,756 – 621,464 NIPT PP3
NIPT PP1 7,986,460 2,433,756 317,485 – –
NIPT PP2 7,915,559 2,433,737 11,340 – –
NIPT PP3 7,846,683 2,433,756 621,464 3809 NIPT PP4
NIPT PP4 7,775,584 2,433,737 18,658 – –
SA8: postpartum management of high-throughput NIPT inconclusive results
Please see Sensitivity analysis 8: sensitivity analysis on postpartum management of inconclusive results
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Discussion of the independent economic assessment
The evidence to support the diagnostic accuracy of NIPT is of good quality. We can combine this with
established evidence for the efficacy of RAADP and postpartum anti-D immunoglobulin in order to
estimate the impact of introducing NIPT on the number of sensitisations. However, there is little evidence
as to the impact of sensitisations in terms of their long-term health and cost consequences. Our model
suggests that each additional sensitisation costs the NHS £3167 and is associated with a loss of
approximately 0.9 QALYs, but these estimates are subject to uncertainty and incorporate expert opinion.
There is uncertainty regarding the cost of introducing high-throughput NIPT. The unit cost will vary with
throughput and may be subject to an additional royalty fee. Unless NIPT can be incorporated seamlessly
into routine antenatal care, it may result in additional costs for blood draw, transportation of samples and
antenatal care visits to administer the test and deliver counselling and results. We conducted extensive SAs
to address this uncertainty and to identify the threshold cost per NIPT. The cost of high-throughput NIPT
has to increase by only (confidential information has been removed) above that modelled in the base case
in order for no test and RAADP to be the preferred strategy. The unit cost of high-throughput NIPT to the
NHS is the most important parameter in determining cost-effectiveness. Although there is uncertainty
as regards the timing of the test, our analysis suggests that this is not influential in determining the
cost-effectiveness results either in terms of diagnostic accuracy or in terms of the extent of management
costs for potentially sensitising events that can be avoided.
As might be expected, the potential NHBs of using NIPT to target care are reduced, as the rate of
inconclusive results is increased. However, our SA indicates that, even with high-throughput NIPT
inconclusive results as high as 14.3%, the introduction of NIPT compares favourably to current practice.
The ability of the NIPT result to avoid unnecessary use of anti-D immunoglobulin varies systematically
according to ethnicity. Although this may not be an equality issue, it should be noted that following the
introduction of NIPT, any unnecessary use of anti-D immunoglobulin will be proportionately higher in
ethnic groups, for example in those of African origin. We can conclude that the identification of the
false-positive results is key to the estimation of the cost-effectiveness outcomes, negatively impacting the
results if this rate is higher and altering the postpartum strategy that would offer the highest NHB.
There are numerous ways in which the results of high-throughput NIPT could be used to guide postpartum
testing and administration of anti-D immunoglobulin. We have compared four alternative postpartum
scenarios, and the results indicate that cord serology testing should be retained in women for whom
NIPT indicates a RhD-negative fetus. This use of cord serology to capture false-negative results has the
potential to undermine the implementation of the test if it impacts on the confidence in the NIPT results.
A postpartum strategy that distinguishes between inconclusive results and positive results offers the
greatest cost savings.
If the cost of the FMH test is high relative to cord serology, then it would make sense to apply cord
serology to women with positive and inconclusive NIPT results. This allows for the low-cost cord serology
test to avoid both the unnecessary use of a much more expensive FMH test and unnecessary postpartum
anti-D immunoglobulin. It is likely that these benefits are almost entirely obtained by applying cord serology
in women with inconclusive results, as 30–40% of these women would be revealed to be carrying a
RhD-negative fetus. In contrast, when the results of NIPT indicate a RhD-positive fetus, the rate of false
positives is very low. In the base-case analysis, women who receive inconclusive results are managed as if
they test positive, but there may be potential for further cost savings if these are treated as a distinct group
in terms of postpartum care. This would allow for a postpartum scenario in which cord serology was applied
to women who test negative and to those who test inconclusive but for whom FMH tests and anti-D
immunoglobulin are provided without cord serology in women who test positive.
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Conclusions of the cost-effectiveness section
The use of high-throughput NIPT to guide the provision of anti-D immunoglobulin prophylaxis is estimated
to be cost saving compared with current practice of providing RAADP to all women who are RhD-negative.
The extent of the cost saving is highly sensitive to the cost of NIPT itself to the NHS, which comprises the
base unit cost per test, the level of any royalty fee and any increase in antenatal care costs required to
accommodate an additional test. In the base-case analysis, the extent of the cost saving is sufficient to
outweigh the small increase in sensitisations and the associated small QALY loss through using NIPT.
However, even a small increase in the cost imposed on the NHS of (confidential information has been
removed) or more per test would cause the ICER for no test and RAADP to reduce below £20,000 per QALY.
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Chapter 6 Discussion
Statement of principal findings
Diagnostic accuracy
Eight studies were included in the diagnostic review of high-throughput NIPT. There were three studies
based at Bristol (UK). The majority of included studies were judged as having a low risk of bias.
Meta-analyses showed very high diagnostic accuracy of high-throughput NIPT. In the primary analyses,
for which women with inconclusive test results were treated as being testing positive, the summary FNR
(i.e. women at risk of sensitisation) was 0.34% (95% CI 0.15% to 0.76%) and the FPR (i.e. women needlessly
receiving anti-D) was 3.86% (95% CI 2.54% to 5.82%). SAs did not materially alter the overall result.
A subgroup analysis of three high-quality studies based at Bristol (UK) showed a slightly lower FNR of
0.21% (95% CI 0.09% to 0.48%) and a higher FPR of 5.73% (95% CI 4.58% to 7.16%). This suggests
that the Bristol NIPT approach may be using a different threshold for the detection algorithm that further
reduces false-negative error rates, consequently increasing the false-positive error rate. The FPR found was
mostly as a result of treating the roughly 7% of women (in the UK) who have an inconclusive test result as
if they had a positive test. Excluding these women from analysis resulted in a lower FPR of 1.26% (95% CI
0.87% to 1.83%). We were unable to conduct the subgroup analysis based on ethnicity because of lack
of relevant data from included studies.
The diagnostic accuracy performance of high-throughput NIPT varied by gestational age. The data suggest
that high-throughput NIPT is insufficiently accurate before around 11 weeks’ gestation (i.e. in first trimester)
but is consistently accurate at any time after 11 weeks’ gestation. This may be because of a low
concentration of cell-free fetal DNA in early pregnancy92 but an increased concentration of cell-free fetal
DNA after the end of the first trimester.93
Clinical effectiveness
Seven studies18,20,22,24–27 were included in the clinical effectiveness review. Only two studies20,26 had a
control group, but both studies were judged as having a high risk of bias. One large prospective cohort
study26 reported that use of high-throughput NIPT for targeted antenatal anti-D prophylaxis was associated
with a significant risk reduction in sensitisation (adjusted odds ratio 0.41, 95% CI 0.22 to 0.87) compared
with historical controls (routine management, postpartum anti-D only).
Three non-comparative studies18,20,22 reported outcome measures relating to anti-D doses administrated.
All studies found that the use of NIPT reduced the total use of anti-D immunoglobulin doses (decreasing
by 29% in one UK study by Soothill et al.18) because around 35% of RhD-negative women avoided
unnecessary anti-D administration.
Four studies20,26,27,49 reported moderate to high compliance with antenatal anti-D immunoglobulin
administration. The compliance with antenatal anti-D administration after a positive NIPT result ranged
from 86% to 96.1% (four studies20,26,27,49). High-throughput NIPT uptake rates ranged from 70% to
> 95% (seven studies.12,18,20,22,25–27).
The results from the simulation study suggested that the use of NIPT to determine antenatal anti-D use
would substantially reduce the number of women receiving anti-D unnecessarily from 38.9% to 5.7%.
Results were sensitive to the rate of compliance. NIPT use could increase sensitisation rates by up to 15
sensitisations per 100,000 women if postpartum cord blood testing is continued or up to 28 per 100,000
women if cord blood testing is withdrawn and postpartum anti-D given on the basis of the NIPT result.
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Sensitisation rates are minimised by ensuring that women who do not receive NIPT are still offered, and
receive, antenatal anti-D. The results suggest that NIPT results (if available and conclusive) could potentially
be used in place of cord blood testing for administration of postpartum anti-D, if the small increase in
sensitisations rates can be considered ethically acceptable.
Implementation
Twelve studies13,17,18,20–28 were included in the review of implementation. Most of the included studies
were large cohort studies13,17,20,21,23–27 reporting implementation data along with diagnostic accuracy data,
although one study was a survey that was based in the UK (London).28 All the large cohort studies reported
high diagnostic accuracy of high-throughput NIPT and suggested that high-throughput RhD genotyping
of fetuses in all RhD-negative women was feasible and should be recommended. A number of studies
reported potential issues of implementation such as those relating to programme anti-D prophylaxis
compliance.20,27 Some studies highlighted the importance of short transport times of samples and the need
for effective management of transporting samples.13,17,24 Some studies also identified the need for greater
knowledge of NIPT among physicians, midwives and pregnant women.27,28
Cost-effectiveness
Seven cost-effectiveness studies58,68–73 were included in the review. Conflicting results were identified across
the existing economic studies, with three of the studies68,71,72 reporting that NIPT fetal RhD genotyping did
not appear to be cost-effective. The unit cost of the test was consistently identified as a key driver of the
cost-effectiveness results and the potential for the use of NIPT to result in overall cost savings. Only one of
the studies68 was undertaken in a UK context, but this study did not explicitly explore how the introduction
of NIPT could impact on costs relating to potentially sensitising events. For the studies undertaken outside the
UK, differences in health-care systems and in implementation of anti-D immunoglobulin policies limit their
relevance to UK practice. In conclusion, none of the existing studies was considered to be sufficiently
generalisable to inform the specific decision problem as set out in the NICE scope for the current assessment.
A de novo independent economic model was developed to assess the cost-effectiveness of high-throughput
NIPT to identify fetal rhesus D status in women who are RhD negative and not known to be sensitised to
the RhD antigen. The model was made up of two main elements: (1) an identification part reflecting the
diagnostic performance and costs of the alternative identification strategies and (2) a treatment part that
evaluated the subsequent costs and outcomes (expressed in QALYs) of alternative care pathways. Four
alternative ways in which the use of high-throughput NIPT may impact on the existing postpartum care
pathway were evaluated (cord serology, FMH testing and postpartum anti-D immunoglobulin). These
included scenarios in which the result of NIPT was used to guide RAADP only (with all women continuing to
receive cord serology with FMH testing and postpartum anti-D immunoglobulin as required, irrespective of
NIPT result) and scenarios for which the NIPT result guided both RAADP and separate aspects of postpartum
care. A series of additional sensitivity and scenario analyses was also performed.
Our de novo economic model indicated that the use of high-throughput NIPT to guide the prenatal and
postpartum provision of anti-D immunoglobulin prophylaxis is estimated to be cost saving compared with
the current practice of providing RAADP to all women who are RhD negative. The magnitude of the cost
saving appears to be highly sensitive to the cost of NIPT itself to the NHS, which comprises the base unit
cost per test, the level of any royalty fee and any increase in antenatal care costs required to accommodate
an additional test. In the base-case analysis, the extent of the cost saving appears sufficient to outweigh the
small increase in sensitisations and the associated small QALY loss through using NIPT compared with current
practice. However, even a small increase in the cost imposed on the NHS of (confidential information has
been removed) or more per test would alter these conclusions.
In the base-case analysis, all four separate postpartum scenarios were estimated to be cost saving but also
less effective than current practice. Based on a cross-section of 100,000 pregnancies, the magnitude of
cost savings varied between approximately £485,000 and £671,000. The magnitude of the QALY loss
varied between 0.5 QALYs and 19.1 QALYs (per 100,000 pregnancies). Although the magnitude of the
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cost savings was sufficient to outweigh the associated QALY loss when each postpartum scenario was
separately compared with current practice, these four separate scenarios potentially represent separate and
distinct testing and management strategies that should be directly compared. In the base-case analysis,
the strategy in which the NIPT result is used to guide RAADP only (i.e. all women continuing to receive
cord serology with FMH testing and postpartum anti-D immunoglobulin) was associated with the highest
NHB and had the highest probability of being cost-effective for threshold values of £20,000 and £30,000
per QALY (probability of 0.65 and 0.73, respectively). However, the use of cord serology to capture
false-negative results has the potential to undermine the implementation of the test if it impacts on the
confidence in the NIPT results. The most efficient postpartum strategy was also shown to vary across
several of the main SAs.
A postpartum strategy that distinguishes between inconclusive results and positive results offers the
greatest cost savings. In the base-case analysis, women who receive inconclusive results were assumed to
be managed as if they test positive, but there may be potential for further cost savings if these are treated
as a distinct group in terms of postpartum care. This could allow for a postpartum scenario in which cord
serology was applied to women who test negative and who test inconclusive but in which FMH tests and
anti-D immunoglobulin are provided without cord serology in women who test positive.
Strengths and limitations of the assessment
Clinical effectiveness
Extensive literature searches were conducted in an attempt to maximise retrieval of potentially relevant
studies. These included electronic searches of a variety of bibliographic databases as well as screening of
clinical trial registers and conference proceedings to identify unpublished studies. The search strategy did
not restrict by study design. The review process followed recommended methods to minimise the potential
for error and/or bias. The quality of the included studies was assessed and accounted for when interpreting
the review results. Appropriate synthesis methods were employed by taking into account the heterogeneity
of study characteristics.
There was some evidence of inconsistency in the meta-analysis of diagnostic accuracy studies. The observed
heterogeneity may be explained by variations in methods used in the high-throughput NIPT approach
(including diagnostic accuracy thresholds and number and types of exons targeted), gestational age at the
time of testing and different methods of handling inconclusive test results. There were also variations in the
reporting of included studies. Particularly, two studies19,21 did not report the number of inconclusive results
of the test and some studies12,18,22 did not report detailed reasons for inconclusive results.
There was very limited evidence relating to the clinical effectiveness of high-throughput NIPT. No studies
were identified reporting adverse effects of high-throughput NIPT.
Owing to limited evidence, the generalisability of the review findings to non-white women and multiple
pregnancies is unclear.
Cost-effectiveness
The de novo economic model was specifically developed to address the limitations of existing studies and
concerns regarding the generalisability to current UK practice. The main strength of the decision model is
the linkage between the diagnostic accuracy of a given identification strategy, the impact on subsequent
treatment decisions and the ultimate effect on health outcomes and costs. A key element of the model is
based on the previous economic model underpinning NICE TA15662 on RAADP ensuring consistency
between the separate diagnostic and TAs. A broad range of scenario analyses and SAs were undertaken to
address key assumptions and uncertainties.
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Uncertainties
Clinical effectiveness
In this assessment we identified very limited data on the evaluation of clinical effectiveness for using
high-throughput NIPT to detect fetal RhD status in RhD-negative women. Therefore, the potential role of
high-throughput NIPT in terms of its clinical impact on the care pathway and adverse effects to the mother
and fetus remains unclear. In particular, we did not identify any studies reporting comparative data relating
to patient-related outcomes, such as quality-of-life measures.
Owing to a lack of sufficient data from included studies, we were unable to conduct subgroup analyses
based on ethnicity. Therefore, whether or not the diagnostic performance of high-throughput NIPT differs
between different ethnic groups remains unclear.
In terms of implementing high-throughput NIPT in health-care settings, no studies were identified reporting
compliance rates to prenatal anti-D treatment in UK settings. Although a few non-UK studies reported
compliance rates to prenatal anti-D treatment, the generalisability of their findings to the UK settings remains
uncertain because of variations in national guidelines and health policies between different countries.
Cost-effectiveness
There is uncertainty regarding the cost of introducing high-throughput NIPT. The unit cost will vary with
throughput and may be subject to an additional royalty fee. Unless NIPT can be incorporated seamlessly
into routine antenatal care, it may result in additional costs for blood draw, transportation of samples and
antenatal care visits to administer the test and deliver counselling and results. We conducted extensive SAs
to address this uncertainty and to identify the threshold cost per NIPT. The cost of high-throughput NIPT
has to increase by only (confidential information has been removed) above that modelled in the base case
in order for current practice to be the preferred strategy.
Although there remains uncertainty as regards the timing of the test, our analysis suggests that this does not
appear to be influential in determining the cost-effectiveness results either in terms of diagnostic accuracy or
in terms of the extent of management costs for potentially sensitising events that can be avoided.
Although the evidence to support the diagnostic accuracy of NIPT is of good quality, existing evidence
informing the impact of sensitisations in terms of their long-term health and cost consequences are more
limited and highly uncertain.
Other relevant factors
Owing to a lack of relevant evidence, we have not considered any adverse health impacts from the
provision of a blood-based product. Although widespread global use of anti-D immunoglobulin would
suggest that is it safe, there remains uncertainty as regards the potential for risk associated with prion
disease or other unknown pathogens. There may also be ethical considerations concerning the
unnecessary administration of a blood-based product.
We also have not considered any adverse consequences from the introduction of the high-throughput NIPT
over and above the slight increase in risk of sensitisation. Women who know that they are sensitised may
factor this into their family planning decisions but we have assumed no such impact within the model. It is
possible that NIPT could inadvertently reveal mistaken paternity of the child in cases in which a woman’s
partner knows that he is RhD negative and the baby is revealed to be RhD positive. Concerns about
revealed paternity have been noted in relation to testing the father’s blood type in order to target anti-D
immunoglobulin only to those women with RhD-positive partners. The inclusion of an additional prenatal
test could potentially have adverse impacts on the uptake of other antenatal care if the overall quality of
care is compromised by the additional test burden.
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Chapter 7 Conclusions
Implications for service provision
The findings from this assessment demonstrated high diagnostic performance of high-throughput NIPT for
the detection of fetal RhD status in RhD-negative women from 11 weeks’ gestation, with very low FPR
and FNR. About 0.7% of women will have an incorrect test result and approximately 7% will have an
inconclusive result. SAs did not materially alter the results. These findings have important implications for
service provision.
The use of high-throughput NIPT as a routine screening test for fetal RhD status in RhD-negative women
can largely remove unnecessary exposure to prophylactic anti-D treatment, without substantially altering
the rate of sensitisations. However, there will be a very small number of women (about 0.1%) with a
false-negative test result who are at increased risk of sensitisation because they do not receive antenatal
anti-D prophylaxis. This risk will be increased if postnatal cord blood testing is withdrawn from clinical
practice. However, the numbers of additional sensitisations is likely to be very small.
Based on a cross-section of 100,000 pregnancies, the magnitude of expected cost savings is estimated to
range between £296,000 and £409,000 depending on the impact of high-throughput NIPT on postpartum
management.
Suggested research priorities
For future research priorities, evidence on the diagnostic accuracy of high-throughput NIPT in women of
non-white ethnicity is needed, for which large prospective cohort studies collecting diagnostic accuracy
data will be required. This is of particular concern as non-white women are more likely to have less
accurate test results. For example, in people with African ethnicity, because of the presence of the RHD
pseudogene,5 the prenatal detection of fetal RhD type from maternal blood would lead to higher rates of
false-positive results in this particular population. Future diagnostic accuracy studies should systematically
record and report the number of and reasons for inconclusive results and how these were dealt with when
deriving estimates of diagnostic accuracy.
Given the limited evidence on the clinical impact of NIPT, further cohort studies comparing the use of
high-throughput NIPT with universal antenatal anti-D administration are required. Such studies would
ideally include a consecutive and representative sample of pregnant women in the UK. These should focus
on recording relevant clinical outcomes (such as sensitisation rates, test and anti-D compliance and costs
and quality of life) and adjust for relevant and clearly defined confounders (such as compliance with anti-D,
timing of anti-D uptake and gestational age at time of NIPT). There is also limited existing evidence on the
impact of sensitisations in terms of their long-term health and cost consequences. Although well-conducted
cohort studies that comprehensively assess the full impact of sensitisations over mothers and children would
be ideal, the complexity and cost associated with such studies means that promoting more systematic
reporting and good-quality national audit data collection may be preferred. Surveys conducted in
representative samples of women that assess the impact on quality of life of NIPT appear to be warranted.
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Appendix 1 Search strategies
MEDLINE (via Ovid, http://ovidsp.ovid.com/)
Date range searched: 1946 to October Week 5 2015.
Date searched: 5 November 2015.
Records retrieved: 1815.
The search was updated on 26 February 2016, retrieving 77 records from MEDLINE and 40 records from
MEDLINE In-Process & other Non-Indexed Citations.
1. Rh-Hr Blood-Group System/ (10,006)
2. (RhD or “rhesus D” or “Rh(D)” or “Rh-(D)” or Rh D).ti,ab. (3323)
3. (Rh-negative or Rh-positive).ti,ab. (898)
4. (Rhesus negative or Rhesus positive).ti,ab. (228)
5. ((rh or rhesus) adj2 (factor or factors or antigen$ or system or group)).ti,ab. (3438)
6. or/1-5 (13,812)
7. Rh Isoimmunization/ (1505)
8. ((isoimmuni$ or iso-immuni$ or isoimmune or iso-immune) adj6 (rh or rhesus or maternal or
pregnan$)).ti,ab. (1164)
9. ((alloimmuni$ or allo-immuni$ or alloimmune or allo-immune) adj6 (rh or rhesus or maternal or
pregnan$)).ti,ab. (870)
10. ((unsensiti#ed or un-sensiti#ed or non-sensiti#ed) adj6 (rh or rhesus or maternal or pregnan$)).ti,ab.
(25)
11. ((sensiti#ation$ or sensiti#ed) adj6 (rh or rhesus or maternal or pregnan$)).ti,ab. (1074)
12. ((fetomaternal or feto-maternal or foetomaternal or foeto-maternal) adj2 immuni#ation).ti,ab. (80)
13. ((rh or rhesus) adj2 (immuni#ation or autoimmuni#ation)).ti,ab. (695)
14. or/7-13 (4428)
15. exp Erythroblastosis, Fetal/ (11,006)
16. ((hemolytic or haemolytic) adj2 (disease$ or disorder$)).ti,ab. (4465)
17. HDFN.ti,ab. (95)
18. ((rhesus or rh) adj2 (disease$ or disorder$)).ti,ab. (742)
19. ((rhesus or rh or RhD) adj2 (incompatib$ or antagonism)).ti,ab. (750)
20. ((erythroblastoses or erythroblastosis) adj2 f?etal$).ti,ab. (760)
21. or/15-20 (13,551)
22. 6 or 14 or 21 (25,723)
23. Prenatal Diagnosis/ (33,273)
24. Maternal Serum Screening Tests/ (153)
25. Hematologic Tests/ (5564)
26. ((prenatal or pre-natal or antenatal or ante-natal) adj3 (test$ or screen$ or diagnos$ or determin$ or
detect$)).ti,ab. (32,925)
27. ((fetal or foetal or fetus$ or foetus$) adj3 (test$ or screen$ or diagnos$ or determin$ or detect$)).ti,ab.
(20,036)
28. (NIPD or NIPT).ti,ab. (328)
29. or/23-28 (69,981)
30. Genotyping Techniques/ (2761)
31. ((genotype$ or genotyping) adj2 (fetal or foetal or fetus$ or foetus$ or prenatal or pre-natal or
antenatal or ante-natal)).ti,ab. (606)
32. ((genotype$ or genotyping) adj2 (maternal or pregnan$)).ti,ab. (789)
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33. ((genotype$ or genotyping) adj2 (noninvasive or non-invasive)).ti,ab. (71)
34. cell-free f?etal DNA.ti,ab. (489)
35. cffDNA.ti,ab. (87)
36. or/30-35 (4483)
37. 22 and 29 (1795)
38. 22 and 36 (276)
39. 37 or 38 (1869)
40. (editorial or comment).pt. (946,538)
41. 39 not 40 (1824)
42. exp animals/ not humans/ (4,137,930)
43. 41 not 42 (1815)
Key
/ = indexing term [medical subject heading (MeSH) heading]
exp = exploded indexing term (MeSH heading)
$ = truncation
# =mandated wildcard – stands for one character
? = optional wildcard – stands for zero or one character
.ti,ab. = terms in either title or abstract fields
.pt. = publication type
adj = terms next to each other (order specified)
adj2 = terms within two words of each other (any order)
Cumulative Index to Nursing & Allied Health (via EBSCOhost,
www.ebscohost.com)
Date range searched: inception to 5 November 2015.
Date searched: 6 November 2015.
Records retrieved: 290.
The search was updated on 26 February 2016, retrieving 31 records.
# Query Results
S39 S37 OR S38 290
S38 S22 AND S36 73
S37 S22 AND S29 268
S36 S30 OR S31 OR S33 OR S34 OR S35 2737
S35 TI cffDNA OR AB cffDNA 20
S34 TI “cell-free f#etal DNA” OR AB “cell-free f#etal DNA” 124
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# Query Results
S33 TI ( ((genotype* or genotyping) N2 (noninvasive or non-invasive)) ) OR AB ( (genotype* or genotyping) N2
(noninvasive or non-invasive)) )
21
S32 TI ( ((genotype* or genotyping) N2 (maternal or pregnan*)) ) OR AB ( ((genotype* or genotyping) N2
(maternal or pregnan*)) )
105
S31 TI ( ((genotype* or genotyping) N2 (fetal or foetal or fetus* or foetus* or prenatal or pre-natal or
antenatal or ante-natal)) ) OR AB ( ((genotype* or genotyping) N2 (fetal or foetal or fetus* or foetus* or
prenatal or pre-natal or antenatal or ante-natal)) )
103
S30 MM “Genetic Techniques” 2529
S29 S23 or S24 or S25 or S26 or S27 or S28 22,920
S28 TI ( (NIPD or NIPT) ) OR AB ( (NIPD or NIPT) ) 93
S27 TI ( (fetal or foetal or fetus* or foetus*) N3 (test* or screen* or diagnos* or determin* or detect*) ) OR
AB ( (fetal or foetal or fetus* or foetus*) N3 (test* or screen* or diagnos* or determin* or detect*) )
2644
S26 TI ( (prenatal or pre-natal or antenatal or ante-natal) N3 (test* or screen* or diagnos* or determin* or
detect*) ) OR AB ( (prenatal or pre-natal or antenatal or ante-natal) N3 (test* or screen* or diagnos* or
determin* or detect*) )
5033
S25 (MH “Noninvasive Procedures”) 1538
S24 (MH “Hematologic Tests”) 11,530
S23 (MH “Prenatal Diagnosis”) 5562
S22 S6 OR S14 OR S21 1924
S21 S15 OR S16 OR S17 OR S18 OR S19 OR S20 998
S20 TI ( (erythroblastoses or erythroblastosis) N2 (fetal* or foetal*) ) OR AB ( (erythroblastoses or
erythroblastosis) N2 (fetal* or foetal*) )
16
S19 TI ( (rhesus or rh or RhD) N2 (incompatib* or antagonism) ) OR AB ( (rhesus or rh or RhD) N2
(incompatib* or antagonism) )
45
S18 TI ( (rhesus or rh) N2 (disease* or disorder*) ) OR AB ( (rhesus or rh) N2 (disease* or disorder*) ) 76
S17 TI HDFN OR AB HDFN 20
S16 TI ( (hemolytic or haemolytic) N2 (disease* or disorder*) ) OR AB ( (hemolytic or haemolytic) N2 (disease*
or disorder*) )
298
S15 (MH “Erythroblastosis, Fetal+”) 775
S14 S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 446
S13 TI ( (rh or rhesus) N2 (immuni?ation or autoimmuni?ation) ) OR AB ( (rh or rhesus) N2 (immuni?ation or
autoimmuni?ation) )
17
S12 TI ( (fetomaternal or feto-maternal or foetomaternal or foeto-maternal) N2 immuni?ation ) OR AB
( (fetomaternal or feto-maternal or foetomaternal or foeto-maternal) N2 immuni?ation )
2
S11 TI ( (sensiti?ation* or sensiti?ed) N6 (rh or rhesus or maternal or pregnan*) ) OR AB ( (sensiti?ation* or
sensiti?ed) N6 (rh or rhesus or maternal or pregnan*) )
61
S10 TI ( (unsensiti?ed or un-sensiti?ed or non-sensiti?ed) N6 (rh or rhesus or maternal or pregnan*) ) OR AB
( (unsensiti?ed or un-sensiti?ed or non-sensiti?ed) N6 (rh or rhesus or maternal or pregnan*) )
3
S9 TI ( (alloimmuni* or allo-immuni* or alloimmune or allo-immune) N6 (rh or rhesus or maternal or
pregnan*) ) OR AB ( (alloimmuni* or allo-immuni* or alloimmune or allo-immune) N6 (rh or rhesus or
maternal or pregnan*) )
126
S8 TI ( (isoimmuni* or iso-immuni* or isoimmune or iso-immune) N6 (rh or rhesus or maternal or pregnan*) )
OR AB ( (isoimmuni* or iso-immuni* or isoimmune or iso-immune) N6 (rh or rhesus or maternal or
pregnan*) )
47
S7 (MH “RH Isoimmunization”) 297
S6 S1 OR S2 OR S3 OR S4 OR S5 870
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# Query Results
S5 TI ( (rh or rhesus) N2 (factor or factors or antigen* or system or group) ) OR AB ( (rh or rhesus) N2 (factor
or factors or antigen* or system or group) )
167
S4 TI ( “Rhesus negative” or “Rhesus positive” ) OR AB ( “Rhesus negative” or “Rhesus positive” ) 24
S3 TI ( Rh-negative or Rh-positive ) OR AB ( Rh-negative or Rh-positive ) 53
S2 TI ( RhD or “rhesus D” or “Rh(D)” or “Rh-(D)” or Rh D ) OR AB ( RhD or “rhesus D” or “Rh(D)” or
“Rh-(D)” or “Rh D” or “Rh-D” )
492
S1 (MH “Rh-Hr Blood-Group System”) 458
Key
MH = indexing term (CINAHL heading)
* = truncation
? =wildcard – stands for one character
# = optional wildcard – stands for zero or one character
TI =words in the title
AB =words in the abstract
“ “ = phrase search
N2 = terms within two words of each other (any order)
PT = publication type
Cochrane Central Register of Controlled Trials (via Wiley Online Library,
http://onlinelibrary.wiley.com/)
Issue 10 of 12, October 2015.
Date searched: 6 November 2015.
Records retrieved: 16.
The search was updated on 26 February 2016, retrieving 17 records from CENTRAL.
#1 MeSH descriptor: [Rh-Hr Blood-Group System] this term only(62)
#2 (RhD or “rhesus D” or “Rh(D)” or “Rh-(D)” or “Rh D” or “Rh-D”):ti,ab,kw(94)
#3 (Rh-negative or Rh-positive):ti,ab,kw(20)
#4 (“Rhesus negative” or “Rhesus positive”):ti,ab,kw(16)
#5 (rh or rhesus) near/2 (factor or factors or antigen* or system or group):ti,ab,kw(106)
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#6 #1 or #2 or #3 or #4 or #5(238)
#7 MeSH descriptor: [Rh Isoimmunization] this term only(40)
#8 (isoimmuni* or iso-immuni* or isoimmune or iso-immune) near/6 (rh or rhesus or maternal or
pregnan*):ti,ab,kw(68)
#9 (alloimmuni* or allo-immuni* or alloimmune or allo-immune) near/6 (rh or rhesus or maternal or
pregnan*):ti,ab,kw(22)
#10 (unsensitised or unsensitized or un-sensitised or un-sensitized or non-sensitised or non-sensitized)
near/6 (rh or rhesus or maternal or pregnan*):ti,ab,kw(3)
#11 (sensitisation* or sensitization* or sensitised or sensitized) near/6 (rh or rhesus or maternal or
pregnan*):ti,ab,kw(32)
#12 (fetomaternal or feto-maternal or foetomaternal or foeto-maternal) near/2 (immunisation or
immunization):ti,ab,kw(1)
#13 (rh or rhesus) near/2 (immunisation or immunization or autoimmunisation or autoimmunization):
ti,ab,kw(29)
#14 #7 or #8 or #9 or #10 or #11 or #12 or #13(123)
#15 MeSH descriptor: [Erythroblastosis, Fetal] explode all trees(72)
#16 (hemolytic or haemolytic) near/2 (disease* or disorder*):ti,ab,kw(99)
#17 HDFN:ti,ab,kw(3)
#18 (rhesus or rh) near/2 (disease* or disorder*):ti,ab,kw(628)
#19 (rhesus or rh or RhD) near/2 (incompatib* or antagonism):ti,ab,kw(22)
#20 (erythroblastoses or erythroblastosis) near/2 (fetal* or foetal*):ti,ab,kw(72)
#21 #15 or #16 or #17 or #18 or #19 or #20(732)
#22 #6 or #14 or #21(978)
#23 MeSH descriptor: [Prenatal Diagnosis] this term only(363)
#24 MeSH descriptor: [Maternal Serum Screening Tests] this term only(5)
#25 MeSH descriptor: [Hematologic Tests] this term only(196)
#26 (prenatal or pre-natal or antenatal or ante-natal) near/3 (test* or screen* or diagnos* or determin*
or detect*):ti,ab,kw(868)
#27 (fetal or foetal or fetus* or foetus*) near/3 (test* or screen* or diagnos* or determin* or
detect*):ti,ab,kw(571)
#28 (NIPD or NIPT):ti,ab,kw(10)
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#29 #23 or #24 or #25 or #26 or #27 or #28(1480)
#30 MeSH descriptor: [Genotyping Techniques] this term only(18)
#31 (genotype* or genotyping) near/2 (fetal or foetal or fetus* or foetus* or prenatal or pre-natal or
antenatal or ante-natal):ti,ab,kw(5)
#32 ((genotype* or genotyping) near/2 (maternal or pregnan*)):ti,ab,kw(15)
#33 ((genotype* or genotyping) near/2 (noninvasive or non-invasive)):ti,ab,kw(0)
#34 (“cell-free foetal DNA” or “cell-free fetal DNA”):ti,ab,kw(7)
#35 cffDNA:ti,ab,kw(1)
#36 #30 or #31 or #32 or #33 or #34 or #35(42)
#37 #22 and #29(33)
#38 #22 and #36(4)
#39 #37 or #38(34)
Note: The strategy above was used to search CENTRAL and CDSR. The 34 results at line #39 include
Cochrane reviews, DARE, HTA and NHS EED records as well as trials from CENTRAL.
Key
MeSH descriptor = indexing term (MeSH heading)
* = truncation
:ti,ab,kw = terms in either title or abstract or keyword fields
near/2 = terms within two words of each other (any order)
next = terms are next to each other
“ “ = phrase search
Cochrane Database of Systematic Reviews (via Wiley Online Library,
http://onlinelibrary.wiley.com/)
Issue 11 of 12, November 2015.
Date searched: 6 November 2015.
Records retrieved: 8.
See Cochrane Central Register of Controlled Trials for search strategy used.
The search was updated on 26 February 2016, retrieving nine records from CDSR.
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Database of Abstracts of Reviews of Effects (via Centre for
Reviews and Dissemination, www.crd.york.ac.uk/CRDWeb)
Date range searched: inception to 31 March 2015.
Date searched: 6 November 2015.
Records retrieved: 9.
The strategy below was used to search DARE, NHS EED and the HTA database. The hits column shows the
total number of records found in all three databases.
Line Search Hits
1 MeSH DESCRIPTOR Rh-Hr Blood-Group System EXPLODE ALL TREES 16
2 (RhD or “rhesus D” or Rh-D) 24
3 (Rh-negative or Rh-positive) 7
4 (“Rhesus negative” or “Rhesus positive”) 9
5 ((rh or rhesus) NEAR2 (factor or factors or antigen* or system or group)) 18
6 ((factor or factors or antigen* or system or group) NEAR2 (rh or rhesus)) 1
7 #1 OR #2 OR #3 OR #4 OR #5 OR #6 35
8 MeSH DESCRIPTOR Rh Isoimmunization 15
9 ((isoimmuni* or iso-immuni* or isoimmune or iso-immune) NEAR6 (rh or rhesus or maternal or pregnan*)) 10
10 ((rh or rhesus or maternal or pregnan*) NEAR6 (isoimmuni* or iso-immuni* or isoimmune or iso-immune) ) 17
11 ((alloimmuni* or allo-immuni* or alloimmune or allo-immune) NEAR6 (rh or rhesus or maternal or
pregnan*))
12
12 ((rh or rhesus or maternal or pregnan*) NEAR6 (alloimmuni* or allo-immuni* or alloimmune or allo-immune)) 8
13 ((unsensitised or unsensitized or un-sensitised or un-sensitized or non-sensitised or non-sensitized) NEAR6
(rh or rhesus or maternal or pregnan*))
3
14 ((rh or rhesus or maternal or pregnan*) NEAR6 (unsensitised or unsensitized or un-sensitised or un-sensitized
or non-sensitised or non-sensitized))
0
15 ((sensitisation* or sensitization* or sensitised or sensitized )NEAR6 (rh or rhesus or maternal or pregnan*)) 6
16 ((rh or rhesus or maternal or pregnan*) NEAR6 (sensitisation* or sensitization* or sensitised or sensitized)) 5
17 ((fetomaternal or feto-maternal or foetomaternal or foeto-maternal) NEAR2 (immunisation or immunization)) 0
18 ((immunisation or immunization) NEAR2 (fetomaternal or feto-maternal or foetomaternal or foeto-maternal)) 0
19 ((rh or rhesus) NEAR2 (immunisation or immunization or autoimmunisation or autoimmunization)) 4
20 ((immunisation or immunization or autoimmunisation or autoimmunization) NEAR2 (rh or rhesus)) 0
21 #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 29
22 MeSH DESCRIPTOR Erythroblastosis, Fetal EXPLODE ALL TREES 18
23 ((hemolytic or haemolytic) NEAR2 (disease* or disorder*)) 16
24 ((disease* or disorder*) NEAR2 (hemolytic or haemolytic)) 1
25 (HDFN) 1
26 ((rhesus or rh) NEAR2 (disease* or disorder*)) 3
27 ((disease* or disorder*) NEAR2 (rhesus or rh)) 1
28 ((rhesus or rh or RhD) NEAR2 (incompatib* or antagonism)) 3
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Line Search Hits
29 ((incompatib* or antagonism) NEAR2 (rhesus or rh or RhD)) 0
30 ((erythroblastoses or erythroblastosis) NEAR2 (fetal* or foetal*)) 14
31 #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 28
32 #7 OR #21 OR #31 56
33 MeSH DESCRIPTOR Prenatal Diagnosis 216
34 MeSH DESCRIPTOR Maternal Serum Screening Tests 5
35 MeSH DESCRIPTOR Hematologic Tests 30
36 ((prenatal or pre-natal or antenatal or ante-natal) NEAR3 (test* or screen* or diagnos* or determin* or
detect*))
380
37 ((test* or screen* or diagnos* or determin* or detect*) NEAR3 (prenatal or pre-natal or antenatal or
ante-natal))
171
38 ((test* or screen* or diagnos* or determin* or detect*) NEAR3 (fetal or foetal or fetus* or foetus*)) 124
39 ((fetal or foetal or fetus* or foetus*) NEAR3 (test* or screen* or diagnos* or determin* or detect*)) 130
40 (NIPD or NIPT) 6
41 #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 534
42 MeSH DESCRIPTOR Genotyping Techniques 6
43 ((genotype* or genotyping) NEAR2 (fetal or foetal or fetus* or foetus* or prenatal or pre-natal or antenatal
or ante-natal))
3
44 ((fetal or foetal or fetus* or foetus* or prenatal or pre-natal or antenatal or ante-natal) NEAR2 (genotype*
or genotyping))
3
45 ((genotype* or genotyping) NEAR2 (maternal or pregnan*)) 2
46 ((maternal or pregnan*) NEAR2 (genotype* or genotyping)) 2
47 ((genotype* or genotyping) NEAR2 (noninvasive or non-invasive)) 1
48 ((noninvasive or non-invasive) NEAR2 (genotype* or genotyping)) 4
49 (“cell-free foetal DNA” or “cell-free fetal DNA”) 7
50 (cffDNA) 2
51 #42 OR #43 OR #44 OR #45 OR #46 OR #47 OR #48 OR #49 OR #50 18
52 #32 AND #41 16
53 #32 AND #51 6
54 #52 OR #53 18
Key
MeSH DESCRIPTOR = indexing term (MeSH heading)
* = truncation
NEAR2 = terms within two words of each other (order specified)
“ ” = phrase search
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EMBASE (via Ovid, http://ovidsp.ovid.com/)
Date range searched: 1974 to 2015 November 04.
Date searched: 5 November 2015.
Records retrieved: 3092.
The search was updated on 26 February 2016, retrieving 221 records.
1. blood group rhesus system/ (8133)
2. rhesus D antigen/ (785)
3. (RhD or “rhesus D” or “Rh(D)” or “Rh-(D)” or Rh D).ti,ab. (5254)
4. (Rh-negative or Rh-positive).ti,ab. (1197)
5. (Rhesus negative or Rhesus positive).ti,ab. (320)
6. ((rh or rhesus) adj2 (factor or factors or antigen$ or system or group)).ti,ab. (4401)
7. or/1-6 (15,398)
8. rhesus isoimmunization/ (1536)
9. ((isoimmuni$ or iso-immuni$ or isoimmune or iso-immune) adj6 (rh or rhesus or maternal or
pregnan$)).ti,ab. (1313)
10. ((alloimmuni$ or allo-immuni$ or alloimmune or allo-immune) adj6 (rh or rhesus or maternal or
pregnan$)).ti,ab. (1319)
11. ((unsensiti#ed or un-sensiti#ed or non-sensiti#ed) adj6 (rh or rhesus or maternal or pregnan$)).ti,ab. (37)
12. ((sensiti#ation$ or sensiti#ed) adj6 (rh or rhesus or maternal or pregnan$)).ti,ab. (1306)
13. ((fetomaternal or feto-maternal or foetomaternal or foeto-maternal) adj2 immuni#ation).ti,ab. (90)
14. ((rh or rhesus) adj2 (immuni#ation or autoimmuni#ation)).ti,ab. (772)
15. or/8-14 (5218)
16. exp newborn hemolytic disease/ (11,867)
17. ((hemolytic or haemolytic) adj2 (disease$ or disorder$)).ti,ab. (5302)
18. HDFN.ti,ab. (294)
19. ((rhesus or rh) adj2 (disease$ or disorder$)).ti,ab. (838)
20. ((rhesus or rh or RhD) adj2 (incompatib$ or antagonism)).ti,ab. (913)
21. ((erythroblastoses or erythroblastosis) adj2 f?etal$).ti,ab. (739)
22. rhesus incompatibility/ (1131)
23. or/16-22 (16,217)
24. 7 or 15 or 23 (30,562)
25. prenatal diagnosis/ (50,220)
26. prenatal screening/ (6356)
27. maternal serum screening test/ (145)
28. blood examination/ (10,293)
29. non invasive procedure/ (17,457)
30. diagnostic accuracy/ (195,290)
31. ((prenatal or pre-natal or antenatal or ante-natal) adj3 (test$ or screen$ or diagnos$ or determin$ or
detect$)).ti,ab. (40,821)
32. ((fetal or foetal or fetus$ or foetus$) adj3 (test$ or screen$ or diagnos$ or determin$ or detect$)).ti,ab.
(25,280)
33. (NIPD or NIPT).ti,ab. (561)
34. or/25-33 (301,546)
35. genotyping technique/ (4081)
36. ((genotype$ or genotyping) adj2 (fetal or foetal or fetus$ or foetus$ or prenatal or pre-natal or
antenatal or ante-natal)).ti,ab. (800)
37. ((genotype$ or genotyping) adj2 (maternal or pregnan$)).ti,ab. (924)
38. ((genotype$ or genotyping) adj2 (noninvasive or non-invasive)).ti,ab. (90)
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39. cell-free f?etal DNA.ti,ab. (741)
40. cffDNA.ti,ab. (168)
41. or/35-40 (6300)
42. 24 and 34 (3084)
43. 24 and 41 (419)
44. 42 or 43 (3160)
45. (editorial or note).pt. (1,117,567)
46. 44 not 45 (3107)
47. animal/ (1,701,987)
48. exp animal experiment/ (1,895,782)
49. nonhuman/ (4,645,212)
50. (rat or rats or mouse or mice or hamster or hamsters or animal or animals or dog or dogs or cat or
cats or bovine or sheep).ti,sh. (4,564,702)
51. 47 or 48 or 49 or 50 (7,266,921)
52. exp human/ (16,514,549)
53. human experiment/ (344,858)
54. 52 or 53 (16,515,997)
55. 51 not (51 and 54) (5,693,442)
56. 46 not 55 (3092)
Key
/ = indexing term (Emtree heading)
exp = exploded indexing term (Emtree heading)
$ = truncation
# =mandated wildcard – stands for one character
? = optional wildcard – stands for zero or one character
.ti,ab. = terms in either title or abstract fields
.pt. = publication type
sh. = subject heading field
adj = terms next to each other (order specified)
adj2 = terms within two words of each other (any order)
Health Technology Assessment database (via www.crd.york.ac.uk/CRDWeb)
Date range searched: inception to 31 March 2015.
Date searched: 6 November 2015.
Records retrieved: 3.
See above under Database of Abstracts of Reviews of Effects for search strategy used.
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Maternity and infant care (via Ovid, http://ovidsp.ovid.com/)
Date range searched: 1971 to September 2015.
Date searched: 5 November 2015.
Records retrieved: 238.
The search was updated on 26 February 2016, retrieving 11 records.
1. Rh-Hr blood-group system.de. (26)
2. (RhD or “rhesus D” or “Rh(D)” or “Rh-(D)” or Rh D).ti,ab. (285)
3. (Rh-negative or Rh-positive).ti,ab. (81)
4. (Rhesus negative or Rhesus positive).ti,ab. (76)
5. ((rh or rhesus) adj2 (factor or factors or antigen$ or system or group)).ti,ab. (57)
6. 1 or 2 or 3 or 4 or 5 (439)
7. (Rh isoimmunisation or Rh isoimmunisation - therapy or “Rh isoimmunisation - prevention and
control”).de. (317)
8. Alloimmunisation.de. (29)
9. ((isoimmuni$ or iso-immuni$ or isoimmune or iso-immune) adj6 (rh or rhesus or maternal or
pregnan$)).ti,ab. (148)
10. ((alloimmuni$ or allo-immuni$ or alloimmune or allo-immune) adj6 (rh or rhesus or maternal or
pregnan$)).ti,ab. (201)
11. ((unsensiti#ed or un-sensiti#ed or non-sensiti#ed) adj6 (rh or rhesus or maternal or pregnan$)).ti,ab. (9)
12. ((sensiti#ation$ or sensiti#ed) adj6 (rh or rhesus or maternal or pregnan$)).ti,ab. (96)
13. ((fetomaternal or feto-maternal or foetomaternal or foeto-maternal) adj2 immuni#ation).ti,ab. (3)
14. ((rh or rhesus) adj2 (immuni#ation or autoimmuni#ation)).ti,ab. (61)
15. 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 (616)
16. Erythroblastosis - fetal.de. (118)
17. ((hemolytic or haemolytic) adj2 (disease$ or disorder$)).ti,ab. (281)
18. HDFN.ti,ab. (24)
19. ((rhesus or rh) adj2 (disease$ or disorder$)).ti,ab. (96)
20. rhesus.sx. (435)
21. ((rhesus or rh or RhD) adj2 (incompatib$ or antagonism)).ti,ab. (42)
22. ((erythroblastoses or erythroblastosis) adj2 f?etal$).ti,ab. (27)
23. 16 or 17 or 18 or 19 or 20 or 21 or 22 (669)
24. 6 or 15 or 23 (1005)
25. Prenatal diagnosis.de. (4460)
26. ((prenatal or pre-natal or antenatal or ante-natal) adj3 (test$ or screen$ or diagnos$ or determin$ or
detect$)).ti,ab. (7133)
27. ((fetal or foetal or fetus$ or foetus$) adj3 (test$ or screen$ or diagnos$ or determin$ or detect$)).ti,ab.
(4763)
28. (NIPD or NIPT).ti,ab. (89)
29. 25 or 26 or 27 or 28 (12,193)
30. ((genotype$ or genotyping) adj2 (fetal or foetal or fetus$ or foetus$ or prenatal or pre-natal or
antenatal or ante-natal)).ti,ab. (96)
31. ((genotype$ or genotyping) adj2 (maternal or pregnan$)).ti,ab. (89)
32. ((genotype$ or genotyping) adj2 (noninvasive or non-invasive)).ti,ab. (6)
33. cell-free f?etal DNA.ti,ab. (148)
34. cffDNA.ti,ab. (31)
35. (genotype$ or genotyping).ti,ab. (881)
36. 30 or 31 or 32 or 33 or 34 (291)
37. 24 and 29 (237)
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38. 24 and 36 (67)
39. 37 or 38 (245)
40. (editorial or commentary).pt. (14,906)
41. 39 not 40 (238)
Key
.de. = subject heading search
$ = truncation
# =mandated wildcard – stands for one character
? = optional wildcard – stands for zero or one character
.ti,ab. = terms in either title or abstract fields
.pt. = publication type
adj = terms next to each other (order specified)
adj2 = terms within two words of each other (any order)
NHS Economic Evaluations Database (via Centre for Reviews
and Dissemination, www.crd.york.ac.uk/CRDWeb)
Date range searched: inception to 31 March 2015.
Date searched: 6 November 2015.
Records retrieved: 6.
See above under Database of Abstracts of Reviews of Effects for search strategy used.
PubMed (www.ncbi.nlm.nih.gov/pubmed)
Date searched: 26 February 2016.
Records retrieved: 112.
((((((((((((“Prenatal Diagnosis”[Mesh:NoExp]) OR “Maternal Serum Screening Tests”[Mesh:NoExp]) OR
“Hematologic Tests”[Mesh:NoExp]) OR ((((test[Title/Abstract] OR tests[Title/Abstract] OR testing[Title/
Abstract] OR tested[Title/Abstract] OR screen*[Title/Abstract] OR diagnos*[Title/Abstract] OR determin*
[Title/Abstract] OR detect*[Title/Abstract]))) AND ((prenatal[Title/Abstract] OR pre-natal[Title/Abstract] OR
antenatal[Title/Abstract] OR ante-natal[Title/Abstract] OR fetal[Title/Abstract] OR foetal[Title/Abstract]
OR fetus*[Title/Abstract] OR foetus*[Title/Abstract])))) OR ((NIPD[Title/Abstract] OR NIPT[Title/Abstract])))) OR
(((“Genotyping Techniques”[Mesh:NoExp]) OR ((((genotype*[Title/Abstract] OR genotyping[Title/Abstract])))
AND ((((fetal[Title/Abstract] OR foetal[Title/Abstract] OR fetus*[Title/Abstract] OR foetus*[Title/Abstract] OR
prenatal[Title/Abstract] OR pre-natal[Title/Abstract] OR antenatal[Title/Abstract] OR ante-natal[Title/
Abstract])) OR (maternal[Title/Abstract] OR pregnan*[Title/Abstract])) OR (noninvasive[Title/Abstract] OR
non-invasive[Title/Abstract])))) OR ((“cell-free fetal DNA”[Title/Abstract] OR “cell-free foetal DNA”[Title/
Abstract] OR cffDNA[Title/Abstract])))))) AND ((((((((((“Erythroblastosis, Fetal”[Mesh]) OR ((“hemolytic
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disease”[Title/Abstract] OR “hemolytic diseases”[Title/Abstract] OR “hemolytic disorder”[Title/Abstract]
OR “hemolytic disorders”[Title/Abstract]))) OR ((“haemolytic disease” OR “haemolytic diseases” OR
“haemolytic disorder” OR “haemolytic disorders”))) OR HDFN[Title/Abstract]) OR ((“rhesus disease”
[Title/Abstract] OR “rhesus diseases”[Title/Abstract] OR “rhesus disorder”[Title/Abstract] OR “rhesus
disorders”[Title/Abstract] OR “rh disease”[Title/Abstract] OR “rh diseases”[Title/Abstract] OR “rh
disorder”[Title/Abstract] OR “rh disorders”[Title/Abstract]))) OR (((rhesus[Title/Abstract] OR rh[Title/Abstract]
OR RhD[Title/Abstract])) AND (incompatib*[Title/Abstract] OR antagonism[Title/Abstract]))) OR
(((erythroblastoses[Title/Abstract] OR erythroblastosis[Title/Abstract])) AND (fetal*[Title/Abstract] OR foetal*
[Title/Abstract])))) OR (((((“Rh Isoimmunization”[Mesh:noexp]) OR ((((((((isoimmuni*[Title/Abstract] OR
iso-immuni*[Title/Abstract] OR isoimmune[Title/Abstract] OR iso-immune[Title/Abstract]))) OR ((alloimmuni*
[Title/Abstract] OR allo-immuni*[Title/Abstract] OR alloimmune[Title/Abstract] OR allo-immune[Title/
Abstract]))) OR ((unsensitised[Title/Abstract] OR unsensitized[Title/Abstract] OR un-sensitised[Title/Abstract]
OR un-sensitized[Title/Abstract] OR non-sensitised[Title/Abstract] OR non-sensitized[Title/Abstract]))) OR
((sensitisation*[Title/Abstract] OR sensitization*[Title/Abstract] OR sensitised[Title/Abstract] OR sensitized
[Title/Abstract])))) AND ((rh[Title/Abstract] OR rhesus[Title/Abstract] OR maternal[Title/Abstract] OR pregnan*
[Title/Abstract]))))) OR (((fetomaternal[Title/Abstract] OR feto-maternal[Title/Abstract] OR foetomaternal[Title/
Abstract] OR foeto-maternal[Title/Abstract])) AND (immunisation[Title/Abstract] OR immunization[Title/
Abstract]))) OR (((rh[Title/Abstract] OR rhesus[Title/Abstract])) AND (immunisation[Title/Abstract] OR
autoimmunisation[Title/Abstract] OR immunization[Title/Abstract] OR autoimmunization[Title/Abstract]))))
OR (((((“Rh-Hr Blood-Group System”[Mesh:noexp]) OR (((RhD[Title/Abstract] OR “rhesus D”[Title/Abstract]
OR “Rh(D)”[Title/Abstract] OR “Rh-(D)”[Title/Abstract] OR “Rh D”[Title/Abstract]))) OR ((Rh-negative[Title/
Abstract] OR Rh-positive[Title/Abstract]))) OR ((“Rhesus negative”[Title/Abstract] OR “Rhesus positive”[Title/
Abstract]))) OR ((“rh factor”[Title/Abstract] OR “rh factors”[Title/Abstract] OR “rh antigen”[Title/Abstract]
OR “rh antigens”[Title/Abstract] OR “rh system”[Title/Abstract] OR “rh group”[Title/Abstract]))) OR
((“rhesus factor”[Title/Abstract] OR “rhesus factors”[Title/Abstract] OR “rhesus antigen”[Title/Abstract] OR
“rhesus antigens”[Title/Abstract] OR “rhesus system”[Title/Abstract] OR “rhesus group”[Title/Abstract]))))))
AND ((((pubstatusaheadofprint OR publisher[sb] OR pubmednotmedline[sb]))) OR (((inprocess[sb] or medline
[sb])) AND (“2016/02/20”[Date - Entrez] : “3000”[Date - Entrez]))))
Science Citation Index (via Web of Science, Thomson Reuters,
http://thomsonreuters.com/thomson-reuters-web-of-science)
Date range searched: 1900 to 4 November 2015.
Date searched: 6 November 2015.
Records retrieved: 801.
The strategy below was used to search Science Citation Index and the Conference Proceedings Citation
Index: Science. As both databases were searched together the records retrieved refer to results from
both databases.
The searches for Science Citation Index and the Conference Proceedings Citation Index: Science were
updated on 26 February 2016, retrieving 811 records.
# 34 801 #32 NOT #33
Indexes = SCI-EXPANDED, CPCI-S Timespan = All years
# 33 20 #31 OR #30
Refined by:DOCUMENT TYPES: (EDITORIAL MATERIAL)
Indexes = SCI-EXPANDED, CPCI-S Timespan = All years
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# 32 821 #31 OR #30
Indexes = SCI-EXPANDED, CPCI-S Timespan = All years
# 31 287 #29 AND #19
Indexes = SCI-EXPANDED, CPCI-S Timespan = All years
# 30 744 #23 AND #19
Indexes = SCI-EXPANDED, CPCI-S Timespan = All years
# 29 2378 #28 OR #27 OR #26 OR #25 OR #24
Indexes = SCI-EXPANDED, CPCI-S Timespan = All years
# 28 79 TS=cffDNA
Indexes = SCI-EXPANDED, CPCI-S Timespan = All years
# 27 543 TS=(“cell-free foetal DNA” or “cell-free fetal DNA”)
Indexes = SCI-EXPANDED, CPCI-S Timespan = All years
# 26 204 TS=((genotype* or genotyping) NEAR/2 (noninvasive or non-invasive))
Indexes = SCI-EXPANDED, CPCI-S Timespan = All years
# 25 1222 TS=((genotype* or genotyping) NEAR/2 (maternal or pregnan*))
Indexes = SCI-EXPANDED, CPCI-S Timespan = All years
# 24 779 TS=((genotype* or genotyping) NEAR/2 (fetal or foetal or fetus* or foetus* or prenatal or pre-natal or
antenatal or ante-natal))
Indexes = SCI-EXPANDED, CPCI-S Timespan = All years
# 23 51,060 #22 OR #21 OR #20
Indexes = SCI-EXPANDED, CPCI-S Timespan = All years
# 22 632 TS=(NIPD or NIPT)
Indexes = SCI-EXPANDED, CPCI-S Timespan = All years
# 21 21,197 TS=((fetal or foetal or fetus* or foetus*) NEAR/3 (test* or screen* or diagnos* or determin* or detect*))
Indexes = SCI-EXPANDED, CPCI-S Timespan = All years
# 20 36,396 TS = ((prenatal or pre-natal or antenatal or ante-natal) NEAR/3 (test* or screen* or diagnos* or
determin* or detect*))
Indexes = SCI-EXPANDED, CPCI-S Timespan = All years
# 19 15,143 #18 OR #12 OR #5
Indexes = SCI-EXPANDED, CPCI-S Timespan = All years
# 18 5220 #17 OR #16 OR #15 OR #14 OR #13
Indexes = SCI-EXPANDED, CPCI-S Timespan = All years
# 17 581 TS = ((erythroblastoses or erythroblastosis) NEAR/2 f$etal*)
Indexes = SCI-EXPANDED, CPCI-S Timespan = All years
# 16 413 TS = ((rhesus or rh or RhD) NEAR/2 (incompatib* or antagonism))
Indexes = SCI-EXPANDED, CPCI-S Timespan = All years
# 15 1248 TS = ((rhesus or rh) NEAR/2 (disease* or disorder*))
Indexes = SCI-EXPANDED, CPCI-S Timespan = All years
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# 14 102 TS= HDFN
Indexes = SCI-EXPANDED, CPCI-S Timespan = All years
# 13 3593 TS= ((hemolytic or haemolytic) NEAR/2 (disease* or disorder*))
Indexes = SCI-EXPANDED, CPCI-S Timespan = All years
# 12 2937 #11 OR #10 OR #9 OR #8 OR #7 OR #6
Indexes = SCI-EXPANDED, CPCI-S Timespan = All years
# 11 565 TS= ((rh or rhesus) NEAR/2 (immuni?ation or autoimmuni?ation))
Indexes = SCI-EXPANDED, CPCI-S Timespan = All years
# 10 32 TS= ((fetomaternal or feto-maternal or foetomaternal or foeto-maternal) NEAR/2 immuni?ation)
Indexes = SCI-EXPANDED, CPCI-S Timespan = All years
# 9 899 TS= ((sensiti?ation* or sensiti?ed) NEAR/6 (rh or rhesus or maternal or pregnan*))
Indexes = SCI-EXPANDED, CPCI-S Timespan = All years
# 8 15 TS= ((unsensiti?ed or un-sensiti?ed or non-sensiti?ed) NEAR/6 (rh or rhesus or maternal or pregnan*))
Indexes = SCI-EXPANDED, CPCI-S Timespan = All years
# 7 981 TS= ((alloimmuni* or allo-immuni* or alloimmune or allo-immune) NEAR/6 (rh or rhesus or maternal or
pregnan*))
Indexes = SCI-EXPANDED, CPCI-S Timespan = All years
# 6 736 TS= ((isoimmuni* or iso-immuni* or isoimmune or iso-immune) NEAR/6 (rh or rhesus or maternal or pregnan*))
Indexes= SCI-EXPANDED, CPCI-S Timespan=All years
# 5 8522 #4 OR #3 OR #2 OR #1
Indexes = SCI-EXPANDED, CPCI-S Timespan = All years
# 4 5198 TS= ((rh or rhesus) NEAR/2 (factor or factors or antigen* or system or group))
Indexes = SCI-EXPANDED, CPCI-S Timespan = All years
# 3 121 TS= (“Rhesus negative” or “Rhesus positive”)
Indexes = SCI-EXPANDED, CPCI-S Timespan = All years
# 2 479 TS= (Rh-negative or Rh-positive)
Indexes = SCI-EXPANDED, CPCI-S Timespan = All years
# 1 3491 TS= (RhD or “rhesus D” or “Rh(D)” or “Rh-(D)” or “Rh D” or “Rh-D”)
Indexes = SCI-EXPANDED, CPCI-S Timespan = All years
Ongoing, unpublished or grey literature search strategies
ClinicalTrials.gov (https://clinicaltrials.gov/)
Date searched: 10 November 2015.
Records retrieved: 44.
RhD OR “rhesus D” OR “Rh(D)” OR “Rh-(D)” OR “Rh D” OR “Rh-negative” OR “Rh-positive” OR “Rhesus
negative” OR “Rhesus positive”
The search was updated on 26 February 2016, retrieving two new records.
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Conference Proceedings Citation Index: Science (via Web of Science, Thomson Reuters,
http://thomsonreuters.com/thomson-reuters-web-of-science)
Date range searched: 1990 to 4 November 2015.
Date searched: 6 November 2015.
Records retrieved: 801.
See Science Citation Index for search strategy used. As both databases were searched together, the
records retrieved refers to results from both databases.
The searches for Science Citation Index and the Conference Proceedings Citation Index: Science were
updated on 26 February 2016, retrieving 811 records.
EU Clinical Trials Register (www.clinicaltrialsregister.eu/ctr-search/search)
Date searched: 10 November 2015.
Records retrieved: 4.
“RhD” OR “rhesus D” OR “Rh(D)” OR “Rh-(D)” OR “Rh D” OR “Rh-negative” OR “Rh-positive” OR
“Rh negative” OR “Rh positive” OR “Rhesus negative” OR “Rhesus positive”
The search was updated on 26 February 2016 but no new records were retrieved.
PROSPERO (www.crd.york.ac.uk/PROSPERO)
Date searched: 10 November 2015.
Records retrieved: 4.
RhD or Rh-D or Rh-negative or Rh-positive in all fields.
The search was updated on 26 February 2016, retrieving one new record.
World Health Organization’s International Clinical Trials Registry Platform
(www.who.int/ictrp/search/en)
Date searched: 10 November 2015.
Records retrieved: 29.
RhD OR rhesus OR Rh-negative OR Rh-positive.
The search was updated on 26 February 2016 but no new records were retrieved.
Guideline searches
The following websites were searched for relevant guidelines.
All guideline website searches were updated on 4 March 2016; however, no new guidelines
were retrieved.
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National Guidelines Clearinghouse (www.guideline.gov)
Date searched: 17 November 2015.
(rhd or rhesus or ‘rh negative” or “rh positive”)‘ and ‘(pregnan* or maternal or antenatal or ante-natal or
prenatal or pre-natal or intrapartum)
A total of 23 results were retrieved and browsed for relevance; 18 relevant guidelines were found.
National Institute for Health and Care Excellence (www.nice.org.uk)
Date searched: 13 November 2015.
1. Browsed for relevant guidance in the fertility, pregnancy and childbirth section: www.nice.org.uk/
guidance/conditions-and-diseases/fertility–pregnancy-and-childbirth.
2. Searched NICE website using general search box with keyword RhD.
3. Searched NICE website using general search box with keyword Rhesus.
4. Relevant guidelines found.
NHS Evidence (www.evidence.nhs.uk)
Searched on: 17 November 2015.
(rhd OR rhesus OR “rh negative” OR “rh positive”) AND (pregnan* OR maternal OR antenatal OR
ante-natal OR prenatal OR pre-natal OR intrapartum) limited to guidelines.
A total of 81 results were retrieved and browsed for relevance. Seven relevant guidelines were found.
Royal College of Obstetricians and Gynaecologists (www.rcog.org.uk/en)
Date searched: 13 November 2015.
1. Browsed all guidelines.
2. Searched all guidelines by keyword – RhD or rhesus.
Four relevant guidelines were found.
Turning Research into Practice database (www.tripdatabase.com)
Date searched: 17 November 2015.
(rhd OR rhesus OR “rh negative” or “rh positive”) AND title:(pregnan* OR maternal OR antenatal OR
ante-natal OR prenatal OR pre-natal OR intrapartum)
A total of 37 results were retrieved and browsed for relevance; 17 relevant guidelines were found.
UK National Screening Committee (www.gov.uk/government/groups/
uk-national-screening-committee-uk-nsc)
Date searched: 13 November 2015.
Recommendations list was filtered by antenatal and the resulting list browsed.
One relevant report was found.
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Search strategies: systematic reviews of antenatal anti-D prophylaxis
MEDLINE and MEDLINE In-Process & Other Non-Indexed Citations
(via Ovid, http://ovidsp.ovid.com/)
Date range searched: 1946 to October Week 5 2015.
Date searched: 18 January 2016.
Records retrieved: 45.
The search was updated on 4 March 2016, retrieving 45 records.
1. systematic$ review$.ti,ab. (75,835)
2. meta-analysis as topic/ (14,365)
3. meta-analytic$.ti,ab. (4298)
4. meta-analysis.ti,ab,pt. (89,180)
5. metanalysis.ti,ab. (140)
6. metaanalysis.ti,ab. (1210)
7. meta analysis.ti,ab. (70,616)
8. meta-synthesis.ti,ab. (331)
9. metasynthesis.ti,ab. (166)
10. meta synthesis.ti,ab. (331)
11. meta-regression.ti,ab. (3249)
12. metaregression.ti,ab. (344)
13. meta regression.ti,ab. (3249)
14. (synthes$ adj3 literature).ti,ab. (1689)
15. (synthes$ adj3 evidence).ti,ab. (4926)
16. integrative review.ti,ab. (1177)
17. data synthesis.ti,ab. (7985)
18. (research synthesis or narrative synthesis).ti,ab. (1041)
19. (systematic study or systematic studies).ti,ab. (8551)
20. (systematic comparison$ or systematic overview$).ti,ab. (2200)
21. evidence based review.ti,ab. (1467)
22. comprehensive review.ti,ab. (8251)
23. critical review.ti,ab. (11,964)
24. quantitative review.ti,ab. (517)
25. structured review.ti,ab. (542)
26. realist review.ti,ab. (102)
27. realist synthesis.ti,ab. (73)
28. or/1-27 (187,703)
29. review.pt. (2,049,547)
30. medline.ab. (68,680)
31. pubmed.ab. (46,181)
32. cochrane.ab. (39,786)
33. embase.ab. (40,092)
34. cinahl.ab. (12,936)
35. psyc?lit.ab. (879)
36. psyc?info.ab. (10,559)
37. (literature adj3 search$).ab. (32,390)
38. (database$ adj3 search$).ab. (30,393)
39. (bibliographic adj3 search$).ab. (1461)
40. (electronic adj3 search$).ab. (11,252)
41. (electronic adj3 database$).ab. (13,910)
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42. (computeri?ed adj3 search$).ab. (2857)
43. (internet adj3 search$).ab. (2045)
44. included studies.ab. (9670)
45. (inclusion adj3 studies).ab. (8188)
46. inclusion criteria.ab. (44,510)
47. selection criteria.ab. (22,215)
48. predefined criteria.ab. (1258)
49. predetermined criteria.ab. (787)
50. (assess$ adj3 (quality or validity)).ab. (48,127)
51. (select$ adj3 (study or studies)).ab. (43,640)
52. (data adj3 extract$).ab. (34,903)
53. extracted data.ab. (8161)
54. (data adj2 abstracted).ab. (3617)
55. (data adj3 abstraction).ab. (1017)
56. published intervention$.ab. (121)
57. ((study or studies) adj2 evaluat$).ab. (121,595)
58. (intervention$ adj2 evaluat$).ab. (7046)
59. confidence interval$.ab. (258,288)
60. heterogeneity.ab. (106,141)
61. pooled.ab. (53,158)
62. pooling.ab. (8496)
63. odds ratio$.ab. (171,463)
64. (Jadad or coding).ab. (133,119)
65. or/30-64 (923,716)
66. 29 and 65 (141,974)
67. review.ti. (299,976)
68. 67 and 65 (62,549)
69. (review$ adj4 (papers or trials or studies or evidence or intervention$ or evaluation$)).ti,ab. (119,221)
70. 28 or 66 or 68 or 69 (340,645)
71. letter.pt. (897,674)
72. editorial.pt. (391,059)
73. comment.pt. (647,299)
74. 71 or 72 or 73 (1,445,828)
75. 70 not 74 (331856)
76. exp animals/ not humans/ (4,171,020)
77. 75 not 76 (321762)
78. “Rho(D) Immune Globulin”/ (1190)
79. (immune adj2 globulin adj2 rh$).ti,ab. (257)
80. anti-D.ti,ab. (2610)
81. (D-Gam or Partobulin or Rhophylac or WinRho).ti,ab. (47)
82. or/78-81 (3165)
83. 77 and 82 (45)
Key
/ = indexing term (MeSH heading)
$ = truncation
? = optional wildcard – stands for zero or one character
.ti,ab. = terms in either title or abstract fields
.pt. = publication type
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adj = terms next to each other (order specified)
adj2 = terms within two words of each other (any order)
Cochrane Database of Systematic Reviews (via Wiley Online Library,
http://onlinelibrary.wiley.com/)
Issue 1 of 12, January 2016.
Date searched: 18 January 2016.
Records retrieved: 6.
The search was updated on 4 March 2016, retrieving six records from CDSR.
#1 MeSH descriptor: [Rho(D) Immune Globulin] this term only(51)
#2 (immune near/2 globulin near/2 rh*):ti,ab,kw(5)
#3 anti-D:ti,ab,kw(110)
#4 (D-Gam or Partobulin or Rhophylac or WinRho):ti,ab,kw(10)
#5 #1 or #2 or #3 or #4(119)
#6 #1 or #2 or #3 or #4 in Cochrane Reviews (Reviews and Protocols)(6)
Key
MeSH descriptor = indexing term (MeSH heading)
* = truncation
:ti,ab,kw = terms in either title or abstract or keyword fields
near/2 = terms within two words of each other (any order)
Database of Abstracts of Reviews of Effects (via Centre for Reviews and Dissemination,
www.crd.york.ac.uk/CRDWeb)
Date range searched: inception to 31 March 2015.
Date searched on: 20 January 2016.
Records retrieved: 8.
1. (anti-D) IN DARE, HTA (15)
2. ((D-Gam or Partobulin or Rhophylac or WinRho)) IN DARE, HTA (1)
3. ((immune NEAR globulin NEAR rh*)) IN DARE, HTA (0)
4. ((immune NEAR rh* NEAR globulin)) IN DARE, HTA (0)
5. ((rh* NEAR immune NEAR globulin)) IN DARE, HTA (5)
6. ((rh* NEAR globulin NEAR immune)) IN DARE, HTA (0)
7. ((globulin NEAR rh* NEAR immune)) IN DARE, HTA (0)
8. ((globulin NEAR immune NEAR rh*)) IN DARE, HTA (0)
9. MeSH DESCRIPTOR Rho(D) Immune Globulin IN DARE,HTA (5)
10. #1 OR #2 OR #5 OR #9 (15)
11. (#1 or #2 or #5 or #9) IN DARE (8)
12. (#1 or #2 or #5 or #9) IN HTA (7)
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Health Technology Assessment database (via Centre for Reviews and
Dissemination, www.crd.york.ac.uk/CRDWeb)
Date range searched: inception to 31 March 2015.
Date searched: 20 January 2016.
Records retrieved: 7.
See above under Database of Abstracts of Reviews of Effects for search strategy used.
PubMed (www.ncbi.nlm.nih.gov/pubmed)
Date searched on: 20 January 2016.
Records retrieved: 57.
The search was updated on 4 March 2016, retrieving 58 records.
(((“Rho(D) Immune Globulin”[Mesh:noexp] OR “rh* immune globulin”[Title/Abstract]) OR (“RHO(D)
antibody”[Supplementary Concept] OR “RHO(D) antibody”[All Fields] OR “anti d”[All Fields])) OR
(Partobulin[Title/Abstract] OR Rhophylac[Title/Abstract] OR WinRho[Title/Abstract])) AND systematic[sb]
Search strategies: cost-effectiveness
EconLit (via Ovid, http://ovidsp.ovid.com/)
Date range searched: 1886 to November 2015.
Date searched: 4 December 2015.
Records retrieved: 4.
1. (RhD or “rhesus D” or “Rh(D)” or “Rh-(D)” or Rh D).ti,ab. (3)
2. (Rh-negative or Rh-positive).ti,ab. (0)
3. (Rhesus negative or Rhesus positive).ti,ab. (0)
4. ((rh or rhesus) adj2 (factor or factors or antigen$ or system or group)).ti,ab. (1)
5. ((isoimmuni$ or iso-immuni$ or isoimmune or iso-immune) adj6 (rh or rhesus or maternal or pregnan
$)).ti,ab. (0)
6. ((alloimmuni$ or allo-immuni$ or alloimmune or allo-immune) adj6 (rh or rhesus or maternal or
pregnan$)).ti,ab. (0)
7. ((unsensiti#ed or un-sensiti#ed or non-sensiti#ed) adj6 (rh or rhesus or maternal or pregnan$)).ti,ab. (0)
8. ((sensiti#ation$ or sensiti#ed) adj6 (rh or rhesus or maternal or pregnan$)).ti,ab. (0)
9. ((fetomaternal or feto-maternal or foetomaternal or foeto-maternal) adj2 immuni#ation).ti,ab. (0)
10. ((rh or rhesus) adj2 (immuni#ation or autoimmuni#ation)).ti,ab. (0)
11. ((hemolytic or haemolytic) adj2 (disease$ or disorder$)).ti,ab. (0)
12. HDFN.ti,ab. (0)
13. ((rhesus or rh) adj2 (disease$ or disorder$)).ti,ab. (0)
14. ((rhesus or rh or RhD) adj2 (incompatib$ or antagonism)).ti,ab. (0)
15. ((erythroblastoses or erythroblastosis) adj2 f?etal$).ti,ab. (0)
16. or/1-15 (4)
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Key
$ = truncation
# =mandated wildcard – stands for one character
? = optional wildcard – stands for zero or one character
.ti,ab. = terms in either title or abstract fields
adj2 = terms within two words of each other (any order)
NHS Economic Evaluations Database (via Centre for Reviews and Dissemination,
www.crd.york.ac.uk/CRDWeb)
Date range searched: inception to 31 March 2015.
Date searched on: 4 December 2015.
Records retrieved: 6.
1 MeSH DESCRIPTOR Rh-Hr Blood-Group System EXPLODE ALL TREES 16
2 (RhD or “rhesus D” or Rh-D) 24
3 (Rh-negative or Rh-positive) 7
4 (“Rhesus negative” or “Rhesus positive”) 9
5 ((rh or rhesus) NEAR2 (factor or factors or antigen* or system or group)) 18
6 ((factor or factors or antigen* or system or group) NEAR2 (rh or rhesus)) 1
7 #1 OR #2 OR #3 OR #4 OR #5 OR #6 35
8 MeSH DESCRIPTOR Rh Isoimmunization 15
9 ((isoimmuni* or iso-immuni* or isoimmune or iso-immune) NEAR6 (rh or rhesus or maternal or pregnan*)) 10
10 ((rh or rhesus or maternal or pregnan*) NEAR6 (isoimmuni* or iso-immuni* or isoimmune or iso-immune) ) 17
11 ((alloimmuni* or allo-immuni* or alloimmune or allo-immune) NEAR6 (rh or rhesus or maternal or pregnan*)) 12
12 ((rh or rhesus or maternal or pregnan*) NEAR6 (alloimmuni* or allo-immuni* or alloimmune or allo-immune)) 8
13 ((unsensitised or unsensitized or un-sensitised or un-sensitized or non-sensitised or non-sensitized) NEAR6
(rh or rhesus or maternal or pregnan*))
3
14 ((rh or rhesus or maternal or pregnan*) NEAR6 (unsensitised or unsensitized or un-sensitised or un-sensitized
or non-sensitised or non-sensitized))
0
15 ((sensitisation* or sensitization* or sensitised or sensitized )NEAR6 (rh or rhesus or maternal or pregnan*)) 6
16 ((rh or rhesus or maternal or pregnan*) NEAR6 (sensitisation* or sensitization* or sensitised or sensitized)) 5
17 ((fetomaternal or feto-maternal or foetomaternal or foeto-maternal) NEAR2 (immunisation or immunization)) 0
18 ((immunisation or immunization) NEAR2 (fetomaternal or feto-maternal or foetomaternal or foeto-maternal)) 0
19 ((rh or rhesus) NEAR2 (immunisation or immunization or autoimmunisation or autoimmunization)) 4
20 ((immunisation or immunization or autoimmunisation or autoimmunization) NEAR2 (rh or rhesus)) 0
21 #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 29
22 MeSH DESCRIPTOR Erythroblastosis, Fetal EXPLODE ALL TREES 18
23 ((hemolytic or haemolytic) NEAR2 (disease* or disorder*)) 16
24 ((disease* or disorder*) NEAR2 (hemolytic or haemolytic)) 1
25 (HDFN) 1
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26 ((rhesus or rh) NEAR2 (disease* or disorder*)) 3
27 ((disease* or disorder*) NEAR2 (rhesus or rh)) 1
28 ((rhesus or rh or RhD) NEAR2 (incompatib* or antagonism)) 3
29 ((incompatib* or antagonism) NEAR2 (rhesus or rh or RhD)) 0
30 ((erythroblastoses or erythroblastosis) NEAR2 (fetal* or foetal*)) 14
31 #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 28
32 #7 OR #21 OR #31 56
33 MeSH DESCRIPTOR Prenatal Diagnosis 216
34 MeSH DESCRIPTOR Maternal Serum Screening Tests 5
35 MeSH DESCRIPTOR Hematologic Tests 30
36 ((prenatal or pre-natal or antenatal or ante-natal) NEAR3 (test* or screen* or diagnos* or determin* or detect*)) 380
37 ((test* or screen* or diagnos* or determin* or detect*) NEAR3 (prenatal or pre-natal or antenatal or ante-natal)) 171
38 ((test* or screen* or diagnos* or determin* or detect*) NEAR3 (fetal or foetal or fetus* or foetus*)) 124
39 ((fetal or foetal or fetus* or foetus*) NEAR3 (test* or screen* or diagnos* or determin* or detect*)) 130
40 (NIPD or NIPT) 6
41 #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 534
42 MeSH DESCRIPTOR Genotyping Techniques 6
43 ((genotype* or genotyping) NEAR2 (fetal or foetal or fetus* or foetus* or prenatal or pre-natal or antenatal or
ante-natal))
3
44 ((fetal or foetal or fetus* or foetus* or prenatal or pre-natal or antenatal or ante-natal) NEAR2 (genotype* or
genotyping))
3
45 ((genotype* or genotyping) NEAR2 (maternal or pregnan*)) 2
46 ((maternal or pregnan*) NEAR2 (genotype* or genotyping)) 2
47 ((genotype* or genotyping) NEAR2 (noninvasive or non-invasive)) 1
48 ((noninvasive or non-invasive) NEAR2 (genotype* or genotyping)) 4
49 (“cell-free foetal DNA” or “cell-free fetal DNA”) 7
50 (cffDNA) 2
51 #42 OR #43 OR #44 OR #45 OR #46 OR #47 OR #48 OR #49 OR #50 18
52 #32 AND #41 16
53 #32 AND #51 6
54 #52 OR #53 18
Please note that the total number of hits at line 54 refers to the total number of results from DARE, HTA
database and NHS EED.
Key
MeSH DESCRIPTOR = indexing term (MeSH heading)
* = truncation
NEAR2 = terms within two words of each other (order specified)
“ ” = phrase search
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Research Papers in Economics (http://repec.org/)
Date searched: 4 December 2015.
Records retrieved: 0.
“RhD” | rhesus | “hemolytic disease” | “haemolytic disease” | HDFN | erythroblastoses | erythroblastosis |
“fetomaternal immunisation” | “fetomaternal immunization” | “foetomaternal immunisation” |
“foetomaternal immunization”
Key
“ ” = phrase search
| = OR
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Appendix 2 Included studies
TABLE 35 List of included studies
Study
(author, date) Full title Country Linked publications
Included studies: diagnostic accuracy
Akolekar et al.,
201119
Fetal RHD genotyping in maternal plasma at
11–13 weeks of gestation. Fetal Diagn Ther
29:301–6
UK (London) None
Banch Clausen
et al., 201420
Routine non-invasive prenatal screening for
fetal RHD in plasma of RhD-negative
pregnant women – 2 years of screening
experience from Denmark. Prenat Diagn
34:1000–5
Denmark Full-text papers: Damkjaer et al.,
2012;27 and Banch Clausen et al.,
201224
Abstracts: Banch Clausen;35 and
Dziegiel et al., 201237
Chitty et al.,
201412
Diagnostic accuracy of routine antenatal
determination of fetal RHD status across
gestation: population based cohort study.
BMJ 349:g5243
UK (Bristol) Full-text paper: none
Abstracts: Chitty et al., 2011,29 2012;30
and Daniels et al., 201231
Finning et al.,
200817
Effect of high throughput RHD typing of fetal
DNA in maternal plasma on use of anti-RhD
immunoglobulin in RhD negative pregnant
women: prospective feasibility study. BMJ
336:816–18
UK (Bristol) None
Grande et al.,
201322
Clinical application of midtrimester
non-invasive fetal RHD genotyping and
identification of RHD variants in a
mixed-ethnic population
Spain None
Soothill et al.,
201518
Use of cffDNA to avoid administration of
anti-D to pregnant women when the fetus is
RhD-negative: implementation in the NHS.
BJOG 122:1682–6
UK (Bristol) None
Thurik et al.,
201521
Analysis of false-positive results of fetal RHD
typing in a national screening program
reveals vanishing twins as potential cause for
discrepancy
The
Netherlands
Full-text paper: de Haas et al., 201225
Abstracts: de Haas et al., 2012;46,47
Scheffer et al., 2013;44 Thurik et al.,
2014;42,43 van der Schoot et al., 2005;45
and Veldhuisen et al., 2013,41 201440
Wikman et al.,
201223
Non-invasive single-exon fetal RHD
determination in a routine screening program
in early pregnancy. Obstet Gynecol
120:227–34
Sweden Full-text papers: none
Abstracts: Tiblad et al., 2010;54
Wikman et al., 2010,53 2011,51 2012;50
and Wikman 201352
Included studies: clinical effectiveness
Banch Clausen
et al., 201420
Routine non-invasive prenatal screening for
fetal RHD in plasma of RhD-negative
pregnant women – 2 years of screening
experience from Denmark. Prenat Diagn
34:1000–5
Denmark Full-text papers: Banch Clausen et al.,
2012;24 and Damkjaer et al., 201227
Abstracts: Banch Clausen et al., 2011;38
Banch Clausen 2012;35,36 Dziegiel et al.,
2012;37 and Steffensen et al., 201239
continued
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TABLE 35 List of included studies (continued )
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(author, date) Full title Country Linked publications
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et al., 201224
Report of the first nationally implemented
clinical routine screening for fetal RHD in
D- pregnant women to ascertain the
requirement for antenatal RhD prophylaxis.
Transfusion 52:752–8
Denmark Full-text papers: Banch Clausen et al.,
2014;20 and Damkjaer et al., 201227
Abstracts: Banch Clausen et al., 2011;38
Banch Clausen 2012;35,36 Dziegiel et al.,
2012;37 and Steffensen et al., 201239
Damkjaer
et al., 201227
Study of compliance with a new, targeted
antenatal D immunisation prevention
programme in Denmark. Vox Sang
103:145–9
Denmark Full-text papers: Banch Clausen et al.,
2012,24 201420
Abstracts: Banch Clausen et al., 2011;38
Banch Clausen 2012;35,36 Dziegiel et al.,
2012;37 and Steffensen et al., 201239
de Haas et al.,
201225
A nation-wide fetal RHD screening
programme for targeted antenatal and
postnatal anti-D. ISBT Sci Ser 7:164–7
The
Netherlands
Full-text paper: Thurik et al., 201521
Abstracts: de Haas et al., 2012,46
2013;47 Thurik et al., 2014;42,43 Scheffer
et al., 2013;44 van der Schoot et al.,
2005;40–45 and Veldhuisen et al., 2013,41
201440
Grande et al.,
201322
Clinical application of midtrimester
non-invasive fetal RHD genotyping and
identification of RHD variants in a
mixed-ethnic population
Spain None
Soothill et al.,
201518
Use of cffDNA to avoid administration of
anti-D to pregnant women when the fetus is
RhD-negative: implementation in the NHS.
BJOG 122:1682–6
UK (Bristol) Full-text paper: none
Abstracts: Finning et al., 2014,33 201532
Tiblad et al.,
201326
Targeted routine antenatal anti-D prophylaxis
in the prevention of RhD immunisation–
outcome of a new antenatal screening and
prevention program. PLOS ONE 8(8)
Sweden Full-text paper: none
Abstracts: Tiblad 2012;57 and Tiblad
et al., 2012,55 201456
Included studies: implementation
Banch Clausen
et al., 201420
Routine non-invasive prenatal screening for
fetal RHD in plasma of RhD-negative
pregnant women – 2 years of screening
experience from Denmark. Prenat Diagn
34:1000–5
Denmark Report: Banch Clausen et al., 201224
Full-text papers: Banch Clausen et al.,
2013;13 and Damkjaer et al., 201227
Abstract: Banch Clausen et al., 201138
Banch Clausen
et al., 201224
Report of the first nationally implemented
clinical routine screening for fetal RHD in
D- pregnant women to ascertain the
requirement for antenatal RhD prophylaxis.
Transfusion 52:752–8
Denmark Linked to above
Clausen et al.,
201313
Pre-analytical conditions in non-invasive
prenatal testing of cell-free fetal RHD. PLOS
ONE 8:e76990
Denmark Linked to above
Damkjaer
et al., 201227
Study of compliance with a new, targeted
antenatal D immunisation prevention
programme in Denmark. Vox Sang
103:145–9
Denmark Linked to above
Brojer et al.,
200594
Non-invasive determination of fetal RHD
status by examination of cell-free DNA in
maternal plasma.’ Transfusion 45:1473–80
Poland None
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TABLE 35 List of included studies (continued )
Study
(author, date) Full title Country Linked publications
Finning et al.,
200817
Effect of high throughput RHD typing of fetal
DNA in maternal plasma on use of anti-RhD
immunoglobulin in RhD negative pregnant
women: prospective feasibility study. BMJ
336:816–18
UK (Bristol) Full-text paper: none
Abstract: Finning et al., 2014,33 201532
Grande et al.,
201322
Clinical application of midtrimester
non-invasive fetal RHD genotyping and
identification of RHD variants in a
mixed-ethnic population
Spain None
Thurik et al.,
201521
Analysis of false-positive results of fetal RHD
typing in a national screening program
reveals vanishing twins as potential cause for
discrepancy
The
Netherlands
Full-text paper: none
Abstracts: Veldhuisen et al., 201440
de Hass et al.,
201225
A nation-wide fetal RHD screening
programme for targeted antenatal and
postnatal anti-D. ISBT Sci Ser 7:164–7
The
Netherlands
Linked to Thurik et al.21
Oxenford
et al., 201328
Routine testing of fetal Rhesus D status in
Rhesus D negative women using cell-free
fetal DNA: an investigation into the
preferences and information needs of
women. Prenat Diagn 33:688–94
UK (London) None
Soothill et al.,
201518
Use of cffDNA to avoid administration of
anti-D to pregnant women when the fetus is
RhD-negative: implementation in the NHS.
BJOG 122:1682–6
UK (Bristol) None
Wikman et al.,
201223
Non-invasive single-exon fetal RHD
determination in a routine screening program
in early pregnancy. Obstet Gynecol
120:227–34
Sweden Full-text paper: Tiblad et al., 201326
Abstract: Wikman et al., 2011,51 201250
Tiblad et al.,
201326
Targeted routine antenatal anti-D prophylaxis in
the prevention of RhD immunisation–outcome
of a new antenatal screening and prevention
program. PLOS ONE 8:e70984
Sweden Linked to Wikman et al.23
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Appendix 4 Characteristics of diagnostic
accuracy studies
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TABLE 36 Characteristics of diagnostic accuracy studies
Study Country Study dates
Number
tested
Number
analysed
Gestational age
(weeks), median
(range) Ethnicity (%)
Multiple
pregnancies
included?
DNA extraction
tool PCR technology
Multiple testing
performed?
Akolekar et al.,
2011
19
England NR 591 586 12.4 (11–14) White European 77.3,
Asian 1.2, African
19.3, mixed 2.2
No MDx BioRobot
(Qiagen, Crawley,
UK)
ABI 7900 detection
system (ABI, Applied
Biosystems, Foster
City, CA, USA)
Yes (for RHD
variants)
Banch Clausen et al.,
2014
20
Denmark 2010–11 14,547 12,668 25 (73% between
23 and 28)
NR NR QIAsymphony SP;
MagNA Pure LC;
MagNA Pure
Compact
Instrument (Roche
Ltd, Rotkreuz,
Switzerland)
ABI 7900 detection
system (Applied
Biosystems)
LightCycler 480
(Roche) PCR ABI
7500 (Applied
BioSystems)
NR
Chitty et al., 2014
12
England 2009–12 4913 4913 19 (5–35)
(18% under
11 weeks)
White European 78,
Asian 6, Black or
mixed race 4,
unknown 12
No MDx BioRobot
(Qiagen, Crawley,
UK)
ABI Prism 7900HT
(Applied Biosystems)
Up to four samples
per woman
Finning et al., 2008
17
England NR 1997 1869 28 (8–38)
(92% at 26–32)
White European 55,
Asian 8, African 2,
other 2, unknown 33
Yes (n= 13
pregnancies)
MDx BioRobot
(Qiagen, Crawley,
UK)
ABI Prism 7900HT
(Applied Biosystems)
NR
Grande et al., 2013
22
Spain February 2010–
October 2011
284 282 24–26 White European 84,
Asian 1.5, African 1.8,
Latin American 12,
other 0.7
Yes (n= 16
pregnancies)
COBAS AmpliPrep
(Roche Ltd,
Rotkreuz,
Switzerland)
7300 Real-Time PCR
System (Applied
Biosystems)
Yes, two
independent assays
performed in
triplicate for all
Soothill et al., 2015
18
England April–September
2013
526 499 15–26 NR No MDx BioRobot
(Qiagen, Crawley,
UK)
NR NR
Thurik et al., 2015
21
The
Netherlands
July 2011–October
2012
24,986 18,383 26 NR No MagNa Pure 96
(Roche Ltd,
Rotkreuz,
Switzerland)
StepOnePlus Real-
Time PCR System
(Applied Biosystems)
Yes, PCR in
triplicate
Wikman et al., 2012
23
Sweden September 2009–
May 2011
4118 3291 10 (3–40) (75.5%
first trimester,
10% tested
before 8 weeks)
NR Yes (n= 61
pregnancies)
MagNA Pure LC
(Roche Ltd,
Rotkreuz,
Switzerland)
PCR ABI 7500
(Applied BioSystems)
Yes, PCR on all
samples in triplicate
211 samples
reanalysed because
of uninterpretable
results
NR, not reported.
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Appendix 5 Risk of bias and applicability of
findings of diagnostic accuracy studies
TABLE 37 Risk of bias: patient selection
Study
Was a
consecutive
sample of
patients
enrolled?
Did the
study avoid
inappropriate
exclusions?
Were key study
population
characteristics
reported?
(including
ethnicity, GA,
multiple
pregnancies) Risk of bias
Applicability: are
there concerns that
the included
patients do not
match the target
population?
Akolekar
et al., 201119
Unclear No, excluded
multiple
pregnancies
Yes High, reporting of
selection process
limited, much
higher proportion
of African than
general population
(19.3%)
Yes, much higher
proportion of people
of African ethnicity
than general
population (19.3%)
Banch Clausen
et al., 201420
Unclear, not
stated but
seems likely
Unclear,
appears fine
No, population
characteristics
(including ethnicity)
NR
Low Unclear, population
characteristics
(including ethnicity) NR
Chitty et al.,
201412
Unclear, not
stated but
seems likely
No, excluded
multiple
pregnancies
Yes Low No
Finning et al.,
200817
Unclear, not
stated but
seems likely
Yes Yes Low No
Grande et al.,
201322
Unclear Yes Yes Low Yes, ethnic
distribution differs
from general UK
population (12%
Latin American)
Soothill et al.,
201518
Unclear, not
stated but
seems likely
Yes No, ethnicity and
multiple pregnancy
NR. Gestational
range could be
inferred but was not
clearly reported
Low No
Thurik et al.,
201521
Unclear, not
stated but
seems likely
No, multiple
pregnancies
excluded and
treated as
positive
No, ethnicity and
number of multiple
pregnancies NR
Low Yes, exclusion
of multiple
pregnancies
Wikman et al.,
201223
Unclear, not
stated but
seems likely
Unclear,
exclusion
criteria not
reported
No, ethnicity NR Low Unclear, ethnicity
unknown
NR, not reported.
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TABLE 38 Risk of bias: index test
Study
Were the index test
results interpreted
without knowledge
of the results of the
reference standard?
If a threshold was used,
was it prespecified?
Were results
from replicate
samples
dealt with
appropriately?
Were results from multiple
pregnancies dealt with
appropriately
Risk of bias: could
the conduct or
interpretation of
the index test have
introduced bias?
Applicability: are
there concerns
that the index
test, its conduct or
interpretation
differ from the
review question?
Reporting:
did the study
report any
adverse
effect of the
index test?
Akolekar et al.,
201119
Unclear, likely not Unclear, thresholds were
reported, but unclear if
prespecified
Yes N/A, only singleton pregnancies High, inconclusive results
were not included in the
main analysis. This may
have inflated the
accuracy estimates
Low No
Banch Clausen
et al., 201420
Yes Yes Unclear, NR Unclear, NR Low Low No
Chitty et al.,
201412
Yes Yes Unclear, NR N/A, only singleton pregnancies Low Low No
Finning et al.,
200817
Yes Unclear, unclear if
prespecified
Unclear, NR Yes Low Low No
Grande et al.,
201322
Unclear Unclear, unclear if
prespecified
Yes Yes Low Low No
Soothill et al.,
201518
Unclear, presumably
as in Chitty et al.12
Unclear, presumably as in
Chitty et al.12
Unclear, NR Unclear, NR Unclear, Presumably as in
Chitty et al.12
Low No
Thurik et al.,
201521
Unclear, unclear for
back-up plasma
analysis, yes for
samples not
reanalysed
No, prediction algorithm is
judged daily and adjusted
as needed.
If we would have
strictly followed the
computed algorithm,
the repeat rate would
have been almost
halved, with the
expense of one
false-negative and
20 more false-positive
results
Yes No, all treated as positive and
prescribed anti-D
High, change of
diagnostic algorithm after
start of study may have
introduced bias
Low No
Wikman et al.,
201223
Unclear, likely not Unclear Yes Yes Low High, only exon 4
was targeted
No
NR, not reported.
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TABLE 39 Risk of bias: reference standard
Study
Is the reference standard
likely to correctly classify
the target condition?
Were the reference
standard results
interpreted without
knowledge of the results
of the index test?
Risk of bias: could the
reference standard,
its conduct or its
interpretation have
introduced bias?
Applicability: are there
concerns that the study
used a non-standard
reference standard?
Reporting: did the
study report any
adverse effect of the
reference standard?
Akolekar et al., 201119 Unclear, method NR Unclear, NR Unclear, method NR Unclear, method NR No
Banch Clausen et al., 201420 Yes Unclear, NR Low Low No
Chitty et al., 201412 Yes Unclear, NR Low Low No
Finning et al., 200817 Yes Yes Low Low No
Grande et al., 201322 Yes Unclear, NR Low Low No
Soothill et al., 201518 Yes Unclear, NR Low Low No
Thurik et al., 201521 Yes Unclear, NR Low Low No
Wikman et al., 201223 Yes Unclear, NR Low Low, author contacted:
appropriate except 5% of
samples processed in citrate
tubes
No
NR, not reported.
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TABLE 40 Risk of bias: flow and timing
Study
Was there an appropriate
interval between index
test(s) and reference
standard?
Did all patients (who
provided data) receive a
reference standard?
Did all patients
receive the same
reference standard?
Were all patients included
in the analysis?
Risk of bias: could the
patient flow have
introduced bias?
Akolekar et al., 201119 Yes No, only those with
reference standard result
and live birth were included
in the study
Unclear No, only those with
reference standard result
and live birth were included
in the study
Low
Banch Clausen et al., 201420 Yes No Yes Yes Low
Chitty et al., 201412 Yes No, 185 without cord blood
result, but unlikely
significant bias
Yes No, 13% excluded for
various reasons (all reported)
Low
Finning et al., 200817 Yes No, four did not because of
fetal death
Yes No, 128 fetal phenotypes
were not available for paired
analysis because 124 cord
samples were untraceable
and there were four fetal
deaths
Low
Grande et al., 201322 Yes Yes, appears so Yes No, only two RhD-positive
mothers who underwent
NIPT were excluded
Low
Soothill et al., 201518 Yes No, 5% did not have cord
blood serology results
Yes Yes Low
Thurik et al., 201521 Yes No, 80% did. No reason
provided for 20% not
providing cord blood
serology
Yes No, 20% samples received
NIPT but not cord serology
High, 20% samples received
NIPT but not cord serology.
No reasons provided
Wikman et al., 201223 Yes No, 11% pregnancies with
no reference standard
measurement
No, 5% citrate samples
(author contacted)
No, 11% pregnancies with
no reference standard
measurement
Low, despite limitations, risk
of diagnostic accuracy
results being significantly
affected was not considered
high
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Appendix 6 Additional figures and tables for
diagnostic accuracy analyses
0 1 2 3 4
FNR (%)
Estimates with 95% CI
Finning 200817
Akolekar 201119
Wikman 201223
Banch Clausen 201420
Chitty 201412
Soothill 201518
Pooled
Study
0.26 (0.09 to 0.76)
1.46 (0.67 to 3.16)
1.11 (0.74 to 1.66)
0.14 (0.08 to 0.25)
0.13 (0.04 to 0.37)
0.32 (0.06 to 1.78)
0.36 (0.11 to 0.60)
FNR (95% CI)
(a)
0 2 64 108 12
FPR (%)
Estimates with 95% CI
Finning 200817
Akolekar 201119
Wikman 201223
Banch Clausen 201420
Chitty 201412
Soothill 201518
Pooled
Study
6.03 (4.51 to 8.03)
6.82 (3.94 to 11.54)
1.81 (1.20 to 2.72)
2.73 (2.31 to 3.23)
4.98 (4.04 to 6.13)
7.61 (4.59 to 12.37)
4.35 (2.91 to 5.80)
FPR (95% CI)
(b)
FIGURE 19 Forest plots for analysis case 2.
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Receiver operating characteristic plot for analysis case 3
20
0.0
0.5
1.5
1.0
2.0
4 6 108
FPR
F
N
R
Study
    Akolekar et al., 201119
    Banch Clausen et al., 201420
    Chitty et al., 201412
    Finning et al., 200817
    Grande et al., 201322
    Soothill et al., 201518
    Thurik et al., 201521
    Wikman et al., 201223
FIGURE 20 Receiver operating characteristic plot for analysis case 3.
TABLE 41 Results of diagnostic SAs
Analysis FNR, % (95% CI) FPR, % (95% CI)
Excluding Akelokar et al., 201119 and Thurik et al., 201521
Inconclusives treated as positive (with Grande et al., 201322) 0.315 (0.14 to 0.70) 3.837 (2.36 to 6.19)
Inconclusives treated as positive (without Grande et al., 201322) 0.260 (0.10 to 0.65) 4.004 (2.40 to 6.60)
Excluding inconclusives 0.349 (0.16 to 0.77) 1.205 (0.87 to 1.67)
Excluding Wikman et al., 201223
Inconclusives treated as positive (with Thurik et al., 201521 and
Grande et al., 201322)
0.292 (0.13 to 0.65) 4.478 (2.92 to 6.81)
Inconclusives treated as positive (without Thurik et al., 201521
and Grande et al., 201322)
0.334 (0.13 to 0.84) 5.245 (3.54 to 7.71)
Excluding inconclusives 0.279 (1.12 to 0.67) 1.142 (0.69 to 1.90)
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Appendix 7 Quality assessment of clinical
effectiveness studies
This appendix presents quality assessment tables performed for the two comparative studies included inthe review of effectiveness studies.
When multiple outcomes were assessed within the same study, risk-of-bias judgements did not differ across
outcomes unless otherwise specified. Further details of the quality assessment, including prespecified target
randomised trials, target comparisons and specified confounding domains are available on request.
For full guidance, see Sterne JAC, Higgins JPT, Reeves BC on behalf of the development group for
ACROBAT-NRSI. A Cochrane Risk Of Bias Assessment Tool: for Non-Randomized Studies of Interventions
(ACROBAT-NRSI). Version 1.0.0. 2014. URL: www.riskofbias.info (accessed 1 March 2016).
Risk-of-bias assessment: Banch Clausen et al.20
Outcomes and results assessed
Outcomes assessed Compliance with prenatal anti-D
Compliance with postnatal anti-D
Compliance with RHD screening
Specific results being assessed Compliance with antenatal anti-D: 93.2% vs. not applicable (not recommended in
patients not receiving RHD screening)
Compliance with postnatal anti-D: 99.7% vs. 95.7%
Compliance with RHD screening: 84.2%
Risk-of-bias table for Banch Clausen et al.20
Bias domain Signalling question Judgement Comment
Bias attributable to
confounding
Is confounding of the effect of
intervention unlikely in this study?
PN Unadjusted analyses
Were participants analysed according to
their initial intervention group throughout
follow-up?
PY
Did the authors use an appropriate
analysis method that adjusted for all the
critically important confounding domains?
No Unadjusted analyses
Risk-of-bias judgement Critical Analyses not adjusted for several
potential confounders (including
potential sensitising event, anti-D
prophylaxis compliance,
gestational age)
What is the predicted direction of bias due
to confounding?
Unpredictable
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Bias domain Signalling question Judgement Comment
Bias in selection of
participants into the
study
Was selection into the study unrelated to
intervention or unrelated to outcome?
No
Do start of follow-up and start of
intervention coincide for most subjects?
Yes
Were adjustment techniques used that
are likely to correct for the presence of
selection biases?
No
Risk-of-bias judgement NI Only participants from one of
the five regions over 1 year
(690/12,668) were included.
Reasons were not provided
What is the predicted direction of bias due
to selection of participants into the study?
Unpredictable
Bias in measurement
of interventions
Is intervention status well defined? Yes RHD screening
Was information on intervention status
recorded at the time of intervention?
PY
Was information on intervention status
unaffected by knowledge of the outcome
or risk of the outcome?
Yes
Risk-of-bias judgement Low
What is the predicted direction of bias
due to measurement of outcomes or
interventions?
Towards null Low risk of bias
Bias due to departures
from intended
interventions
Were the critical cointerventions balanced
across intervention groups?
NI No information on non-routine
anti-D and whether or not it was
measured as separate from
routine administration
Were numbers of switches to other
interventions low?
Yes N/A
Was implementation failure minor? PY No information but unlikely
Were adjustment techniques used that are
likely to correct for these issues?
No
Risk-of-bias judgement Low
What is the predicted direction of bias
due to departures from the intended
interventions?
Towards null Low risk of bias
Bias due to missing
data
Are outcome data reasonably complete? NI No information on missing data
Was intervention status reasonably
complete for those in whom it was
sought?
NI
Are data reasonably complete for other
variables in the analysis?
No Lack of reported data on
confounders
Are the proportion of participants and
reasons for missing data similar across
interventions?
NI No information on missing data
Were appropriate statistical methods used
to account for missing data?
N/A
Risk-of-bias judgement NI
What is the predicted direction of bias due
to missing data?
Unpredictable
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Bias domain Signalling question Judgement Comment
Bias in measurement
of outcomes
Was the outcome measure objective? Yes
Were outcome assessors unaware of
the intervention received by study
participants?
NI
Were the methods of outcome assessment
comparable across intervention groups?
PY
Were any systematic errors in measurement
of the outcome unrelated to intervention
received?
NI
Risk-of-bias judgement Low No information to suggest
otherwise
What is the predicted direction of bias due
to measurement of outcomes?
Towards null
Bias in selection of the
reported result
Is the reported effect estimate unlikely to
be selected, on the basis of the results,
from:
Multiple outcome measurements within
the outcome domain?
PY
Multiple analyses of the
intervention–outcome relationship?
PY
Different subgroups? NI Only participants from one of
the five regions over 1 year
(690/12,668) were included.
Reasons were not provided
Risk-of-bias judgement NI
What is the predicted direction of bias due
to selection of the reported result?
Unpredictable
Overall bias Risk-of-bias judgement Critical Only participants from one of
the five regions over 1 year
(690/12,668) were included.
Analyses were not adjusted for
any potential confounders
What is the overall predicted direction of
bias for this outcome?
Unpredictable Unpredictable because of
insufficient information, although
may be more likely to favour the
intervention
N/A, not applicable; NI, no information; PN, probably no; PY, probably yes.
Risk-of-bias assessment: Tiblad et al.26
Outcomes and results assessed
Outcomes assessed Sensitisation (measured as development of anti-D antibodies after the first trimester of
pregnancy or post partum)
Results Adjusted odds ratio 0.41 (95% CI 0.22 to 0.78), 0.19% vs. 0.46% (favours intervention)
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Risk-of-bias table for Tiblad et al.26
Bias domain Signalling question Judgement Comment
Bias due to confounding Is confounding of the effect of
intervention unlikely in this study?
No Study with historical control and
insufficiently adjusted analysis
Were participants analysed
according to their initial intervention
group throughout follow-up?
No In the reference group, no routine
postpartum antibody testing was
performed. The outcome was
measured in the first trimester of
the subsequent pregnancy
Were intervention discontinuations
or switches unlikely to be related to
factors that are prognostic for the
outcome?
PN
Did the authors use an appropriate
analysis method that adjusted for all
the critically important confounding
domains and for time-varying
confounding?
PN Analyses adjusted for NIPT
sensitivity. No significant differences
in gestational age and preterm
births. Compliance with RAADP not
adjusted for
Were confounding domains that
were adjusted for measured validly
and reliably by the variables available
in this study?
N/A
Risk-of-bias judgement Serious Study with historical control. No
adjustment for RAADP compliance
or sensitising event
What is the predicted direction of
bias due to confounding?
Unpredictable
Bias in selection of
participants into the study
Was selection into the study
unrelated to intervention or
unrelated to outcome?
No The control group was historical,
pretargeted routine anti-D
prophylaxis. In the reference group,
immunisation after delivery was
defined as presence of anti-D
antibodies in the first trimester in
the subsequent pregnancy. Routine
antibody testing at 25 weeks in
nulliparous women in routine
management group was not
performed
Do start of follow-up and start of
intervention coincide for most
subjects?
PN Only clear for intervention group,
probably not for routine
management group
Were adjustment techniques used
that are likely to correct for the
presence of selection biases?
No
Risk-of-bias judgement Serious The control group was historical,
pre-targeted routine anti-D
prophylaxis. In the reference group,
immunisation was defined as
presence of anti-D antibodies in the
first trimester in a subsequent
pregnancy. This means that any
pregnant woman with no recorded
subsequent pregnancy was
excluded
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Bias domain Signalling question Judgement Comment
What is the predicted direction of
bias due to selection of participants
into the study?
Unpredictable Insufficient information to assess,
although it is possible events were
underestimated in the reference
group as sensitisation was not
measured post partum in this
group. On the other hand, it is
plausible, as the authors stated,
that not all women in the reference
cohort had a subsequent
pregnancy when antibodies from
sensitisation late in the third
trimester or at delivery in the
previous pregnancy would be
found, leading to rates of new RhD
immunisations being somewhat
underestimated
Bias in measurement of
interventions
Is intervention status well defined? Yes
Was information on intervention
status recorded at the time of
intervention?
Yes
Was information on intervention
status unaffected by knowledge of
the outcome or risk of the outcome?
Yes ‘Hard’ outcome
Risk-of-bias judgement Low
What is the predicted direction of
bias due to measurement of
outcomes or interventions?
Towards null
Bias due to departures
from intended
interventions
Were the critical cointerventions
balanced across intervention groups?
NI
Were numbers of switches to other
interventions low?
PY
Was implementation failure minor? NI
Were adjustment techniques used
that are likely to correct for these
issues?
No
Risk-of-bias judgement Low
What is the predicted direction of
bias due to departures from the
intended interventions?
Unpredictable
Bias due to missing data Are outcome data reasonably
complete?
NI In the control group, it appears that
any pregnant woman with no
recorded subsequent pregnancy
was excluded
Was intervention status reasonably
complete for those in whom it was
sought?
NI Insufficient information
Are data reasonably complete for
other variables in the analysis?
No Limited data on participants
excluded from the analyses as there
was no recorded subsequent
pregnancy in the reference group
Are the proportion of participants
and reasons for missing data similar
across interventions?
NI
Were appropriate statistical methods
used to account for missing data?
No
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Bias domain Signalling question Judgement Comment
Risk-of-bias judgement NI In the control group, it appears that
any pregnant woman with no
recorded subsequent pregnancy was
excluded (based on Tiblad et al.26)
What is the predicted direction of
bias due to missing data?
Unpredictable
Bias in measurement of
outcomes
Was the outcome measure
objective?
Yes
Were outcome assessors unaware of
the intervention received by study
participants?
NI No mention of blinding
Were the methods of outcome
assessment comparable across
intervention groups?
Yes
Were any systematic errors in
measurement of the outcome
unrelated to intervention received?
PN
Risk-of-bias judgement Low
What is the predicted direction of
bias due to measurement of
outcomes?
Towards null
Bias in selection of the
reported result
Is the reported effect estimate
unlikely to be selected, on the basis
of the results, from:
multiple outcome measurements
within the outcome domain?
PN
multiple analyses of the
intervention–outcome relationship?
PN
different subgroups? PN
Risk-of-bias judgement Low
What is the predicted direction of
bias due to selection of the reported
result?
Towards null
Overall bias Risk-of-bias judgement Serious Primarily because of risk of
selection bias, confounding and
missing data
What is the overall predicted
direction of bias for this outcome?
Unpredictable Unpredictable because of
insufficient information. Note: the
generalisability of the study findings
to the UK is limited given that
RAADP is recommended as part of
routine care
N, no; NI, no information; PN, probably no; PY, probably yes; Y, yes.
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Appendix 8 Summary of anti-D reviews
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TABLE 42 Summary of anti-D reviews
Review
Review details Results
Studies Anti-D group Control Outcome
Anti-D
group
Control
group RR
Lower
CI
Upper
CI
McBain et al., 201564 2 Anti-D after 28 weeks No treatment (standard care) Alloimmunisation in
pregnancy or post partum
5 13 0.42 0.15 1.17
2 Alloimmunisation within
one year
6 16 0.39 0.10 1.62
1 Positive Kleihauer at birth 73 119 0.60 0.46 0.79
1 Jaundice 1 4 0.26 0.03 2.30
Turner et al., 201263 10 Anti-D (500 IU) 28–34 weeks Standard postpartum or at
sensitisation
Postpartum sensitisation 0.31 0.17 0.56
Pilgrim et al., 200962 8 (total) Anti-D (various doses)
28–34 weeks
No antenatal anti-D Sensitisation
4 500 IU 0.30% 0.89% 0.33 0.20 0.55
3 1500 IU 0.34% 1.60% 0.20 0.13 0.29
2 500 IU community 0.35% 0.95% 0.37 0.21 0.65
1 Compliance 90% dose 1,
79% dose 2
Fyfe et al., 201461 8 Not described None Compliance 80–90%
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Appendix 9 Existing cost-effectiveness evidence:
list of excluded papers
1. Bernhofen DM. The empirics of comparative advantage: overcoming the tyranny of nonrefutability.
Rev Int Econ 2005;13:1017–23.
2. Druzic G. Bankarski sustav u RH. [Banking System in the Republic of Croatia. With English summary.]
Zbornik Radova Ekonomskog Fakulteta u Rijeci: Casopis za Ekonomsku Teoriju i Praksu. J Econ Bus
2002;20:67–90.
3. Du Laney T, Dibner M, Moise K. Pharmacoeconomic analysis of prenatal determination of fetal RHD
genotype through non-invasive maternal serum testing. Am J Obst Gynecol 2006;195:S119.
4. Duan Q, Liao TW. Optimization of blood supply chain with shortened shelf lives and ABO compatibility.
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6. Ma KK, Rodriguez MI, Cheng YW, Norton ME, Caughey AB. Should cell-free DNA testing be used to
target antenatal rhesus immune globulin administration? J Matern Fetal Neonatal Med 2015;29:1866–70.
7. Moise KJ. Costs and clinical outcomes of noninvasive fetal RhD typing for targeted prophylaxis. Obstet
Gynecol 2013;122:1306. http://dx.doi.org/10.1097/AOG.0000000000000036
8. Roque H. Fetal RhD genotyping by maternal serum analysis: a two-year experience. Am J Obstet
Gynecol 2006;194:905–6.
9. Szczepura A, Bonsel G, Krauth C, Osipenko L, Haverkamp A. Fetal RHD typing: Is fetal RHD typing in all
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Appendix 10 Previous National Institute for
Health and Care Excellence technology appraisals
Two previous TAs were carried out on RAADP. The more recent appraisal (NICE TA156) concluded that,compared with having no RAADP, RAADP reduces the incidence of sensitisation and, consequently, of
haemolytic disease of the newborn infant. The economic analysis undertaken suggested that RAADP given
to all RhD-negative pregnant women was likely to be cost-effective at a threshold of around £30,000 per
QALY gained (Table 43). The total cost of providing RAADP to RhD-negative multigravidae in England and
Wales was estimated to be around £2M–2.6M per year (2008 values). Table 43 considers only results
relating to the multigravidae option as, in the current work, we assume that anti-D immunoglobulin and
high-throughput NIPT would be provided in all eligible pregnancy (women RhD-negative and not
previously sensitised) and not restricted based on whether or not it was the woman’s first pregnancy.
An updated assessment of RAADP was done under the current assessment. The following amendments
and updating were performed:
l We made amendments to discount the total QALYs according to the timing of subsequent pregnancies
and to retain a constant probability of RhD-positive fetus per pregnancy across the whole cohort of
RhD-negative pregnant women.
l We updated the model to the current price year and more recent NHS reference costs.
l We updated the model to more recent population values, estimates of birth rates and sensitisation.
The previous model compared RAADP plus postpartum anti-D immunoglobulin with postpartum anti-D
immunoglobulin only. Many elements that were common to both arms were omitted from the model but
we are required to introduce them as they may be affected by the introduction of high-throughput NIPT.
The following alterations to address the current decision problem were performed:
l We included the costs relating to potentially sensitising events (including phlebotomy, FMH test and
anti-D immunoglobulin treatment).
l We included the costs relating to postpartum treatment (including cord serology, phlebotomy, FMH
test and anti-D immunoglobulin treatment).
The routine anti-D immunoglobulin characterised in our model is determined by the results of the audit.
We used actual rates of single- and two-dose regimen implementation to determine a weighted cost that
is based on the lowest BNF price available. As a result of the amendments, the update and, most
significantly, the introduction of additional doses of anti-D immunoglobulin for potentially sensitising
events and post partum, the total costs in our updated model are significantly higher for every strategy but
the QALYs are not markedly different (Table 44). The total cost of RAADP is estimated to be £16.7M and
the total QALYs 2.4 million. The updated results are in line with the previous HTA showing that, under a
probabilistic set up, RAADP has an ICER of £14,444 compared with no RAADP. This is lower than the
previous estimate of £20,108, largely a result of the reduced unit cost of anti-D immunoglobulin based on
updated BNF prices and the increased birth rate.
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TABLE 43 Incremental cost-effectiveness outcomes associated with RAADP vs. no RAADP (multigravidae) – NICE TA15662
Strategies
Incremental
cost (£)
Number of
sensitisations
avoided
Number of
affected
pregnancies
avoided
Number of
fetal losses
avoided
Life-years
gained
Incremental
QALYs
Cost per
sensitisation
avoided (£)
Cost per
affected
pregnancy
avoided (£)
Cost per
fetal loss
avoided (£)
Cost per
life-year
gained (£)
ICER, cost
per QALY
gained (£)
No RAADPa 1,796,546 630.5 353.4 14.1 2,878,648 2,533,240 – – – – –
2 × 500 IU
RAADP (multi)
2,645,120 232.9 72.1 2.9 120.4 100.0 11,358 36,679 916,982 21,977 26,455
1 × 1500 IU
RAADP (multi)
2,010,568 232.9 72.1 2.9 120.4 100.0 8634 27,880 697,002 16,705 20,108
a No RAADP is an absolute amount.
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TABLE 44 Incremental cost-effectiveness outcomes associated with RAADP vs. no RAADP in the current diagnostic assessment (2016): deterministic and probabilistic results
Strategiesa
Incremental
cost (£)
Number of
sensitisations
avoided
Number of
affected
pregnancies
avoided
Number
of fetal
losses
avoided
Life-years
gained
Incremental
QALYs
Cost per
sensitisation
avoided (£)
Cost per
affected
pregnancy
avoided (£)
Cost per
fetal loss
avoided (£)
Cost per
life-year
gained (£)
ICER, cost
per QALY
gained (£)
Deterministic results
No RAADPb 12,412,184 356.8 202.8 10.14 2,764,972 2,433,227 – – – – –
RAADP 3,576,953 218.69 124.38 6.22 257.46 195.13 16,356 28,758 575,167 13,893 18,331
Probabilistic results
No RAADPb 13,203,011 406.29 249.07 12.47 2,764,874 2,432,875 – – – – –
RAADP 3,476,596 249.07 152.84 7.66 317.40 240.69 £13,959 22,747 454,043 10,953 14,444
a For both strategies prophylactic anti-D immunoglobulin after a potentially sensitising event is considered together with further postpartum anti-D immunoglobulin administration to any
RhD-negative women whose baby’s RhD status is confirmed to be positive after cord serology. For the RAADP strategy, treatment is delivered to all RhD-negative pregnant women, under
either single- or two-dose regimens.
b No RAADP is an absolute amount.
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